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1. SUMMARY 
Clarifying the physico-chemical principles of protein-protein interactions is critically 
important to understand the relationships between biological structures and functions in 
all biochemical mechanisms. In this project we aim to develop, validate and apply new 
computational-theoretical methods to study and predict the binding regions of proteins 
starting from 3D structural information and from the analysis of the conformational and 
physico-chemical properties of the constituting amino acids. In particular, this project 
entails the integrated analysis of the energetic properties of different datasets of proteins 
solved at high resolution. In this context, we have focused on four main subjects with 
different, yet highly intertwined, objectives. The first subject will address the application 
of an energy-based computational predictor for the identification of possible antibody-
binding surfaces (epitopes) of protein antigens from the pathogen Burkholderia 
pseudomallei, responsible for human melioidosis. The second will focus on the expansion 
of the same rationale, adapting the method towards different applications, and including 
as a novel functionality the prediction of MHC-II coupled epitopes to elicit the 
intervention of T helper cells. The third objective concerns the design and 
characterization of peptides and peptidomimetics to optimize the properties of the 
identified epitopes as better vaccine candidates. The fourth one will pursue the 
investigation of the energetic determinants of interacting proteins in a more general 
context (not limited to immunogenic epitopes), aiming at the identification of an energy-
based property describing the interaction event at the atomistic level of resolution. This 
part of the project is aimed at the development of a computational tool based on such 
property to help improve the understanding of the determinants of protein interactions 
and help predict their binding interfaces and orientation. All four subjects have been 
investigated in the broad spectrum of activities of an academic consortium, devoted to 
the identification of antigens from B. pseudomallei showing sufficient immunogenic 
potential to be considered as components for a vaccine against the pathogen. The 
computational methods developed and tested within this framework have theoretical as 
well as practical implications, from the physico-chemical study and characterization of 
protein-protein interactions, to the design of biologically active molecules.
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2 - STATE OF THE ART 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter will define the general framework of the thesis project, describing the 
overarching goal of all the endeavors, methods and applications developed during these 
three years of Ph.D., namely the development of better candidate immunodiagnostics and 
vaccines against melioidosis. Therefore, I will first focus on the disease, describing the 
essential facts concerning this endemic infection, its etiological agent and the state of art 
of past and current research initiatives. I will explain the reason why a vaccine is extremely 
desirable to eradicate this life-threatening disease, and why a quick and effective diagnosis 
may save many human lives. I will recapitulate the approaches and advances of 
vaccinology, describing how current technology may finally pave the way to an effective 
vaccine against melioidosis, mentioning the studies that provided us with the necessary 
information to investigate specific protein antigens with the highest protective potential. 
Finally, I will be introducing our Structural Vaccinology approach and our work rationale, 
in which computational biology plays a key role, both at the current level and in future 
advancements and implementations.  
 
There is no such thing on earth 
as an uninteresting subject; the 
only thing that can exist is an 
uninterested person 
G. K. Chesterton 
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2.1   MELIOIDOSIS: A DEADLY DISEASE WITHOUT A VACCINE. 
 
Melioidosis is a serious infectious disease caused by the Gram-negative environmental 
saprophyte Burkholderia pseudomallei, first described in Burma in 1912 as a "glanders-like" 
disease1. Stanton and Fletcher2 named Melioidosis from the Greek words melis, which 
means “distemper of asses”, and eidoes, which means “resemblance”. To date, acute cases 
are most frequently reported from northeast Thailand, where it is the third most common 
cause of death due to infectious diseases, after HIV/AIDS and tuberculosis3, and from 
Darwin in northern Australia where it has been the commonest cause of fatal community-
acquired bacteremic pneumonia4. Melioidosis is also being increasingly reported from 
many countries across South and East Asia as well as parts of South America, Papua New 
Guinea and the Caribbean. It is apparently rare in Africa5, although infection may pass 
unrecognized because diagnostic confirmation relies on microbiological culture, which is 
often unavailable in resource-restricted regions of the world. A map representing the 
endemicity of melioidosis is reported in Figure 1. 
 
 
 
 
B. pseudomallei is also considered to have potential in biological warfare, and is regarded 
as a potential bioterrorist weapon. It appears on the category B list of the critical agents 
published by the US Centers for Disease Control and Prevention6. 
Figure 1: Endemicity of melioidosis across the globe (2013) 
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The preferred host invasion routes for B. pseudomallei are mainly inhalation of 
contaminated dust or droplets, direct contact with contaminated soil or water through 
penetrating wounds and existing skin abrasions, or ingestion7. In few cases it is reported 
to be nosocomial, sexually transmitted, or laboratory acquired. A number of 
epidemiological and animal studies have indicated that melioidosis is not contagious5. 
Clinical manifestations are extremely diverse, and vary from acute sepsis to chronic 
localized pathology, to latent infection, which can reactivate decades later from a yet 
unknown tissue reservoir8,9. The Vietnam War experience drew attention toward more 
chronic forms of the infection or reactivations long after exposure. Such forms were 
described as the “Vietnam time-bomb”, which manifested later in life as a tuberculosis-
like disease6. 
The most common presentation is 
community-acquired pneumonia. 
However, some of the symptomatic 
presentations such as prolonged 
fever, weight loss and chest X-ray 
findings, may be misdiagnosed for 
tuberculosis leading to wrong 
therapies. Other than that, there are 
patients with septic arthritis, 
multiple abscesses in liver, spleen, prostatic abscess (more common in Australia), 
suppurative parotitis (more common in Thailand), osteomyelitis, pyomyositis, cellulitis, 
fasciitis, skin abscesses or ulcers, and bacteremia with or without focus. The protean 
manifestations of melioidosis often lead to clinical under-diagnosis of this fatal disease, 
and confirmation of infections relies heavily on time consuming culture methods for 
bacterial isolation, all of which heavily affects the mortality rate. Healthy individuals can 
develop melioidosis, but the majority of community acquired cases have some underlying 
immunosuppressive condition, particularly diabetes and to a lesser extent chronic renal 
disease, thalassemia or alcoholism9. The mortality rate in acute cases can exceed 50% and 
prolonged treatment with antibiotics may result only in the temporary control of the 
infection, with 10-15% relapse when antibiotic therapy is withdrawn. 
Figure 2: Burkholderia pseudomallei. A) Typical colony 
morphologies. Copyright © 2006 Nature Publishing Group, 
Nature Reviews | Microbiology. B) Scanning Electron 
Microscopy image of B. pseudomallei. Copyright © 2001 
Dennis Kunkel Microscopy, inc. /Dennis Kunkel 
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The treatment of melioidosis is often problematic because the bacteria are inherently 
resistant to many of the commercially available antibiotics and successful therapy often 
requires extended treatment regimens. Typically, melioidosis patients are treated with 
parenterally delivered ceftazidime or a carbapenem class drug for 10-14 days, and then 
with oral trimethoprim-sulfamethoxazole for 12-20 weeks8,10. 
At the present state, there is no vaccine available for use in humans and no candidates are 
close to licensing9. The lack of information on mechanisms of virulence and host 
resistance has limited work to devise vaccines against melioidosis. However, there are 
several reports which indicate that it is feasible to protect against the disease, at least in 
animal models. Atkins et al. constructed a mutant of B. pseudomallei (2D2) which was 
auxotrophic in the branched chain amino acid biosynthetic pathway11. The median lethal 
dose of this mutant was greater than 107 cfu in BALB/c mice by the i.p. route whereas the 
median lethal dose of the parental wild type strain was 80 cfu. Mice which had been dosed 
with 106 cfu of B. pseudomallei 2D2 were protected against a subsequent i.p. challenge 
with 104 MLD doses of the wild type B. pseudomallei11. This protection was abolished by 
mAb depletion of CD4+ but not CD8+ cells from the vaccinated animals prior to 
challenge, indicating a strong helper cell component to the protection12. More recently 
others have extended this work and demonstrate the ability of other live attenuated 
mutants to protect against experimental melioidosis in mice13,14. While this work with live 
attenuated mutants provides a clear demonstration of the feasibility of inducing 
protective immunity, it seems unlikely that a live attenuated mutant derived from a 
bacterium known to persist in the body would be acceptable as a licensable vaccine, 
arguing strongly for the development of a non-living vaccine.  
 
There are several reports which indicate that it is feasible to partially protect against 
melioidosis in animal models of disease, with non-living vaccines. Much of this work has 
been carried out with polysaccharides derived from B. pseudomallei, and the 
immunization of mice with capsular polysaccharide or lipopolysaccharide is able to 
provide some protection against the disease15.  
However, polysaccharides alone are generally poor vaccines that do not produce an 
anamnestic response because of the lack of T cell involvement in the generation of 
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immunity16. In order to convert to a more favorable T-dependent response 
polysaccharides are often conjugated to proteins. This is particularly important when 
polysaccharide vaccines are to be used in children, since this group generally responds 
poorly to this type of vaccine in the absence of a protein carrier16.  
 
The nature of the protective immune response, at least in murine models of disease, has 
also been reported in several previous studies. Both antibodies17,18 and CD4+ T-cells12,19 
have been shown to play key roles in protection. In contrast CD8+ T-cells have previously 
been shown to play a minor role in the induction of a protective immune response after 
the immunization of mice with a live attenuated vaccine19. As highlighted above, several 
studies indicate the importance in protection of antibodies against polysaccharide and 
lipopolysaccharide15,17,20, but there is also good evidence that protein antigens evoke 
protective antibody responses17,20. Several proteins have been identified as able to provide 
low levels of protection against melioidosis21-23. Starting from this rationale, the 
development of a non-living vaccine based on specific peptidic antigens appears to be a 
prime necessity in the effective elicitation of the immune response against meliodisis. 
 
2.2   REVERSE VACCINOLOGY: MAKING VACCINES IN THE POST-
GENOMIC ERA 
 
The first practice to be commonly addressed as “vaccination” possibly originated in Asia 
as early as 1000 CE, based on the inoculation of materials from smallpox lesions to 
somebody’s arm24. The practice diffused to Africa and Turkey as well, before approaching 
Europe, but was formally studied and introduced as a medical practice in 1796 by Edward 
Jenner, a country doctor living in Berkley, England, who “vaccinated” an eight-year-old 
boy by inoculating in his arm pus collected from a cowpox lesion on a milkmaid’s hand. 
Six weeks later Jenner repeated the process with material coming from a lesion caused by 
smallpox, causing no adverse consequences for the boy25. After the episode, Jenner 
conduced one of the first clinical trials in history of medicine, and gathered further 
evidence from twelve subsequent experiments and sixteen additional case histories. In his 
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book “An inquiry into the Causes and Effects of the Variolae Vaccine”26 he described and 
named the first medical immunization, a practice to become in the future one of the most 
successful scientific advances and medical accomplishments in human history. For an 
entire century, vaccines referred only to cowpox inoculation for smallpox, and the practice 
of variolation (the controlled transfer of pus from one person’s active smallpox lesion to 
another person’s arm, usually subcutaneously with a lancet) was not short of wariness, 
hostility or mockery (Figure 3). 
A century later, when it was discovered that infections are caused by microbes, French 
chemist Louis Pasteur started the rational development of vaccines and established the 
basic rules of vaccinology27. He developed what he called a rabies vaccine in 1885, 
although what he really produced was an antitoxin functioning as a post-infection 
antidote. Pasteur proposed that in order to make a vaccine, one should “isolate, inactivate 
and inject the microorganism”28 that causes the disease. Pasteur’s rules were followed for 
a century by vaccine developers, introducing vaccines for a number of serious infectious 
diseases. Jonas Salk used a formaldehyde treatment to kill a poliovirus producing the first 
vaccine effective against poliomyelitis. The second, oral vaccine was developed by Albert 
Sabin29 by attenuating the virus with repeated passages through nonhuman cells at 
subphysiological temperatures. Maurice Hilleman developed vaccines against measles, 
mumps, and rubella by viruses attenuation30. Others, such as Ramon and Glenny, isolated 
essential components from bacterial or viral cultures, inactivated them, and paved the 
way for the development of vaccines against diphtheria and tetanus31,32, Neisseria 
Figure 3: Caricature exaggerating 
the widespread debate over the 
concerns about vaccination. 
Cowpox vaccine is being 
administered to frightened people, 
while cows emerge from different 
parts of their bodies. “The Cow-
Pock-or-the Wonderful Effects of 
the New Inoculation!-vide. the 
Publications of ye Anti-Vaccine 
Society” by satirist artist James 
Gillray, 1802. (Library of Congress, 
Prints & Photographs Division, LC-
USZC4-3147). 
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meningitidis, Streptococcus pneumoniae, Haemophilus influenzae, and so on. In the case 
of hepatitis B, it was found that the causative agent could not be cultured in vitro. As a 
result, the vaccine was initially developed by inactivating viral antigen present in the 
plasma of chronically infected people33. The vaccines developed using Pasteur’s rules 
became powerful tools in the history of medicine and, in less than a century, led to the 
eradication of some of the most devastating infectious diseases globally. 
 
By the end of the 20th century, live vaccines had been widely used for vaccination against 
all sort of infectious diseases. Live vaccines have the ability to replicate and are recognized 
as foreign by human body without causing any pathological or lethal effects. In this period 
a remarkable progress was made by the introduction of recombinant DNA technologies 
and chemical conjugation of proteins to polysaccharides, as well as advances in the use of 
novel adjuvants. Such advancements enabled researchers to specifically inactivate 
essential gene(s) involved in pathogenesis, ultimately leading to the development of well-
defined attenuated live vaccines34. A different strategy involves the use of killed whole cell 
pathogens, non-living vaccines which remain immunogenic for host immune system. This 
type of vaccine is known to induce a narrow range of immune responses due to the 
inability to replicate in the host, making them safe for vaccinations on 
immunocompromised individuals, but usually require multiple doses for long lasting 
protection. Such strategy includes the vaccines against anthrax, Q fever and whooping 
cough35. 
However, in spite of all recent technologies, the original empirical approach for 
vaccinology introduced almost a century before was starting to wear out. The limitations 
of the traditional formula were evident for pathogens incapable of growing in vitro (e.g. 
papilloma virus), for pathogens with an intracellular cycle (tuberculosis, malaria), in 
which the infection is predominantly controlled by T-cell intervention rather than 
humoral immune response, and for microbes presenting antigenic hypervariability, such 
as serogroup B meningococcus, or HIV.  Most of the vaccines that could be discovered by 
traditional means were a reality, and the remaining pathogens required new, game-
changing technology to be tackled. 
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A powerful and game-changing tool came from the ability to access the genomes of 
microorganisms, a new technology that became available in 1995 when Craig Venter 
published the genome of the first free living organism36. This technological revolution 
allowed for the first time the capacity to move beyond the rules of Pasteur, using the 
computer resources to rationally design vaccines starting with information present in the 
genome, without the need to grow the specific microorganisms. This new approach was 
denominated Reverse Vaccinology (RV)37. 
The first pathogen addressed by the RV approach was Meningococcus B (MenB), a 
pathogen that causes 50% of the meningococcal meningitis worldwide, it can kill within 
24 hours and cause serious life-long disabilities38. This bacterium had been refractory to 
vaccine development because its capsular polysaccharide is identical to a human self-
antigen, whereas the bacterial surface proteins are extremely variable39. With the full 
sequencing of MenB genome, researchers were able to identify a priori with bioinformatic 
analyses the sequences of all potential surface located proteins. 600 potential antigens 
were produced and tested for antigenicity, revealing 29 previously unknown surface 
exposed proteins capable of inducing antibodies able to kill bacteria in vitro in the 
presence of complement. Up until that time, only 12 surface antigens of MenB were 
known, and of these, less than half showed bactericidal activity40,41, revealing the power 
of the new approach. In subsequent years, the antigens discovered by this approach 
inducing the best and broadest bactericidal activity were selected and inserted into 
prototype vaccines that were able to induce protective immunity against most of the 
MenB strains in mice42. After successful preclinical and clinical studies, the vaccine has 
been approved by the authorities of Europe, Canada, Australia and USA (2014) with the 
commercial name Bexsero. 
During the last decade, reverse vaccinology has been applied to many other bacterial 
pathogens, expanding the original scheme to take advantage of the latest technologies in 
sequencing and bioinformatics. It is the case of B Streptococcus, whose vaccine has been 
identified with a pan-genomic approach to account for sequence variability across the 
different strains, developing a combination of antigens which is able to protect against all 
serotypes43. The RV approach was also fundamental in the discovery of an effective vaccine 
for A Streptococcus. 
Part I – 2.3 State of the art 
 
10 
 
The intrinsic difficulty here was represented by the cross-reactivity of the antibodies 
induced against the pathogen, targeting human antigens. RV was essential to ensure that 
the selected antigens did not have homology to proteins encoded by the human genome44. 
A similar approach was being used also in the development of protein-based vaccines for 
other antibiotic-resistant pathogens, such as Staphylococcus aureus and Streptococcus 
pneumoniae, and vaccine against Chlamydia is in progress of development45. 
The Reverse Vaccinology strategy, with its early successes and fast improvements to the 
original formula, has therefore revived the expectations to conquer pathogens that were 
previously considered difficult or impossible to address following the traditional rules of 
vaccinology. 
Traditionally, live attenuated vaccines are likely to induce a long-term protection (at least 
a decade) against the disease46, and this may constitute one of their major advantages. 
However, when thinking of a live attenuated vaccine against melioidosis, it may prove 
difficult to license such a mutant for human immunization. B. pseudomallei has the 
potential to reach inside the cells of its host and persist for long periods of time (even 
years or decades), establishing latent infections and potentially revert into a life-
threatening bacterium. For this reason, among the approaches that are currently pursued 
to discover and produce an effective vaccine against B. pseudomallei, RV plays a crucial 
role. 
 
2.3   THE GtA CONSORTIUM: THE RV APPROACH AGAINST 
MELIOIDOSIS. 
 
Following a proteome wide scale study to identify proteins recognized in individuals who 
have been exposed to B. pseudomallei47, the project “From Genome to Antigen: a 
Multidisciplinary Approach towards the Development of an Effective Vaccine against 
Burkholderia pseudomallei, the Etiological Agent of Melioidosis” (GtA) was established. 
This academic consortium is devoted to the identification of a handful of B.pseudomallei 
antigens (i.e. 2 to 5) capable of eliciting a broad, sterilizing immunity and that could 
subsequently lead to the production of a vaccine against this life-threatening pathogen. 
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In the original work performed by Felgner et al.47, the authors fabricated a protein 
microarray containing 1,205 proteins from B. pseudomallei, probed it with 88 melioidosis 
patient sera, and identified 170 reactive antigens. After a second testing on a smaller array 
probed with a collection of 747 individual sera including material from melioidosis 
patients from different endemic and non-endemic areas of Thailand and Singapore, they 
were able to identify 49 antigens, that are significantly more reactive in melioidosis 
patients than in healthy people and in patients with other types of bacterial infections. 
One of the tasks addressed by the GtA project is the investigation of the immunogenic 
potential of each individual protein highlighted by this study, and in parallel use means 
of RV vaccinology to refine the original list and restrict all the efforts toward the most 
promising targets. In this regard, the GtA consortium has embarked into a deep study in 
the genomic and transcriptomic characterization of the bacterium. 
 
Thanks to a large multi-chromosomal genome, one of the largest and most complex 
among any species of bacteria, B. pseudomallei is able to persist and survive in a multitude 
of environments. The first strain to be fully sequenced, B. pseudomallei K96243, contained 
approximately 6,332 predicted coding sequences within 7.25 Mb of DNA spread across 
two circular chromosomes48,49. This large genome encodes an unparalleled arsenal of 
virulence factors, including three type III secretion systems (T3SS), six type VI secretion 
systems (T6SS), multiple antibiotic resistance factors, and at least four polysaccharide 
gene clusters, including a capsular polysaccharide48,50,51. In addition, the genome shows a 
high degree of plasticity, enabling the bacterium to acquire genomic islands by horizontal 
transfer. In an effort to research and discover effective vaccine component against this 
pathogen, a broad vision and understanding of the survival and pathogenesis mechanisms 
are necessary, to focus on the most effective candidate proteins. 
In this regard, comparison between B. thailandensis, a less aggressive environmental 
pathogen, seldom reported to cause melioidosis-like opportunistic infections, and B. 
pseudomallei genomes, may highlight the features responsible for the strong difference in 
virulence between the two species. Genomic studies have shown that, in spite of a strong 
difference in pathogenicity, B. thailandensis shares a large set of putative virulence factors 
with B. pseudomallei52,53 and may be considered an adequate model to study the 
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specificities at the expression level of the two species. Among the activities programmed 
for the GtA project, Peano et al.54 studied the B. thailandensis strain CDC2721121, a known 
clinical isolate55, and investigated its response to oxygen availability and different growth 
temperatures (28°C versus 37°C), mimicking host infection conditions and environmental 
conditions of tropical regions. The global gene expression and cell surface-associated 
protein productions were determined along with the assessment of motility and capsular 
polysaccharide production. 
Another transcriptional study was performed directly on B. pseudomallei56 via whole-
genome transcriptome profiling covering a broad spectrum of conditions and exposures, 
compiling a so-called “condition compendium”. The analysis confirmed many previously-
annotated genes and operons, and at the same time identified novel transcripts including 
anti-sense and non-coding ones. With a systematic approach of expression analysis, held 
with the comparison between different organisms and growing conditions, the search for 
putative antigenic proteins is going to be refined concurrently with integration of new 
data. In addition, the presence of specific conditions can help ascribe putative functions 
to previously uncharacterized genes and identify novel regulatory elements.  
Another important piece of the puzzle has been laid by Moule et al. with a comprehensive 
list of putative essential genes compiled by the construction of a mutant library of 
transposons, consisting of over 106 B. pseudomallei K96243 mutants and the sequence 
analysis of this library57. The list includes known housekeeping genes involved in primary 
metabolic pathways, as well as core lipopolysaccharide biosynthesis genes and many genes 
encoding hypothetical proteins that have not previously been established as essential. 
All these multi-disciplinary efforts contributed to the definition (and refinement) of a list 
of putative targets to be analysed individually by a second branch of the GtA consortium, 
that defines the framework of this thesis project. 
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2.4   STRUCTURAL VACCINOLOGY: FROM ANTIGEN TO EPITOPE 
 
Within the broad framework of the GtA project, which aims to identify a small number of 
peptide/protein antigens with protective potential against melioidosis, the RV approach 
for the identification of the best protein candidates plays a crucial role. Most importantly, 
GtA aims to demonstrate the feasibility of complementing RV with structural information 
on the selected antigens: this constitutes the basis for the rational design and/or redesign 
of novel biomolecules, such as peptides, modified antigens or their domains/fragments as 
actual vaccine components. This approach constitutes a new view of vaccinology termed 
Structural Vaccinology (SV).  
The SV approach combines structural biology, immunology and computational sciences 
to investigate all aspects of immune recognition from full-length antigens to epitopes. 
From the advent of DNA recombination, the focus of vaccinology has in fact gradually 
shifted from the full pathogen to a more rational approach concerning individual antigens, 
based on the principle that the immune system does not react against a pathogen per se, 
but recognizes specific antigens functioning as triggers for the elicitation of the host’s 
defences. The adaptive, long term immunity is no exception, and can be stimulated by the 
combination of potent immunogens in a unique vaccine. 
Although a significant protection can be achieved by the use of strong antigens such as 
bacterial lipopolysaccharide or glyco-conjugates15,58, these components cannot be 
processed and presented to the T-helper cells (CD4+), lacking the principal inductor of 
memory B cells. For this reason they may act as potent adjuvants but must be delivered 
together with a peptidic component, that is processed in the proteasome (for MHC type I 
fragments) or in the phagolysosome (for MHC type II fragments), and loaded on MHC 
molecules to be presented for recognition by CD8+ and CD4+ T cells respectively59,60. The 
short peptidic fragments used by the immune system machinery as beacons to activate 
the T cells are immunogenic epitopes. The antigen-antibody interaction, which is the 
mechanism at the core of the humoral immunity, is also based on the recognition of small, 
and very specific linear and/or discontinuous epitopes on the surface of the antigen. This 
recognition is at the basis of the recruitment and activation of the complement cascade, 
marking the pathogen for ingestion by phagocytosis (opsonisation), and forming a 
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membrane attack complex (MAC), transmembrane channels capable of causing the 
bacterial cell lysis60,61. In addition, the antigen-antibody recognition is essential in the 
mechanism of agglutination, where antibodies coating the bacteria form aggregates, thus 
recruiting other effector cells like phagocytes, mast cells, neutrophils and natural killers, 
actually clearing the infection by phagocytosis and an arsenal of cytotoxic molecules59,60. 
In this context, structure-based antigen design62, a fundamental constituent of SV 
techniques, has generated high expectations toward a ‘new era’ of fast and safe vaccine 
development. The approach relies on the concept that by knowing which parts of an 
antigen are effectively responsible for antigenicity, it is possible to engineer the native 
antigen to optimize its properties as vaccine candidate. In particular, identifying those 
components within the antigen structure that elicit protective immunity can potentially 
permit to carry out antigen manipulation driven by structural considerations (e.g., domain 
stabilization, conformational constraints). In this way, efforts toward vaccine 
optimization can be focused on those antigen regions that play a significant role in 
immunity62. As a further development of the SV approach, it may then be viable to select 
only the antigen regions able to elicit an immune response and translate them in the form 
of peptides, small proteins or conjugates as potential vaccine candidates. 
During the last decade, scaling down a vaccine from the full organism to the isolation of 
some key elements helped overcome the limitation of previous approaches and find a 
solution for those pathogens against which no effective vaccines existed (see previous 
chapter). Now the advent of computer-assisted and computer based methodologies for 
epitope prediction and modification allows further efforts toward structure-based antigen 
and epitope optimization, to improve over the use of the native antigen structure in 
different aspects. 
For instance, a landmark integration of atomic-resolution information with 
computational techniques was reported by Schief and collaborators working on a hybrid 
method for the grafting of functional motifs onto unrelated protein scaffolds to accurately 
replicate the antigenic surface recognized by target antibodies63-65. Epitope scaffolding 
strategy, by mimicking complex antigenic targets, might be particularly useful to 
reproduce discontinuous epitopes and enhance the extent of the immune response 
against antigens for which elicitation of antibodies has been demonstrated to be 
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particularly challenging. Indeed, the scaffold-supported antigen is ‘presented’ in a context 
that lacks pathogen defensive mechanisms that have evolved to elude the immune 
response66. In one example, the authors’ work focused on transplanting a two-segment 
discontinuous HIV gp120 epitope on a scaffold suitable to accommodate the additional 
motif without altering its original functional conformation63. Scaffold selection and design 
for optimal motif transplantation were computationally assisted, as well as the generation 
of a small set of mutagenesis libraries to undergo functional screening. The authors were 
able to generate a scaffold-bound motif displaying specificity and affinity for antibody 
recognition similar to the original gp120. This strategy may be then potentially suitable 
for using grafted epitopes as immunogens to elicit neutralizing antibodies. The plasticity 
of the instruments and methods of the latest SV strategies offer the chance to challenge a 
whole new level of biomolecular mechanisms, such as the maturation of a germline of 
broadly neutralizing antibodies (bNAbs). A similar strategy has been employed for VRC01-
class bNAbs, a recently discovered class of antibodies targeting the CD4 receptor binding 
site on the envelope protein of HIV67-70. These antibodies are detected in patients after 
years of maturation post infection, thus very unlikely to be elicited by a common vaccine 
unless through a complex and lengthy regimen of immunizations. In addition, the 
precursor antibodies for VRC01-class lack affinity for the wild-type envelope protein68,69,71, 
complicating the efforts to produce a vaccine capable of eliciting the maturation of these 
bNAbs. In a recent study from Jardine et al.72 computational interface design was used in 
combination with yeast display screening of computation-guided mutagenesis libraries in 
a process of maturation of the antigen, increasing the affinity for the antibodies and 
optimizing immunogenicity with nanoparticle-based antigen presentation. 
Another application of the antigen and epitope identification paradigm followed by 
rational design, is the adaptation of SV strategies to the search of vaccines against 
antigenically variable pathogens, such as the efforts made on antigen fHbp (factor H 
binding protein) of Neisseria meningitidis serogroup B (MenB). In this study, multiple 
epitopes from variants of fHbp were grafted on a single fHbp structure, in order to elicit a 
broad immunity across different strains73. Another study addressed the structure of type 
2a pilus (BP-2a) from Streptococcus Group B (GBS), identifying an epitope-carrying 
domain responsible for the elicitation of protective antibodies in six different protein 
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variants. From the 3D structure of one isoform, the authors synthesized a construct 
composed of all six epitope carrying domains from all variants, eliciting a broad protection 
in mice74. 
Aside from challenging currently untreatable or unpreventable infectious diseases, similar 
strategies may be pursued to explore non-conventional solutions to non-infectious 
diseases, such as neoplasias, and the increased safety demands from regulation authorities 
are encouraging new attempts to develop protein and peptide-based vaccines for a diverse 
set of diseases.  
 
In the framework of the GtA project on melioidosis, we tested and validated a novel SV 
approach for the identification and design of immunogenic epitopes from the structural 
data on antigens isolated from the bacterium and prioritized using the RV 
methodologies described in the previous chapter. 
 
2.5   THE DIGITAL REVOLUTION OF PROTEIN SCIENCE. 
 
Computational chemistry and computational biology were born by the combination of 
physical chemistry and structural biology with modern informatics and physics, and 
applied in a range of settings to assist in solving chemical or biological problems. The 
foundations of the theories and methods behind these disciplines date back to the 
discoveries in the history of quantum mechanics, and the first theoretical calculations on 
valence bonds by Heitler and London in 192775. Later books influencing the development 
of computational quantum theories applied on chemistry include works from Linus 
Pauling and E. Bright Wilson76, as well as Heitler77 and Charles Coulson78 . 
With the advent of efficient computer technology in the 1940s and 1950s, it first became 
possible to think of the solution of complex atomic systems wave equations as something 
realizable. The first ab initio calculations on diatomic molecules were performed in 1956 
at MIT using the Hartree-Fock approach with a minimal basis set. In parallel, a novel 
computationally-effective method to perform simulations of chemical particles and 
calculate statistical mechanical properties based on classical approximations was in 
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invented by Stanislav Ulam working on nuclear weapons projects at the Los Alamos 
National Laboratory, USA. The name Monte Carlo method, was given by Nicholas 
Metropolis after the Monte Carlo Casino79. This new method encompasses algorithms that 
rely on repeated random sampling in order to obtain the distribution of an unknown 
probabilistic entity, and were subsequently employed for the simulation of complex 
chemical and biological systems. Following the success of the Monte Carlo method, during 
late 50s and 60s, a novel method for the simulation of chemical and biological systems 
was theorized by Alder and Wainwright, despite the lack of computational resources for 
that time in order to fulfill the original vision80. The Molecular Dynamics method, as it 
was named, was (and is) not intended for the simulation of atomic systems by the 
approximation of the actual wave function; rather, it starts from the assumption that an 
atomistic system may be approximated to the rules of classic mechanics and treated 
according to their chemical properties, maintaining their functional characteristics intact. 
In this scenario, the position and force interactions of the simulated particles evolve 
through time according to a set of parameters set in the Force Field. 
Nowadays, the advancing pace of computer science providing better computational 
capabilities at a continuous rate, along with the modern software implementations, are 
helping the solution of a whole new level of chemical and biological challenges. The 
modern methods of computational chemistry allow the generation and the manipulation 
of novel or existing molecular structures, with a range of applications that include the 
theoretical investigation of physico-chemical properties of biological macromolecules, to 
the practical design and simulation of new pharmaceutical compounds. 
With regards to the investigation of complex biological systems, like ligand-receptor 
interactions or cell membrane simulations, the principal methods employed are still based 
on classic potentials, such as Molecular Mechanics, Molecular Dynamics and Docking 
algorithms, but the scale of the system is rapidly changing, allowing to perform 
computationally demanding calculations in a reasonable amount of time. Outstanding 
examples include the use of parallel GPU computing to obtain the first complete atomic 
structure of the HIV capside, composed of more than 64 million atoms81, and the 
introduction of new supercomputers like Anton, allowing to crack the realm of the 
millisecond simulations for conventional protein systems in 200982.  
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Such technical accomplishments are not merely technological showcases, but are followed 
by a parallel non-linear growth in the number of deposited and freely accessible protein 
structures data, including an increasing number of protein and protein-nucleic acid 
complexes, and full biological assemblies. As of September 2014, the Protein Data Bank 
features more than 100,000 protein structures, with a growing pace of almost 10,000 
structures deposited in the last year and 2,200 items referred to human elements83. The 
increasing amount of data coupled to the latest computational resources are a precious 
tool in service of molecular modeling, simulation and design approaches, crucial to the 
field of Structural Vaccinology, as reported in the previous chapter.  
 
2.6   MOLECULAR SIMULATIONS: APPROACHES, FUNCTIONAL 
FORMS, POTENTIAL AND LIMITATIONS. 
 
As it is not possible to observe and interact with individual atoms or molecules directly, 
computational chemistry can help describe and/or predict the properties of a system by 
modeling. Every molecular system presented in a computational model will be strongly 
dependent upon the sophistication of the model itself. Since a higher fidelity comes at the 
price of computational resources and simulation time, it is common practice to choose 
the simplest representation that will illustrate the property of interest satisfactorily. Since 
all macromolecules (DNA, proteins, lipids, etc.) are dynamic entities, most experimental 
properties can be investigated by reconstructing the motions or dynamics of a molecule 
numerically. This can be done by computing a trajectory, i.e. a series of molecular 
configurations as a function of time by the simultaneous integration of the Newton’s 
equations of motion. MD simulations are set to explore the time dependent behavior of 
atomic and molecular systems, providing a detailed description of the way in which that 
system changes from one conformation or configuration to another. Importantly, 
simulations can generate ensembles of representative configurations in such a way that 
accurate values of structural and thermodynamic properties can be obtained with a 
reasonable and feasible amount of computation. 
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In Molecular Dynamics simulations, the motions of the particles obey the laws of classical 
mechanics, which is a suitable approximation for a wide range of applications where 
electronic motions and reorganizations are not involved (i.e. chemical reactions cannot 
be studied). This includes complex biomolecular systems or material science to the study 
of polymers. Each iterative configuration of the system is generated by the application of 
Newton’s laws of motion (F = ma) for every atom in the system. The end result is a 
trajectory that specifies the variation of the positions and velocities of the particles in time, 
and the properties of interest are calculated as time or ensemble averages. 
Newton’s second law is actually a differential equation that can be re-written as: 
 
i
xi
m
F
dt
xd
i
2
2
        (1) 
 
which describes the motion of particle i of mass mi along coordinate xi, and subject to the 
force Fxi  originating from the presence and interaction of all other particles in the system 
with atom i. The force can be expressed as the negative derivative of a potential function 
V(r1, r2, r3, .. rN) describing the fundamental types of interactions in the system.  
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         (2) 
 
In this case, V can be considered as the potential energy of the system as a function of 
atomic positions. The equations are solved simultaneously in small time steps, dt. The 
system is followed for a settled time, keeping the number of particles constant, and 
temperature and pressure at the required values (NPT conditions). The coordinates are 
written to an output file at regular intervals generating the trajectory.  
A typical potential function for all-atom protein simulations is expressed in the form: 
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The potential V reported through equation 3 is called Force Field (FF)84,85. Throughout the 
projects reported in this thesis, we use predominantly the GROMOS 53a6 force field as 
implemented in the Gromacs Package86. Each term describes a pairwise relation, taking 
into account the physico-chemical interactions present in the system. In particular: 
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This term describes the vibrations of covalent bonds around their equilibrium positions 
b0. In a classical framework, the vibration is simply expressed in the form of harmonic 
potential with a spring constant Kb, since the strength of the bond only allows slight 
fluctuations around the equilibrium values. 
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An analogous formulation for the description of the angular vibration around the 
equilibrium position. 
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This term is used to describe dihedral dependencies within the molecule. The "improper" 
dihedral term, also expressed with harmonic potential, functions as a correction factor for 
out-of-plane deviations (e.g. to keep benzene rings planar). The dihedral potential for 1-4 
torsions is described by a cosine expansion and may take any value within 360° depending 
on the height of the barrier between the low energy conformations, which makes the 
precision of the dihedral potential barrier crucial for many polymer properties. 
 
 )4/(/),(/),( 0661212
),(
ijrjiijij
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The final term in the equation describes all non-bonded interactions. The first term is a 
Lennard Jones potential, taking into account Van der Waals interactions, while the second 
one is a formulation of the classical Coulombian electrostatic potential between two 
charges. 
The Force Field is dependent upon various parameters, defining equilibrium distances or 
force and dielectric constants. The parameters are determined by either experimental 
data, or by fitting to high level ab initio calculations. Due to their parametric nature, the 
Force Fields are continuously updated and refined to approximate effectively one or more 
properties of the system they intend to represent. Adding complexity to a FF to increase a 
model’s fidelity does not automatically produce better simulations, while it automatically 
increase the computational cost (and time). Thus, the choice of the Force Field must be 
carefully tailored on the specificity of the system. 
 
The initial state of an MD simulation is the assignment of positions and velocities to all 
atoms/particles in the system. In the case of all protein simulations performed for this 
thesis project, the initial positions coincide with the structural coordinates present in the 
PDB file, surrounded by a pre-equilibrated solvent bath of water molecules enriched with 
Na+ or Cl- counterions to neutralize the protein net charge. Each atom is assigned a 
velocity according to a uniform Maxwellian distribution of velocities consistent with the 
temperature at which the simulation will be run. 
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Ideally, a simulation should be able to reproduce the behavior of an infinite system, so 
that macroscopic quantities would be calculated straightforwardly. This is totally out of 
reach even for the most powerful computers, and one has to study finite-size systems 
characterized by some boundaries. In order to compensate for this limitation, we used 
Periodic Boundary Conditions (PBC) to represent our systems. 
PBCs enable a simulation to be run using a relatively small number of particles, in such a 
way that the particles experience interactions and forces as if they were in a bulk fluid. A 
simple representation of a PBC box of particles is shown in Figure 4. 
The simulation box is replicated by translation at 
the edges in a series of image boxes, identical in 
all aspects to the original one. If a particle leaves 
the box during a simulation, it will be replaced by 
its image coming in from the opposite side of the 
box. The number of particles in the simulation 
box remains fixed, but the solvent behaves as a 
bulk with no border effects.  
PBC conditions are a convenient solution to a 
major limitation of atomistic simulations, but are 
not free from drawbacks. For instance, the range 
of the interactions in the system may be a 
problem when considering long-range potentials 
such as the electrostatics. A common solution 
relies on the use of truncation or cutoff 
approximations to the treatment of long-range 
forces, to avoid generating artefacts such as having a particle interacting with its own 
periodic image (and so with itself). 
When the simulation starts, at each step the algorithm calculates the forces acting on 
every atom then integrate Newton’s equations of motion to calculate the position of the 
particles at the given time step (equation 1), building the trajectory.  
 
 
Figure 4: Example of a bi-dimensional 
PBC box containing moving particles. In 
order to render the system as a continuous 
one, the original box (blue background) is 
replicated by translation as virtual images 
located adjacent the edges. The velocity 
and interaction forces calculated on every 
particle (e.g. the particle at the centre of the 
black circle) are dependent upon the 
position of the nearest particles inside the 
box and the nearest image particles present 
in the image boxes.  
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2.7   EPITOPES AND SIMULATIONS 
 
Antibody-binding epitopes are conventionally classified as continuous, i.e. sequential and 
relatively short peptides from the protein sequence able to bind anti-antigen antibodies, 
or discontinuous, i.e. patches of atoms/fragments from not contiguous protein regions 
which are brought to close proximity by protein folding and whose antigenicity depends 
upon the protein conformation. It is worth underlining that epitopes do not exist as 
discrete and structured entities, but rather have fuzzy boundaries and are defined by their 
functional ability to bind antibodies87. While continuous epitopes can in theory be 
predicted out of the protein sequence by consensus of available datasets of immunogenic 
peptides88, the prediction of discontinuous epitopes relies upon the knowledge of the 
protein 3D structure. Over the last few decades, several approaches have been tested to 
run epitope predictions from protein structure. Some groups attempted to correlate 
antigenicity with protein region properties such as solvent accessibility or flexibility89,90. 
Electrostatic desolvation profiles (EDP) method hypothesizes that surface protein regions 
with a small free energy penalty for water removal may correspond to preferred 
interaction sites and may, accordingly, in the case of antigens, constitute binding sites for 
antibodies91. 
Others based their approach on identifying those regions that protrude out of the protein 
globular surface and relating them to antigenicity92,93. In a reverse approach, Molina and 
colleagues targeted the identification of epitopes within the protein structure through a 
bioinformatic analysis of sets of mimitope sequences, i.e. randomly generated peptides 
mimicking epitopes functional antibody recognition properties94. By integrating 
mimitopes’ alignments and consensus, the authors were able to identify the original 
epitope regions targeted by antibodies within the native antigen in a series of case models 
where antibody–antigen crystal structures were available.  
 
In this direction, our group has recently developed a new way to approach in silico epitope 
prediction based on the integrated analysis of the energetic properties of an antigen, 
namely Matrix of Local Coupling Energies95 (MLCE). MLCE integrates the analysis of the 
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energetic properties of proteins to identify interaction-networks on the surface of the 
isolated antigens. Such networks correspond to conformational patches that can aptly be 
recognized by a binding partner (i.e. the antibody molecule). MLCE was designed to select 
the protein substructures presenting a low energy contribution to the general protein 
stability, formally representing those sites in which interactions networks are not 
energetically optimized. According to the low intensity constraints to the rest of the 
protein, these substructures are characterized by dynamic properties allowing them to 
visit multiple conformations, a subset of which can be recognized by the antibody96,97. 
 
From the computational standpoint, MLCE is based on the calculation of the matrix Mij of 
inter-residue non-bonded interaction energies between residue pairs (thus including only 
van der Waals forces and electrostatics) using a MM-GBSA (Molecular Mechanics 
Generalized Born Surface Area) approximation for implicit solvent treatment. The analysis 
is performed on individual structures visited during an MD trajectory. 
According to the Energy Decomposition method98, all diagonal elements of self-
interactions are neglected, and the matrix Mij is diagonalized and re-expressed in terms of 
eigenvalues and eigenvectors, in the form: 
 

Mij  kwi
kw j
k
k1
N
         (4) 
 
N is the number of protein aminoacids, λk is the eigenvalue associated with the k-th 
eigenvector, and wik is the i-th component of the associated normalized eigenvector. 
Eigenvalues are labelled following an increasing order, so that λ1 is the most negative. 
Throughout this thesis, we refer to first eigenvector as the eigenvector corresponding to 
the eigenvalue λ1. The total non-bonded energy Enb is defined as: 
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And since Mij can be effectively approximated98,99 by: 
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        (6) 
 
The total non bonded energy can be expressed as: 
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From this we can recover an approximation to the global stabilization energy, Enbapp, that 
was shown to correlate with the relative different stabilities of mutants of several test 
proteins99. This method provides information on the mean coupling energy between two 
residues in the native state, revealing the network of most interacting and non-interacting 
residues throughout the structure, whose mutation would have a profound impact on the 
stability of the protein. 
Taking from this analysis, the MLCE methods intersects the energy matrix Enbapp with the 
contact map of the representative structure from MD. The contact map (also referred as 
neighbouring list) is a binary representation of proximity between any two residue pair 
inside the conformation. If the distance between Cβ atoms of any two amino acids is below 
a cut-off value, the corresponding matrix entry is set to 1, otherwise it is set to 0. The 
distance cut-off is set to 6.5 Å. For the sake of homogeneity with the energy matrix, also 
contacts between nearest neighbours i, i+1 are included.  Therefore: 
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The matrix resulting from the intersection of the simplified energy matrix and contact 
map is an energy matrix presenting only the local contributions of non-bonded 
interaction, highlighting pairs within the contact cut-off that are energetically coupled or 
uncoupled. This matrix is referred as the Matrix of Local Coupling Energies95 (MLCE). 
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The coupling interactions inside MLCE are ranked in increasing order according to their 
respective intensities (from weaker to stronger). Starting from the minimum value 
(weakest local coupling interactions), the set of putative interaction sites was defined by 
including increasing residue-residue coupling values until the number of couplings 
corresponding to a given threshold. According to the benchmark95, the optimal threshold 
varies from 10% to 20% of all low-energy pairs, and is set to 15% as standard value. This 
corresponds in our approximation to the set of local interactions with minimal intensities, 
and accordingly they could represent those localized regions that are less energetically 
coupled with the rest of the protein, and that consequentially fit basic criteria for 
representing epitope candidates. The method in its full implementation for the prediction 
of epitopes from the 3D structure of an antigen is named BEPPE (Binding Epitope 
Prediction from Protein Energetics), and it has been chosen along with the EDP profiles 
as a key resource for the identification of antibody-binding sites inside the GtA project. 
Within a broad Structural Vaccinology initiative, the use of modern day computational 
methods for simulation and prediction represent an attractive and challenging 
opportunity for both the identification of epitopes and the structure-based rational design 
of immunogenic peptides. 
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3 - AIM OF THE PROJECT 
 
 
 
 
 
 
 
 
 
The aim of this project, in the broader framework of GtA, may be subdivided into four, 
distinct main objectives. 
First, my research work aims at providing the GtA project with the computational 
resources necessary to identify putative binding epitopes with immunogenic potential. 
The relevance of this task becomes clear when considering the GtA project in a global 
view, since the first element required to its Structural Vaccinology approach is to connect 
the 3D structure of one antigen to information on predicted binding epitopes. Once the 
epitopes are defined, a second step takes place, focused on the rational design of effective 
vaccine-like components starting from the prior knowledge of the antigen structure and 
the epitopes location. This endeavor aims to develop an interdisciplinary research 
pipeline, comprehensive of structural biology, molecular biology and computational 
chemistry, to fill the gap between structure and epitopes. Therefore, one of the main 
objectives of my project is to integrate different computational methods in the definition 
of such pipeline. The methods to be employed revolve around the Molecular Dynamics 
From now on we live in a world 
where man has walked on the 
Moon. It's not a miracle; we 
just decided to go. 
James A. Lovell. JR. 
commander of Apollo 13 
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simulation approaches, Homology modeling and the energy-based computational method 
for analysis and prediction of antibody-binding sites defined by Scarabelli et al.95 
The second main objective of this project is the expansion of such defined pipeline beyond 
its original concept, integrating novel functionalities and exploring different application 
scenarios. Specifically, the energy-based predictor originally designed and validated for 
antibody-binding sites will be extended and adapted to the prediction of MHC-II loaded 
epitopes. A similar functionality is extremely desirable, not only in the perspective of a 
unique, comprehensive tool for epitope prediction, but also in the specificity of 
melioidosis infections. As described in chapter 2.1, antibodies and T-helper response are 
the primary routes for recovery and sterilizing immunity. Another significant expansion 
of the original concept will be explored in the application of the predictive pipeline in the 
field of immunodiagnostics, to identify epitopes with the potential to be employed as 
biomarkers in a diagnostic tool. 
The next objective is right downstream of the predictive pipeline. Once an immunogenic 
epitope is identified, it may be conveniently designed into a mimic of the original protein, 
in order to maintain the epitope in a stable and soluble form, retaining its original folding 
conformation and displaying maximal exposure to the immune system. Such a design will 
be the third objective of this project. 
The fourth and last aim of this project is more general, and is not strictly related to the 
development of a vaccine against melioidosis, but is equally relevant. Starting from the 
experience gained with energy-based predictor of binding epitopes, the reach of my 
studies has been expanded to include a dataset of interacting proteins and explore in detail 
their interaction energetics, both at the inter-molecular and intra-molecular level. The 
purpose of such a comparison is the identification of an energetic property, indicative of 
the productive positioning of possible PPI patch. Such property would therefore be 
employed as a descriptor of the interaction process, leading to the development of a 
computational tool for the analysis and the prediction of this interaction property. The 
method, once validated, may be employed in a range of applications, from the ab-initio 
characterization of PPIs, to protein-protein docking algorithms, to the evolutionary and 
functional investigation of interactions.
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4 - MAIN RESULTS 
 
 
 
 
 
 
 
 
 
 
 
In this chapter, I will summarize the results and perspectives of the works presented in 
PART II in the form of published or submitted articles, putting them in their proper 
context within the global framework of the project and according to the four main 
objectives stated in section 3. I will also present the results of one work still unpublished 
and in phase of completion. 
 
4.1   DEFINING THE STRUCTURAL VACCINOLOGY PIPELINE 
 
As described in Section 3, the initial focus of the project was on the definition of a working 
pipeline going from the structure of the antigen to the identification of immunogenic 
epitopes. Based on the results of a seminal study based on protein microarrays to 
investigate the interaction of the host immune system with B. pseudomallei over 1,000 
proteins47, our shortlist of antigenic candidates was composed of 49 proteins. 
The most exciting phrase to 
hear in science, the one that 
heralds new discoveries, is not 
'Eureka!' but 'That's funny...' 
Isaac Asimov 
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Among the first antigens to be further studied for their immunogenic properties, we 
considered the oligopeptide-binding protein A (OppABp)100. 
OppABp is part of an ATP-binding cassette (ABC) transport system, a group of proteins 
regarded as potential targets for the development of therapeutic interventions against 
bacterial infections, given their key role in bacterial survival, virulence, and pathogenicity. 
Components of several ABC transporter systems, from both Gram-negative and Gram-
positive bacteria, have been proposed as candidates for vaccine development because they 
were shown to react with convalescent patient sera101,102. OppA is part of the oligopeptide 
transport system OppABCDF involved in nutrient uptake and recycling of cell-wall 
peptides103. The transport system consists of five subunits: two integral membrane 
proteins forming the pore, two proteins responsible for ATP hydrolysis, and a substrate-
binding protein (SBP)103. OppA is a receptor, or substrate-binding protein, and determines 
the recognition properties of the system, delivering the substrates to its cognate-binding 
partners. Previous studies on OppA from different pathogens revealed that OppA from 
Listeria monocytogenes is a virulence factor important for intracellular survival104 and that 
OppA from Yersinia pestis is a protective antigen102. With regard to OppABp, it is 
recognized by T cells primed by B. pseudomallei, triggers IFN-γ production, and stimulates 
both humoral and cell-mediated responses. However, sera raised against OppABp failed to 
offer protection in a mouse infection model22. Therefore, OppABp is seen as a suitable 
target for structure-based antigen analysis and improvement of its antigenic properties, 
and was chosen as a reference protein for the definition of our Structural Vaccinology 
pipeline. In this framework, we studied the crystal structure of OppABp (gene access 
BPSL2141) determined for residues 39-554 at 2.1 Å resolution (Rgen and Rfree values of 
15.8% and 20.9%, respectively), devoid of its predicted signal peptide (residues 1–38). The 
3D structure of this protein, as inferred from its density map, is shown in Figure 5, and is 
composed of two lobes, comprising respectively domains AB and C. 
Part I – 4.1 Main results 
31 
 
 
 
Concerning the epitope prediction and detection, we used three different methodologies, 
two of them consisting in computational methods, and relying on the solved 3D structure 
and subsequent MD simulation, while the last one consisted of an experimental epitope 
mapping. The first computational method, named BEPPE, is an energy-based predictor 
for antigenic epitopes based on the MLCE approach, as described in section 2.6. The 
second computational method, named Energy Desolvation Profiles91 (EDP), is more 
general, having been developed to identify protein-protein interaction interfaces based on 
the desolvation potential on the surface of proteins, and is being validated for antigen-
antibody interactions. 
The third, experimental method to be used for the mapping of epitopes used recombinant 
OppABp and cognate polyclonal sera.  The approach involves proteolytic digestion (using 
diverse proteases) of the target antigen prior to immunocapturing and subsequent 
analysis of antibody-bound peptides by mass spectrometry. The sera collected from three 
immunized mice were independently analyzed and produced identical results. From the 
computationally predicted epitopes we drew a consensus prediction leading to the 
identification of three epitopes (COMP1, COMP2 and COMP3). Similarly, three epitopes 
were identified via experimental mapping (EXP4, EXP5, EXP6). All six epitopes were 
produced in the form of BSA-conjugated peptides, and tested for immunoreactivity, 
against sera collected from 19 healthy donors (subdivided in seronegative and seropositive 
 
 
Figure 5: Tertiary structure of 
OppABp. Secondary structure 
ribbon representation of OppABp 
bound to its tripeptide ligand 
(purple balls-and-sticks). Domains 
A, B and C are illustrated in yellow-
red and green, respectively. β 
Strands, α helices, and 310 helices 
are labeled S1–S17, H1–H15, and h1–
h7, respectively. The N and C 
termini (N term and C term, 
respectively) of OppABp are labeled. 
This figure was generated using 
PyMOL. 
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categories) and 20 cases of melioidosis recovery. The results of this test are displayed in 
Figure 6, showing for epitopes COMP1-3 a generally higher reactivity against the recovery 
sera. COMP1 and COMP3, in particular, were significantly recognized by plasma from 
seropositive subjects, and interestingly, the reactivity in COMP3 was sufficiently diverse 
in the three groups to indicate some discriminating potential if used as a biomarker tool.  
The EXP4–EXP6 peptides showed a distinct reactivity pattern toward plasma of all three 
groups. In fact, the EXP peptides reacted strongly with the plasma from asymptomatic 
healthy patients relative to the seronegative individuals. Particularly, EXP5 and EXP6 were 
not significantly recognized by the plasma from recovered subjects, hinting at the 
potential application of both peptides for discriminating between asymptomatic versus 
clinical melioidosis in endemic areas. 
From the results of the epitope prediction and mapping, we learnt that both 
computational and experimental means are effective in the identification of immunogenic 
antibody binding sites. 
 
Figure 6: Antibody response to B. 
pseudomallei OppABp epitopes in 
plasma of healthy and recovered 
melioidosis subjects: Crude B. 
pseudomallei antigen (A), recombinant 
OppABp (B), and synthetic peptides 
COMP1 (C), COMP2 (D), COMP3 (E), 
EXP4 (F), EXP5 (G), and EXP6 (H) were 
coated onto ELISA plates and probed 
with diluted plasma samples of healthy 
seropositive individuals (S+; n = 12) 
tested by means IHA (titer >40), healthy 
seronegative individuals (S-; n = 7), and 
recovery melioidosis individuals (R; n = 
20), and quantified by indirect ELISA. 
Data represent the absorbance index (AI) 
of individual samples = (OD tested - OD 
uncoated) / OD uncoated. 
Experiments were performed in 
duplicate, and results represent mean 
(AI) ± SE, Mann-Whitney U test; *p < 
0.05, **p < 0.01, and ***p < 0.001 values. 
ns, not significant. 
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Immunocaptured fragments are only restricted to linear stretches, while computational 
methods are able to identify conformational epitopes, that are composed of amino acids 
in proximity within the 3D structure, even if not close on the primary protein sequence. 
Conversely, the experimental technique is able to identify potential epitopes located 
inside the core of the protein (EXP4, EXP5), while MLCE and EDP are restricted to the 
analysis of the protein solvent accessible area. For this reason perhaps, in addition to the 
large size of the protein, we were not able to draw a consensus between the experimental 
and computational predictions, having only three amino acids in common between 
COMP1 and EXP6. In order to test the validity of the computational predictions in 
replicating the results from the experimental protein digestion and immunocapturing, we 
modeled the protein digestion in silico using an energy-based domain decomposition 
approach that allows in silico dissection of a folded protein into smaller fragments105. The 
underlying hypothesis is that such fragments expose sequence stretches that may be 
targeted by antibodies under conditions of partial unfolding or degradation of the antigen 
protein. Application of the domain decomposition algorithm allowed us to identify six 
cleavage boundaries and cluster the results into three different protein fragments which 
partially overlap with the OppABp structural domains. EXP4 and EXP6 peptides are 
entirely contained in fragments A’ and C’, respectively, whereas EXP5 extends across 
fragments B’ and C’. MLCE and EDP predictions were then applied to the isolated 
fragments, identifying potential epitopes that very satisfactorily overlap with the peptides 
identified by immunocapture (Figure 7). 
Working with OppABp we were able to define our prediction and testing pipeline for 
immunogenic epitopes: the first step is the determination of the antigen’s 3D structure, 
followed by a computational characterization via Molecular Dynamics simulations. The 
representative conformations extracted from the clustering procedure of the simulations 
lay the basis for a computational prediction via MLCE and EDP methods. In parallel, an 
experimental epitope mapping is performed on the full antigen.   
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All three prediction and mapping methods have weaknesses and differences, so a 
consensus must be drawn between all three techniques in order to minimize the possible 
impact of false positives. In case of large, multidomain proteins, if a consensus is indeed 
not reached, another computational approach based on domain decomposition may help 
define a consensus not solely based on solvent exposed epitopes. While this is clearly a 
secondary concern when thinking of antibody binding sites, it may hint at the potential 
of predicting T-cell epitopes (see section 4.5).  
Figure 7: Energy-Based Domain Decomposition of OppABp and Epitope Prediction. The 3D structure 
of OppABp is shown with the defined fragments A’, B’ , and C’ highlighted in yellow, red, and green, 
respectively. The fragments predicted through the decomposition algorithm are also shown individually in 
the shaded circles. The epitope regions mapped by immunocapture (EXP4, EXP5, and EXP6) are highlighted 
in light blue in both the full structure and in the individual fragments. Regions of the EXP epitopes matching 
those predicted by MLCE plus EDP on the isolated fragments are shown in dark blue and marked by arrows. 
Part I – 4.2 Main results 
35 
 
From the analysis of the immunoreactivity of the predicted and synthesized epitopes, it 
appears very likely that this pipeline may be employed in the successful determination of 
immunogenic epitopes, to be tested in vitro for opsonic killing activity. In addition, the 
differential reactivity of COMP3 against seronegative, seropositive and recovered 
melioidosis patients, suggested the possibility to employ the same pipeline in the 
serodiagnostic field (see section 4.4). 
 
4.2   APPLICATION OF THE SV PIPELINE TOWARD THE IDENTIFICATION 
OF ACTIVE EPITOPES. 
 
The work carried out on OppABp antigen allowed the validation of our pipeline from the 
solved 3D structure to the serological tests for immunoreactivity of epitopes. 
Unfortunately, the reactivities of the epitopes identified within this protein were not 
strong enough to justify further tests on this candidate, so we moved on according to the 
priority list. During the three years of this project, our collaborators in Univeristat 
Autònoma de Barcelona, University of Exeter and CNR-ITB, in charge of refining the 
shortlist of antigens through RV applications, modified and restricted the original list. 
Initially comprising 49 antigens, the list was updated at multiple steps, reaching in 2013 
the number of 21 targets, subdivided in acute phase antigens (15) and chronic infection 
antigens (6), and sorted in priority according to expression and antigenicity (Table 1). 
We concentrated our efforts on high priority proteins specifically expressed in the acute 
phase of infection. The first protein in the list is a hemolisin-related protein weighing 
325kDa (3,229 amino acids), extremely challenging to study at the structural level. 
Eventually, during the last two years of this project we analyzed seven antigens, for many 
of which the work is still in progress at different levels of completion: BPSL2765, 
BPSL1445, BPSL2520, BPSL3319, BPSL0919, BPSL1050 and BPSL2063 (being respectively 
number #2, #3, #4, #6, #7, #9 and #12 in priority).  
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The first protein we analyzed is priority #2, BPSL2765, also referred as OmpABp or PalBp, 
since it exhibits high similarity to members of the peptidoglycan-associated lipoprotein 
(Pal) family, involved in maintaining outer membrane integrity and the import of selected 
organic nutrients. In this work106 we applied the prediction and testing pipeline validated 
in the OppA study, using the same computational methods (MLCE and EDP), along with 
the immunocapturing epitope mapping. In the process we identified three putative 
epitopes, one of which based on a full consensus of all three techniques. The resulting 
epitopes were produced in free and BSA-conjugated form, and tested for immunogenicity. 
The results of the test can be seen in Figure 8, panel A. The epitopes were challenged with 
antisera collected from healthy donors, once again subdivided in seropositive and 
seronegative, and patients who recovered from melioidosis. The reactivity against the full 
protein was used as a reference, and according to the image, it is worth noting that the 
reactivity of EPITOPE 3, the consensus one, is proportional to the reactivity of the entire 
protein, both in intensity and in the ability to discriminate between the three categories 
of individuals. For this reason, this epitope moved to the next phase, the test for opsonic 
Table 1: Shortlist of highest-priority antigens of GtA. The proteins are subdivided according to their 
disease stage. Acute phase antigens are displayed on top (red), chronic stage antigens are shown at the 
bottom (yellow). For each protein the gene name is also reported, along with a brief annotation and the 
protein length (number of amino acids). 
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killing activity (OPK). Antibodies against EPITOPE 3 were produced in rabbit, and added 
to cultures of neutrophils incubated with B. pseudomallei, evaluating the phagocytosis 
rate, oxidative burst response and total bacterial killing at increasing concentrations of 
anti-EPITOPE3 antibody (Figure 8, panel B). In addition to the OPK, an agglutination test 
was also performed with the same antibodies (Figure 8, panel C). According to results, the 
antibodies raised against the epitope are active in stimulating the immune response in 
multiple ways, helping the neutrophils clear the culture from the bacteria even in absence 
of the complement system, and triggering an agglutination response even stronger than 
the activity registered with antibodies raised against the full protein. For all these reasons, 
EPITOPE 3 from BPSL2765 appears like an ideal candidate for structure-based design for 
improvements, and for immunization tests in animal models. 
 
Figure 8: Antibody reactivity of epitopes 1-3 from PalBp and OPK/agglutination tests of anti-
Epitope 3 antibodies. A) antibody response to PalBp protein and peptides in plasma of healthy and 
recovered melioidosis subjects. B) Anti-EPITOPE 3 Increased phagocytosis, oxidative Burst, and B. 
pseudomallei killing by Human Neutrophils. Overall percentages of phagocytosis and oxidative burst by 
flow cytometry and total bactericidal activity by standard colony counting from three healthy subjects, 
assayed in the absence or presence of anti-Epitope 3. Data represent means ± SE; *p < 0.05. C) 
Agglutination of B. pseudomallei after Exposure to PalBp or anti-Epitope 3. RFP-expressing B. pseudomallei 
or E. coli were incubated with 1 mg of antibodies for 30 min at 37 C. Bacterial agglutination was observed 
under epifluorescence microscopy, and the images are representative of three independent experiments. 
Arrows indicate agglutination of B. pseudomallei after incubation with PalBp. 
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Another high-ranked candidate to be extensively analyzed was BPSL1050 (priority #9) 
(see section 10.2 of PART II), an uncharacterized protein of unknown function and novel 
structure with no annotated analogues in the Protein Data Bank or on the UniProt 
repository. The 3D structure of this protein was determined via NMR at San Raffaele 
Scientific Institute, producing a bundle of 20 structures, accounting for some 
conformational flexibility, especially in the long loops contained in the protein fold.  
The regular approach for epitope prediction, validated with a high-resolution structure 
solved via diffractometric techniques, involves the simulation of the NMR-structure in 3 
all-atom MD replicas, covering a simulation time of 50ns each at 300K and explicit water. 
In this case, the protocol was adapted using as starting coordinates for the replicas the 3D 
conformations of the first 3 structures in the bundle. The analysis of this target was also 
extended to include the characterization of the internal dynamics properties of the protein 
in terms of the principal motions (Essential Dynamics107) and the mechanical 
coordination among different protein parts (Communication Propensity108), suggesting 
an interesting convergence between NMR and computational characterization of the 
protein dynamic activity. In this case, the epitope prediction and mapping highlighted 
two epitopes, namely L1050#1 and L1050#2. The epitopes were synthesized in free form 
and BSA-conjugated for the serological test, as well as KLH-conjugated for rabbit 
immunization and production of antibodies. The peptide reactivity against human sera, 
carried out in the same conditions as previously tested with OppABp and PalBp denoted a 
poor reactivity of the full protein and the two epitopes in patients’ and donors’ sera (Figure 
9 panel A). 
It is however worth of notice that L1050#2 could show an appreciable increase in intensity, 
compared to the signal of the full protein, indicating one of the advantages of scaling from 
antigen to epitope: the immune response elicited by the single epitope may vary compared 
to the response induced with the native antigen. Antibodies were raised against the 
epitopes and subsequently tested for specificity (they must be able to recognize the full 
antigen to be protective) (Figure 9 panel B), as well as in agglutination experiments 
(Figure 9 panel C). While the antibodies appear perfectly able to recognize the protein, 
they are also marking cross-reactive signals with the peptides, indicating a poor specificity 
(especially for L1050#1). 
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Figure 9: in vitro characterization of peptides 
1050#1, 1050#2 and antibodies anti-1050#1, anti-
1050#2. A) Antibody response to BPSL1050 protein and 
peptides in plasma of healthy and recovered melioidosis 
subjects. 
B) Recognition of rabbit anti-L1050#1 and anti-L1050#2 
sera to BPSL1050 protein/peptides detection by ELISA. 
Crude Bps antigen, BPSL1050 protein, peptides L1050#1 
and L1050#2 were individually coated into 96-well 
polystyrene plates. 0.5 ug/ml of either un-immunised 
rabbit sera or sera from rabbits immunised with L1050#1 
(hatched bars) or L1050#2 (solid bars) were tested in 
duplicate for binding to the plate-immobilised antigens. 
Rabbit antibodies were detected using a suitable HRP-
anti-hIgG conjugate. 
C) Agglutination of B. pseudomallei after exposure to 
antibodies raised against BPSL1050 or L1050#1 and 
L1050#2. RFP-expressing B. pseudomallei was incubated 
with 1 µg of antibodies for 30 min at 37°C. 
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The agglutination test, on the other hand, is delivering nice agglomerates for both 
antibodies against both epitopes. The preliminary results on this protein are not 
sufficiently promising to consider this protein one of our main candidates as a possible 
vaccine component (unlike EPITOPE 3 from PalBp), although L1050#2 and the two 
antibodies raised against the designed peptides may function as an adjuvant or could be 
employed as serodiagnostic tools, similarly to OppABp Epitope 3. 
Concerning the other cadidates, namely BSL1445 (#3), BPSL3319 (#6) and BPSL0919 (#7), 
we followed a similar approach for epitope discovery, for which we are currently 
producing experimental data to evaluate their actual response. 
 
BPSL3319, also known as FliCBp, assembles to form the flagellar filament that permits 
bacterial motility. FliC can induce IFN- responses from human T cells and is recognized 
by antibodies from seropositive individuals living in endemic areas109,110. In addition, FliC 
is recognized as a pathogen associated molecular pattern (PAMP) by Toll-like receptor 5 
(TLR5) and nucleotide-binding oligomerization domain (NOD)-like receptor C4 
(NLRC4), activating both innate and adaptive immunity111. After structural 
characterization, we employed an even broader approach for epitope discovery, since this 
target is most likely able to stimulate the response of the T cells, in addition of being 
targeted by antibodies. In fact, we complemented the MLCE/EDP and immunocapturing 
epitope mapping approach with sequence-based T cell epitope prediction, (using IEDB, 
selecting common HLA-DRB1 type in Thailand) and other sequence-based predictors for 
antibody binding sites (BepiPred112, BCPred and AAP113). From the consensus prediction 
(see  part III, Figure S1) we synthesized four individual epitopes, three were predicted and 
tested as putative B and T cell epitopes, while the remaining was predicted and tested as 
a T cell one. Our preliminary, still unpublished results indicate that two out of three B-
peptides are strongly recognized in human sera (Figure S2), and the polyclonal antibodies 
raised against them are also active in OPK tests, enhancing both phagocytosis rate and 
oxidative burst with similar signal intensity as the full antigen (Figure S3, Figure S4). 
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When tested for the induction of IFNγ and IL-10 in peripheral blood mononuclear cells 
(PBMC), all four putative T-cell epitopes were active (Figure S5), confirming this protein 
as one of our priority ones. Additional tests will be necessary to get an insight of the most 
reactive epitopes to be advanced to the next phase. 
 
BPSL1445, whose structure was solved via NMR, is another uncharacterized protein for 
which we identified three epitopes, based on MD simulations started from structures in 
the NMR bundle (sequences reported in Table S1), which are currently under evaluation 
for immunoreactivity. BPSL0919 corresponds to the gene locus LytBBp, coding for a 4-
hydroxy-3-methylbut-2-enyl diphosphate reductase 1, active in the MEP pathway of 
isoprenoid biosynthesis. Unlike the other candidates analysed so far, this gene codes for a 
cytoplasmic enzyme (and not a membrane or extracellular protein), though our evidence 
suggests that this protein is highly immunogenic and specific of acute infections. 
According to the structural analysis based on homology modelling (58% identity and 82% 
similarity with E.coli IspH), LytBBp is composed of three well-defined domains forming a 
planar shape of three lobes surrounding the iron-sulphur binding site. Because of the 
difficulties encountered in the cloning and expression of the full protein, epitope 
predictions were based on the homology model, and produced a single domain of LytBBp 
for experimental epitope mapping, corresponding to the fragment on which EDP and 
MLCE indications were focusing. During our preliminar investigations, antibodies against 
the full protein were raised and challenged in OPK and agglutination experiments. The 
antibodies were able to agglutinate B. pseudomallei, but were not able to elicit 
phagocytosis, placing this candidate as another target of secondary priority. 
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4.3   RATIONAL DESIGN OF ACTIVE EPITOPES. 
 
The reach of the SV pipeline described in the previous sections is the identification of a 
restricted number of active epitopes. For active we mean capable of inducing an 
immunoreaction in vitro, in other words limited to controlled conditions in which 
epitopes, as well as the antibodies raised against those epitopes, are used in conjugated 
and free forms. When considering the next step in the line, meaning the tests in vivo, some 
further issues need to be addressed. The immunogens (the epitopes) need to be delivered 
as stable and soluble elements. Free peptides are subject to quick degradation inside an 
organism, and conjugated peptides are a solution better suited for the laboratory than a 
vaccine component. At the same time, with the structural design of the epitopes we have 
a chance to increase the immunogenic potential of the original sequences. 
 
From these considerations we started the process of rational design of BPSL2765 (PalBp) 
epitopes. Our first design is a stabilized version of PalBp EPITOPE 3, from now on referred 
as PAL3. This epitope is composed of 20 amino acids, most of them originally part of an 
alpha helix in the full antigen. According to Circular Dicroism (CD) measures, the 
synthesized PAL3 in free form is not capable of maintaining the native conformation, and 
possesses a β-structure propensity instead (Figure S6), a behavior confirmed by MD 
simulations (1 microsecond at 300, 320 and 340K in explicit solvent). In order to stabilize 
the helical conformation of the native peptide, we envisioned the use of an extra-sequence 
rigid oligopeptidic scaffold as folding nucleator to assist the formation and the 
stabilization of the alpha helix . We then exploited a side-chain cyclized pentapeptide 
inserted at the C-terminus of the epitope sequence, that we obtained starting from a linear 
precursor composed of a Gln-Ala-Glu tripeptide encompassed by ω-azido- and ω-yl-α-
amino acid residues. Cyclization occurred via intramolecular copper-catalyzed click 
reaction114 to afford the resulting cyclo-pentapeptide (side-chain) bridged through a 1,4- 
disubstituted 1,2,3-triazolyl moiety. The planar formula of the click reaction can be 
observed in Figure 10, panel A.   
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The addition of this molecule is sufficient to induce the formation of a stable helix, 
according to CD and simulations (Figure S6). The reactivity of this new epitope (PAL3B) 
has been assessed by serological tests along with the regular PAL3 as positive control. The 
results can be seen in  Figure 10, panel B, and show an improved absorbance index for 
PAL3B in comparison to the previous one, especially in recovered melioidosis group. In 
parallel, the new epitope marks a higher reactivity in the group of seronegative 
individuals. This may indicate that the insertion is partially immunogenic, or that the 
helical form is prompting a partially aspecific recognition. Either way, the increased 
baseline could indicate a self-adjuvating effect, which is not necessarily negative for 
vaccination purposes. To evaluate the potential efficacy of PAL3B in the elicitation of the 
Figure 10: 2D structure of the helix stabilizer insertion and antibody reactivity against PAL3 and 
PAL3B in plasma of healthy and recovered melioidosis subjects. A) Planar configuration of the helix 
stabilizer. The blue and red circles identify the N-ter and C-ter respectively. B) Crude-B. pseudomallei (Bps), 
synthetic peptide PAL3 and PAL3B, were coated onto ELISA plates and probed with diluted plasma samples 
of healthy controls, seronegative (n=5), seropositive individuals (n = 7) and recovered melioidosis patients 
(n = 12) and quantified by indirect ELISA.  
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immune system in vivo, we performed experiments of passive immunization in mice. 
Antibodies against PAL3 and PAL3B were raised in rabbit and used to protect mice from 
infection. C57BL6 mice were immunized with PBS, a negative control antibody, PAL3 
antibodies or PAL3B antibodies intraperitoneal route. 6 hours later, the mice were 
challenged with Bps576, nasal route. Unfortunately, PAL3 and PAL3B antibodies were 
unable to elicit any kind of protection (Figure S7), hinting at the fact that an active 
immunization test may be necessary to display some protective effect, and that 
heterologous antibodies alone are not sufficient to trigger an appreciable immune 
reaction in rodents. For this reason, PAL3/PAL3B need to be redesigned into a more stable 
and active construct, ready to be employed in vivo. 
One interesting fact about PalBp is that PAL3, an antibody-binding site, is predicted to be 
located just before the location of a T-cell epitope (PALT) on the protein sequence. This 
proximity can be seen in Figure 11 A, showing the full structure of the protein highlighting 
PAL3 (teal) and PALT (red). From this observation, we started a process of development 
of a protein mimic, i.e. a synthetic construct based on a protein fragment, maintaining the 
original protein fold and presenting the epitopes PAL3 and PALT with maximal solvent 
exposure. 
Figure 11: Structure-based design of PalBp into a protein mimic exposing epitopes PAL3 and PALT. A) 
Native 3D structure of PalBp. The B epitope PAL3 and the T epitope PALT are highlighted in teal and red 
color, respectively. B) First step design: part of the original folding unit comprising the epitopes are excised 
from the 3D structure and connected by a short turn (DPRO,GLY orange and lines). C) Second step design: 
the mimic is further enhanced with the addition of a helix-inducing insertion between PAL3 and PALT, the 
reduction of the upper loop and the addition of a disulfide bridge closing the β-hairpin (orange and lines). 
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All modifications in the design of this mimic and all the testing process have been 
performed ab initio with computational resources for molecular modeling and assessing 
the protein stability via MD simulations. This project is currently work in progress, so a 
final fold to be synthesized and employed for preliminary in vitro tests is yet to be 
prepared. Nevertheless, we are drawing close to a final design. The main advances are 
summarized in panels B and C of Figure 11. In the first step (panel B) we simply operated 
a virtual excision of the epitopes PAL3 and PALT from the original 3D structure, including 
part of the surrounding folding unit and joined the gap between the two antiparallel 
sheets with a bridge composed of a D-Alanine and a Glycine (orange). The sequence of 
this mimic is reported in Figure S8. Taking this structure as a starting point for 
simulations, we assessed the ability of an already folded construct to remain stable in 
solution. In all replicas, part of the helix was lost and the overall stability compromised 
within the first 50 ns of simulation. By these preliminary indications we identified some 
crucial spots for subsequent interventions. With the second batch of modifications 
(Figure 11 C), we reduced the loop located prior to PAL3, we locked the beta sheets by 
adding a disulfide bridge involving positions 34 and 49, and placed the same helix-
inducing insertion we used for epitope PAL3B, positioned between epitopes PAL3 and 
PALT. The insertion was converted in atomic coordinates and force field parameters, and 
connected to the mimic in two possible orientations with respect of the original backbone, 
namely cis and trans (sequence reported in Figure S8). Our latest analysis indicate a 
substantially improved stability compared to the original fragment depicted in panel B. 
The insertion is successful in promoting the formation and stabilization of the helix 
throughout the whole simulation time in both orientations, but introduces an undesired 
effect. The addition of the circular oligopeptide is forcing the backbone to assume a helical 
fold before and after its position, meaning that the epitope PALT is subject to an excessive 
strain resulting in a disrupting effect on the sheets (Figure S9). The solution to this 
problem might be quite simple. In the next modification iteration, we plan to elongate the 
loop connecting PAL3 with PALT, allowing the backbone to dissipate the torsion without 
impairing the following sheets.  
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Other interventions will include the reduction of the N-ter segment, accompanied by 
point mutations to induce the formation of a third anti-parallel sheet and attract the 
nearby helix. At present state, our work of rational design on PalBp antigen is in advanced 
state, and we plan to produce a synthetic construct in the upcoming months, ready to 
start the testing process. 
 
In conclusion I want to remark that the design of protein mimics is just one of the possible 
strategies to produce powerful vaccine components. Another approach would be the 
presentation of multiple active epitopes from different antigens on a scaffolding structure, 
e.g. silica or gold nanoparticles, allowing the presentation of a considerable quantity and 
variety of immunogens to the immune system while retaining the simplicity and 
affordability of peptide synthesis. 
 
4.4   EXPANSION OF THE ORIGINAL S.V. PIPELINE TOWARDS PROTEIN 
TARGETING AND DIAGNOSTICS 
 
In Section 4.1 of this part, when introducing the results on OppABp antigen, I hinted to the 
fact that epitopes lacking the reactivity necessary to be considered for vaccination 
purposes could be useful for other applications, specifically for diagnostic purposes. The 
high mortality of melioidosis is partially to be ascribed to the difficulty of a quick and 
correct diagnosis of the symptoms. In the cases in which an acute infection is 
misinterpreted (and consequently mistreated), the chances to survive drop dramatically. 
In this framework, epitopes showing a differential reactivity profile against human sera 
collected from healthy and infected individuals may be employed as biomarkers to reveal 
a disease state. To explore the possibility of expanding the reach of SV, we set out to 
integrate our epitope prediction methods with high-throughput microarray analysis with 
the aim to translate molecular understanding of protein-antibody recognition into the 
design of efficient and selective protein-based analytical and diagnostic tools. We selected 
two human antigens with known and available tridimensional structure for epitope 
prediction, namely proteins FABP3 (Fatty acid binding protein 3) and S100B, a calcium-
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binding protein involved in the regulation of many cellular pathways, including protein 
phosphorylation and calcium homeostasis, cell growth and differentiation115. Both have 
been proposed as markers for neurological disorders and damage116,117. After simulation 
and epitope prediction, we raised antibodies against the corresponding peptides and 
collected the antisera. Then we employed the protein microarray technology to detect the 
two protein biomarkers by antibody capturing. The overall flowchart of the protocol is 
summarized in Figure 12. The aim of the test is to verify the ability of the individual 
epitopes to elicit an immunoreaction with specificity and potential for quantitative 
detection against the full-length antigen in the sera of patients. 
From the epitope prediction phase we identified two antibody-binding sites on FABP and 
two on S100. The specificity of interaction was tested with FABP, incubating the full-
length protein spotted on the microarray chip with Cy3-labelled antibodies produced 
against two different mimics of the epitopes. 
Figure 12: Graphical representation of the epitope-based protein targeting workflow. The figure 
reassumes the key steps of a modified SV pipeline to fit a protein targeting/diagnostic application. Starting 
from the biomarker’s 3D structure (in this case FABP3), the putative antibody binding sites are predicted 
using the MLCE method (blue and red secondary structure elements). The epitopes are synthesized in 
form of peptides using PEG moieties to account for the native spatial separation of different elements in 
discontinuous epitopes. The peptides are inoculated in rabbits for the production of antisera, and the 
purified antibodies are immobilized on microarray chip surfaces for qualitative and quantitative detection 
assays. 
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Nonrelated negative controls include Human Serum Albumin, Ovoalbumin, Ovomucoid, 
Rabbit, Mouse, and Goat Immunoglobulins. Each of the two anti-FABP antibodies 
produced a clear fluorescent signal in correspondence of FABP spots (see part II, section 
9.2), while control proteins were not recognized, indicating that the predicted epitopes 
were inducing the production of specific antibodies, capable of recognizing the full-length 
parent protein. A slight nonspecific interaction is visible on immunoglobulins spots, 
accounting for antibody aggregation, a well-known drawback in antibody microarrays. In 
a competition assay the antibodies were challenged with equimolar solutions of the 
corresponding peptides, producing a strong quenching effect when incubated on the 
microarray chip. A scrambled version of the peptide did not affect the fluorescence, 
indicating a direct competition for the recognition site on the antibody. 
The epitope mapping on S100, on the other hand, highlighted two epitopes located on 
opposite sides of the three-dimensional protein structure, separated by 25 Å. This led us 
to consider the chance of quantitative detection via sandwich immunoassay. In this case, 
the first set of antibodies (capture antibody) targeted against Epitope 2 were spotted on 
the microarray chip and incubated with increasing concentration of S100 protein. The 
second set of antibodies, targeted against Epitope 1 was labelled with Cy3 and employed 
as detection antibody. The micro-immunoassay generated a dose-dependent fluorescence 
leading to a limit of detection of 16.06 ng/mL (see part II, section 9.2).  
Overall, these results represent a further important validation of the MLCE concept and 
method that we introduced in the context of epitope prediction. The computational 
approach could be used to screen libraries of known antigens and efficiently design a 
diverse, yet focused, collection of epitopes. The combination of this strategy with 
microarrays opens up the opportunity to generate new targeted and high-throughput 
diagnostic platforms, and the analysis of the structural and recognition properties of 
epitopes may further enhance the paradigm allowing for ab-initio design and modification 
of peptidic antigens to elicit specific responses. Currently, we are applying the same 
rationale to active epitopes from proteins OppABp, PalBp, FliCBp and BPSL1050 
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4.5   EXPANSION OF MLCE TOWARD MHC-II EPITOPES AND 
DEVELOPMENT OF A WEB TOOL 
 
Another key element of this project is the expansion of the computational methods 
beyond their original intent, revealing new insights into the physico-chemical properties 
of epitopes, and providing the Structural Vaccinology approach with additional 
functionalities. The computational tool we explored and expanded is once more MLCE. 
MLCE was designed to select the protein substructures carrying a low energy contribution 
to the general protein stability, and characterized by a minimal intramolecular energetic 
couplings to the rest of the protein. These substructures, with their ability to visit multiple 
conformations, represent putative binding sites for antibodies. The predictive power of 
MLCE has been validated in the identification and design of immunogenic antibody-
binding epitopes of the OppABp and PalBp100,106 (see part I, sections 4.1, 4.2). Further 
applications of this method have been discussed in the design and synthesis of peptidic 
variants of predicted epitopes, in order to produce antibodies capable of specific 
interaction with both the peptide and the native protein for diagnostic purposes118 (part I, 
section 4.4). 
Favorable energetics and conformational accessibility, however, could also underlie the 
recognition and binding of proteins dedicated to the processing and proteolytic cleavage 
of antigens, which results in the generation of peptide sequences (T-cell epitopes) for 
presentation to the major histocompatibility complex (MHC) type II system, the other 
fundamental component of immune response. A major intrinsic trait of T-cell epitopes is 
represented by their sequence specificity for different MHC allelic variants, which is per 
se a valid criterion for affinity prediction119,120. At the physico-chemical level, however, 
other intrinsic properties may favor the presentation of a given antigenic peptide. 
Especially considering MHC-II epitopes, during the antigen processing in the 
phagolysososme, the selection of the epitopes to be loaded on the MHC-II is dependent 
upon various criteria, such as the sequence specificity of the proteases (i.e. cathepsins 
B,D,L,S) and the state of unfolding of the antigen121,122. Concurrently, the open groove of 
the MHC-II may bind to large segments of the antigen during the protein unfolding 
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guiding the proteolytic cleavage (guided antigen processing123,124). At the physico-
chemical level, the enthalpic constraints underlying the stability of a protein fold may play 
a key role in the process, helping define the epitope selection. Strongly coupled residues 
allegedly oppose strong resistance to the cleavage process, being the principal responsible 
for the conservation of the fold. Conversely, weakly coupled peptidic segments represent 
easy targets for protein unfolding and digestion, as well as preferential sites for early MHC-
II binding in the guided antigen processing. By this concept the proteolysis of the 
antigenic protein would not follow a random process, rather a stepwise degradation 
beginning with the subdivision of the protein in domains, followed by a further 
fragmentation of the resulting units by the same criteria. In this scenario, the peptides 
featuring a low energy coupling would be the most obvious antigenic candidates as more 
exposed to proteolytic cleavage and MHC binding, and thus more represented among the 
fragments selected for MHC presentation.  
Based on the latter considerations, we set out to investigate the possibility of expanding 
the reach of the MLCE approach to include the prediction of T-cell epitopes. To this end, 
we selected antigens for which the crystal structures of the full-length proteins and related 
T-cell epitopes are available. In particular we focused our attention on those T-cell 
epitopes presented by the MHC type II complex. The data set proposed in this work takes 
into account 13 antigenic proteins. We gathered 57 non-redundant epitope sequences 
annotated in the Epitope Database (IEDB)119, whose 3D structure in complex with the 
MHC molecule has been experimentally solved (and deposited at the RCSB Protein Data 
Bank) for 13 of them (Table S2).  
The overall prediction workflow following the collected data is shown in Figure 13. The 3D 
structure of each antigen was relaxed for 5ns by Molecular Dynamics, in NPT conditions 
and explicit water. The trajectories were clustered to collect the representative frame of 
each main cluster, in order to get a more relaxed and unconstrained 3D structure for the 
following analysis. Potential epitopes were then predicted on the first cluster structure 
using our energy-based approach. In contrast with B epitopes, the T epitopes are 
oligopeptides that are usually not located on surface protein regions, so MLCE prediction 
was coupled to a second energy-based computational method, BLOCKS, able to identify 
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and dissect a protein structure or 
conformation into individual smaller 
subdomains, mimicking the initial cleavage 
of the antigens. This is achieved by 
grouping different protein fragments into 
energy clusters that are found to 
correspond to stable subunits105. Epitope 
prediction is then carried out separately on 
each resulting individual domain (block): 
the resulting energetically uncoupled 
residues may correspond to internal 
sequence stretches in the initial native, full-
length protein structure.  
The results of epitope prediction were 
benchmarked against the available crystal 
structures of the complexes with MHC-II 
molecules and with the annotated IEDB 
epitopes. Statistical analysis of the 
predictive performance of MLCE was 
carried out, and evaluated in the presence 
or absence of the domain decomposition 
approach.  
After building the antigen data set and the 
T-cell epitope list, we applied the Energy 
Decomposition method in its original 
implementation (without BLOCKS 
decomposition, see also Scarabelli et al. 
201095) on representative structures of the proteins sampled from short MD simulations. 
The method returns a binary prediction (a residue belongs either to an epitope or not-an-
epitope) in the form of residues gathered in surface patches. 
Figure 13: Schematic representation of the 
predicton workflow. We started from the PDB 
structure (in figure 3BZH) of antigens for which 
evidence of T epitopes is known (red), and at least 
one epitope is deposited in crystallographic 
complex with its MHC molecule (in the upper 
circle). Then we simulated the full antigen 
structure and dissected it in domains according to 
the energy-based domain decomposition. The 
evaluation of prediction performance was carried 
out after MLCE prediction over the whole structure 
as well as the epitope-carrying fragments. 
Predicted regions for protein 3BZH are shown in 
blue.  
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The overall performance of the method is reported in Table 2. A summary of the statistical 
performance parameters employed is reported in Table S3. 
 
 
The results on the full-length forms of the 13 antigens indicate a statistically significant 
predictive power of MLCE for T epitopes. However, the use of the single MLCE criterion 
fails to yield good results in four cases: 1CB0, 1HA0, 1OVA and 3HLA. With the exception 
of 1CB0, the other proteins present a large multidomain structure, and the prediction may 
be facilitated by domain decomposition. The concept is not exclusive for large multi-
domain proteins. 1EA3 and 2VB1 are antigens presenting at least one epitope sequence 
which is not solvent exposed, although small in size and composed of a single domain. 
The combination of domain decomposition and MLCE prediction revealed such epitopes 
improving the predictor. 
 
 MHC-II EPITOPES
 PREDICTION PERFORMANCE ANALYSIS
PDB ID Cutoff SENS. SPEC. PREC. ACC. MCC p-value
1CB0.A 25% 0.55 0.63 0.06 0.63 0.07 1.42E-059
1D3B.A 15% 0.20 0.94 0.33 0.84 0.17 5.05E-003
1EA3.A 10% 0.14 1.00 1.00 0.36 0.20 4.00E-009
1HA0.A 25% 0.00 0.88 0.00 0.85 -0.06 7.16E-065
1I7Z.A 10% 0.44 0.90 0.16 0.88 0.22 7.32E-021
1OVA.D 25% 0.27 0.59 0.19 0.51 -0.12 3.41E-022
2GIB.B 25% 0.38 1.00 1.00 0.59 0.41 9.80E-008
2JK2.A 15% 0.87 0.86 0.28 0.86 0.44 6.36E-028
2VB1.A 25% 0.34 0.83 0.62 0.60 0.19 1.60E-001
2WA0.A 20% 0.70 0.82 0.16 0.82 0.27 4.27E-031
3BZH.A 25% 0.89 0.74 0.18 0.75 0.33 1.35E-026
3FEY.C 25% 0.50 0.74 0.08 0.73 0.11 1.28E-078
3HLA.A 15% 0.00 0.78 0.00 0.59 -0.25 1.09E-020
AVERAGE 20% 0.41 0.82 0.31 0.69 0.15
Table 2: Overall performance analysis of BEPPE in the task of MHC II epitopes prediction. For every 
protein (PDB code) is reported the optimal cutoff for prediction and the classification performance 
parameters sensitivity, specificity, precision and accuracy97. The Matthews Correlation Coefficient (MCC)125 
test and statistical significance of the analysis (p-value) are also reported. 
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The predictions after domain decomposition are depicted in Table 3, showing the results 
for each protein fragment including mapped epitopes. For such cases we have calculated 
separate statistics for the two fragments. Incorporating the energy-based decomposition 
approach to divide the antigenic protein into fragments prior to MLCE results in a general 
improvement in the performance statistics, but yelding mixed results when predicting 
over multiple protein fragments. This may be due to the inability to decompose very 
compact proteins into domains (1OVA), or when producing protein fragments too small 
(2GIB), or proposing cleavage sites inside annotated epitopes such as in the case of 2VB1 
and 3BZH. 
 
 
 
PDB ID Cutoff SENS. SPEC. PREC. ACCU. MCC. p-value DOMAIN CHANGE
1CB0.A 15% 0.00 0.83 0.00 0.76 -0.13 4.05E-15
1D3B.A 15% 0.22 0.84 0.29 0.70 0.07 1.61E-02
1EA3.A 25% 0.25 1.00 1.00 0.33 0.18 5.67E-12 1
1EA3.A 25% 0.43 0.84 0.80 0.59 0.28 6.61E-03 2
1HA0.A 15% 0.54 0.78 0.13 0.76 0.18 4.41E-32
1I7Z.A 10% 0.44 0.94 0.40 0.89 0.36 5.17E-05
1OVA.D Failed decomposition
2GIB.B 10% 0.30 1.00 1.00 0.66 0.43 1.73E-02 1
2GIB.B Epitope cleavage 2
2JK2.A 25% 0.60 0.64 0.18 0.63 0.16 5.29E-19
2VB1.A 25% 0.00 0.56 0.00 0.36 -0.47 4.13E-07 1
2VB1.A Epitope cleavage 2
2WA0.A 15% 0.90 0.85 0.41 0.86 0.55 1.01E-09
3BZH.A Epitope cleavage
3FEY.C 10% 1.00 0.93 0.53 0.94 0.70 1.50E-08 1
3FEY.C 10% 0.00 0.88 0.00 0.84 -0.08 5.27E-23 2
3HLA.A 25% 0.34 0.63 0.34 0.53 -0.03 8.19E-05
 AFTER DOMAIN
 DECOMPOSITION
Table 3: Performance analysis of MLCE on individual protein fragments. The table includes all the 
previous statistical parameters, accompanied by a DOMAIN column, indicating the proteins featuring two 
fragments containing epitopes. The last column on the right indicate whether the predictive performance is 
enhanced (green), degraded (red) or unchanged (blu) compared to the full protein prediction. The 
performance calculation was not possible (or not significant) in proteins 1OVA, 2GIB-2, 2VB1-2 and 3BZH. 
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With all these limitations and caveats in mind, we can consider the domain 
decomposition method for its ability to improve epitope prediction in all cases in which  
splitting a protein in subparts is a minor concern. These include moderately large proteins, 
or proteins composed of multiple domains. Other examples include known protein 
fragments and domains of interest, for which BLOCKS could suggest the ideal cleavage 
sites for MLCE predictions. 
Overall, the results showed a significantly accurate T-cell epitope identification, with 
greater performance when epitope prediction is carried out after structural decomposition 
via the BLOCKS approach, suggesting the energetic uncoupling may be also a key property 
of MHC epitopes, confined to specific subdomains of the initial protein. From a 
performance standpoint, it must be noticed that MLCE is significantly more capable in 
the prediction of B-cell epitopes, confirming that in the context of MHC epitope selection 
other key factors contribute to the final presentation. 
 
MLCE is a method specifically designed to highlight energetic motifs from a protein 3D 
structure, revealing in many cases the areas containing potential epitopes. The method 
can be successfully employed in a dual purpose (B/T epitopes), giving consistent 
indication of immunogenic sequence location. Building on this consideration, since a 
modern vaccine should stimulate a protective response originated from both the B-cell 
and T-cell mediated recognition using a minimum set of immunogenic components and 
adjuvants, we consider the predictive pipeline of MLCE a flexible tool ready to be 
employed successfully for vaccine development, diagnostics design and protein targeting 
purposes.  
In conclusion, in this study we have expanded the reach of MLCE  to become a more 
general B and T-cell epitope predictor. These mechanisms constitute two major branches 
of the adaptive immune response, and are both fundamental in the eradication of the 
infection and the acquisition of a long-term, active immunological memory. 
Based on these new findings, we adopted the new revisions to the MLCE algorithm to set 
up a free, web-accessible version of the BEPPE server suitable for predictions of B and T 
cell epitopes, as described in part II, section 10.1. The new server accepts single structures 
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of proteins or collections of proteins in 
PDB format, and returns a list of 
predicted epitopes in form of patches, 
along with their BLAST search against 
the human proteome, and a pictorial 
representation of the energy matrices 
produced after the energy 
decomposition. In this version, the user 
can access two advanced options to 
select the energy matrix to be calculated 
(one is to be preferred in case of multi-
domain or multi-chain proteins), and 
the strictness of prediction, that is the 
percentage of low-energy contributions 
to be used for prediction. A schematic 
representation of the server automation 
is shown in Figure 14. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: Layout of the web tool BEPPE: each 
individual PDB file is passed by the User Interface to 
the prediction pipeline (double line exagons). The 
main modules processing the structure, existent even 
in stand-alone format, consist of a preliminary input 
check script, the package ISABEL for the energy 
decomposition and analysis, the program BEPPE for 
the prediction of epitopes, and the BLAST script. All 
results (and eventually all errors) are gathered in a 
unique text file accompanied by supplementary data, 
and sent to the user via email (red, shaded background, 
single line exagons). 
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4.6   THE ROLE OF SURFACE ENERGETICS IN THE FORMATION OF 
PROTEIN-PROTEIN COMPLEXES. 
 
The last part of this project, as stated in section 3, is not directly related to the 
development of a vaccine. Rather it aims at garnering new insights into the biophysical 
aspects at the basis of the energetic analyses used for epitope prediction. The use of 
energy-based analysis tools to predict the location of binding epitopes implies the 
presence of a property defining binding in the general energetics of the protein. Once the 
property is verified, it can be described with a mathematical formulation. Such binding 
property could also be predicted with appropriate algorithmic automation. Thus, in the 
case of MLCE, the observation of a discernible pattern (low coupling) inside the non-
bonded intramolecular energy and solvation terms of antibody binding sites, led 
ultimately to the epitope predictor BEPPE. 
 
We then set out to investigate protein energetics, computed and approximated with 
molecular mechanics techniques, in search of other possible properties. The fact that the 
antibody-binding sites are very peculiar interface of protein-protein recognition, led us to 
formulate the hypothesis that the energetic data could reveal a more general property 
linked to protein-protein interactions (PPIs).  
To investigate these aspects in depth, we gathered a dataset of 30 proteins, subdivided as 
15 binary complexes undergoing transient interactions. The dataset was selected as an 
heterogeneous sample of Benchmark 3.0126, originally compiled to evaluate the 
performance of protein docking algorithms, and is composed of proteins for which high 
resolution structural data is present, completed with detailed annotation of their binding 
interfaces. The methodological outline of this study, starting from the atomic coordinates 
of the proteins and getting to a per-residue representation of the energy of the system, is 
shown in Figure 15. In this work, we collected the structural information of all proteins, 
both in individual form and in dimeric complex (45 PDB codes), and run simulations for 
each one (5ns all-atom MD, at 300K and explicit solvent using GROMACS 4.51127 and 
GROMOS53A6 force field86. The energetic determinants were computed via MM-GBSA 
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calculation approach (Molecular Mechanics 
Generalized Born Surface Area) treated in 
implicit solvent as included in the AMBER 11 
software package128. The total interaction 
energy of the system is decomposed into 
intramolecular and solvation terms on a residue 
pairwise basis. Energy decomposition is used in 
addition to reconstruct a simplified energy 
matrix. The procedure is similar to the methods 
employed by MLCE/BEPPE to generate the 
energy matrix, with a difference: the matrix is 
not reconstructed based on the principal 
eigenvector of the full covariance matrix, 
instead it is generated by the combination of a 
set of principal eigenvectors, selected according 
to their level of representation of the energetic 
covariance105. The resulting energy matrix 
(Figure 15) is filtered by a neighbouring list, 
maintaining solely the energy pairs of surface 
residues, excluding all distal contributions (the 
maximum distance allowed is 7 Å).  
Figure 15: Schematic representation of the workflow 
followed for the energetic description analysis. From 
top to bottom, the 3D structure of 15 complexes and their 
constituting 30 proteins (in table) have been simulated for 
5ns for conformational relaxation (MD box). The 
nonbonded intramolecular and solvation energy terms of 
each protein have been calculated and retrieved via GBSA 
calculation, and expressed in form of a pairwise energy 
matrix via energy decomposition. The energy matrix, 
filtered by a similar, pairwise neighbouring list of surface 
residues, is collapsed to a monodimensional profile, 
averaging all energy contributions for each amino acid. 
From this energetic profile, the weakest elements (energy 
close to 0) are selected to be mapped on the protein 
surface.  
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The final matrix is simplified as an energetic profile, averaging the energetic interactions 
of each residue to a unique value (Figure 15).  
All preliminary investigations in search of a direct correlation between the intensity of 
this energy and the presence of a binding interface were unable to highlight any property 
with significant ability to predict the interaction interface. Instead, all tests highlighted 
interesting motifs of different energy coupling intensity characterizing protein surfaces. 
 
According to these observations, we started 
approaching the investigation with a broader 
perspective. The vast majority of 
computational methods devoted to the 
analysis and the prediction of PPIs focus on the 
identification of the binding interface. The 
reason for this is the necessity to rely on a 
direct, non-ambiguous source of information 
that can be annotated and retrieved for 
practical applications. It is what we call the 
Instruction Manual Strategy: to know exactly 
where two proteins assemble is the most 
efficient way of reconstructing the complex 
(Figure 16). This strategy offers a common and 
intuitive perspective for studying protein-
protein interactions, but it is not the only one. 
Another way to reconstruct the complex or to 
study the mechanisms of interaction may be 
represented by what we call the Watercolor 
Strategy. The concept may be better 
introduced using a familiar analogy: one can 
imagine somebody (e.g. a kid) leaving a mark 
of watercolor on an assembly of toy bricks. 
Figure 16: Conceptual representation of our 
theoretical strategy, expressed by toy 
bricks analogy. On top, The traditional 
approach to protein-protein interaction 
pursues the location of the binding sites and 
use them as guidelines for assembly. In our 
strategy, a mark on the complex persistent on 
each individual part would be able to reveal 
additional information, such as the binding 
orientation 
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If the mark is persistent, it will remain visible on its constituent parts, even after 
disassembling. Based on this mark, one may be able to reconstruct the original assembly 
following the continuity and the orientation of the color, even in absence of instructions 
(Figure 16). A similar perspective may be applied to the PPI problem: according to our 
hypothesis, protein adaptation to their binding partners may have left such a trace in the 
energy of stabilization during the course of evolution, pushing the constituent parts 
toward a sort of energetic complementarity across the binding interface. If such motifs are 
persistent, so that they can be isolated in the energetic footprint of the complexes and the 
isolated constituent proteins in monomeric form, they would represent a property of 
protein-protein interactions. A formal description of such property could be employed in 
the development of a dedicated analysis tool, with potential to reveal the location of a 
binding site or, most likely, the binding orientation. More generally this would contribute 
to the investigation and clarification of another physico-chemical aspect underpinning 
protein-protein interactions. 
From the energetic analysis of the isolated form of each protein in our dataset, we 
observed that surface regions characterized by weak energetic uncoupling define specific 
motifs. Examples of these areas are shown in Figure 17, upper panel. Interestingly, when 
calculated and mapped on their respective crystallographic complexes, the motifs are 
conserved and tend to identify a unique and continuous motif connected across the two 
proteins in 14 out of 15 protein complexes (Table S4), hinting to the possibility to reveal 
an energetic complementarity in the complex state (Figure 17 middle panel). It is worth 
noting the fact that protein 1G0Y undergoes a radical conformational change from the 
closed conformation of the isolated state and the open conformation of the heterodimeric 
form, in complex with protein 1ILR. Despite the difference, the motifs identified in the 
closed conformation produce a sharp continuous mark across the two proteins when 
mapped on the complex structure. Attempts to predict the binding interface on the 
isolated form of this protein using known algorithm would clearly fail exactly due to the 
conformational change. Proteins 1SRR and 1IXM, constituent parts of the complex 1F51, 
represent another interesting case since the two proteins assemble in a tetrameric 
biological form. The continuous motif actually emerges in the tetramer (Figure 17).  
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Figure 17: Motifs of uncoupled energy mapped on the 3D structure of isolate protein and complexes. 
On top, The analysis of the local energetic coordination, performed on the monomeric variants of the protein 
dataset shows that surface regions characterized by weak energetic uncoupling outline specific motifs (in 
blue). In the middle panel, the same motifs are mapped on their respective complexes, outlining unique and 
continuous blue stripes. In the bottom panel, the motifs calculated on monomeric proteins 1SRR and 1IXM 
outline a blue stripe in both dimeric and tetrameric assemblies. (pale green and green proteins correspond to 
further 1IXM and 1SRR proteins, respectively) 
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According to the peculiar representation and colors chosen to display the results of 
analysis during this study, these motifs have been given, for simplicity, the name of blue 
stripes.  
According to our hypothesis, the stripes identified on the monomers would be still visible 
when calculated on the full complex structures, as they are constituents of a continuous 
mark. The energetic analysis run over all the complexes partially confirmed this 
expectation. A continuous motif of weak coupling energy is visible for 12 out of 15 
complexes (Table S4), and in the majority of cases (9 out of 15) the stripes are conserved 
with respect to the previous results. Of the remaining 6 complexes, 3 still present a similar 
(if not equivalent) motif, but showing a spatial translation on the protein surface (1ACB, 
Figure 18). The major difference producing this effect (and producing the majority of 
other, more subtle changes in other complexes) is due to areas characterized by very low 
uncoupling energy that upon binding acquire stability, and new, previously “neutral” 
surface patches that are affected by destabilization, thus being featured in the blue stripes. 
A quantitative indication of identity between results of monomer analysis vs complex 
analysis is shown in Table S4. 
Figure 18: Motifs of uncoupled energy from the energetic analysis of entire complexes. This panel 
depicts an example of the same analysis of energetic uncoupling calculated on the full complex of 
proteins shown in Figure 17. The comparison between monomers and dimers returned similar results 
in 1B6C, 1BUH and 1GPW, only affected by minor differences. 1ACB features a very similar blue stripe, 
but spatially translated upon binding (the structure has been rotated 90 degrees compared to the 
previous image). 1IRA is one of the few examples of poorly persistent blue stripe, although a motif 
continuity can be still appreciated. The differences may be partly due to the vast conformational 
rearrangement of protein 1GOY between free and bound form. 
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The percentage of identity is very high in the majority of cases, indicating that the analysis 
is mainly oriented towards the same surface areas, although with differences.  
The presence of differences between stripes calculated from the isolated protein and the 
ones generated from the complexes are compatible with the common idea of proteins as 
dynamic systems, and differences within the energy of stabilization between different 
levels of protein organizations were not entirely unexpected. The striking detail, in our 
opinion, is the fact that similar stripes can be identified over monomers and complexes, 
so that the analysis of interacting proteins in isolated form is able to approximate a 
property of the final complex.  
 
The presence of a discernible pattern inside the local energetic stability of monomeric 
proteins capable of outlining binding motifs on the complex, suggests a form of energetic 
complementarity between the constituent parts. This complementarity is visible at the 
chemico-physical level of residue interaction and is not dependent on the chemical 
composition of the amino acids involved (Figure S10). This property can be exploited to 
gain information at the protein-protein interaction level, like the presence of a binding 
site or the binding orientation. This led to the development of an automated analysis tool, 
named BLUEPRINT (Beppe-Like Uncoupling Energy for PRotein INTeraction). At the 
current development state, BLUEPRINT is able to process autonomously the energetic 
data from GBSA calculations of an entire dataset of protein monomers and/or complexes. 
The analysis produces data on the location and signal intensity of the blue stripes in textual 
and pictorial format, mapping the results on the structure of the complex when available.  
 
This method may be employed in a range of applications, from the ab-initio 
characterization of PPIs, to protein-protein docking algorithms. One further area of 
interest would be the study of a possible correlation between evolution and energetic 
signature, in order to better understand the mechanisms producing this complementarity, 
and put it in relation with protein function. 
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5 - CONCLUSIONS AND FUTURE PROSPECTS 
 
 
 
 
 
 
 
 
 
 
 
 
Structural Vaccinology is a developing field that aims to devise viable strategies for vaccine 
design, based on the identification of immunogenic determinants (epitopes), through 
computational and 3D structure analyses. In the context of this thesis project, I have 
worked within an international consortium following a Reverse and Structural 
Vaccinology initiative devoted to the identification of active antigens and epitopes from 
the pathogen Burkholderia pseudomallei, etiological agent of the life-threatening disease 
melioidosis. 
The computational methods I developed and used within this framework, mostly 
involving molecular modeling and simulation as well as epitope prediction based on the 
MLCE approach, were successful, in combination with other in silico and in vitro mapping 
systems, in the identification of antibody-binding sites on numerous antigenic X-ray and 
NMR structures. 
We live in a society exquisitely 
dependent on science and 
technology, in which hardly 
anyone knows anything about 
science and technology 
Carl Sagan 
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The integrated pipeline that we first described with OppABp antigen was able to deliver a 
handful of immunogenic peptides identified from different high-priority antigens. These 
peptides were recognized by antibodies present in the plasma of melioidosis-infected 
patients, and were able to elicit agglutination and neutrophils opsonization when tested 
in vitro. Interestingly, the reactivity of the single epitopes, as well as their ability to 
stimulate the immune response in vitro were slightly different from the results we 
registered with their corresponding full-length antigens. Although in many cases this led 
to the identification of less-active epitopes, in other cases such as epitope COMP3 from 
OppABp and PalBp PAL3, they were able to deliver peptides with full potential to 
discriminate between healthy and infected patients. In one case also, Epitope PAL3 from 
PalBp, the single epitope showed enhanced activity with respect of the native antigen. 
These peptides are ideal targets for the rational engineering of stable and potent vaccine 
components. Preliminary results on a conformationally constrained version of PAL3 are 
showing increased immunoreactivity, strongly encouraging future efforts in structure-
based design of the identified epitopes. 
The results shown here demonstrate the feasibility of a structure-based and epitope-based 
vaccine initiative, and expand the original concept toward other fields of application. Our 
method has recently proven that it is possible to use synthetic peptides to raise antibodies 
that retain full specificity for the epitope region and fully recognize the full-length protein, 
opening perspectives for the development of antibody-based screening diagnostic 
platforms. 
From the practical point of view, designed biomolecules can have importance in the 
development of diverse applications, ranging from analytics and diagnostics, to drug-
discovery and biotechnology. Hence, by increasing our understanding of the molecular-
level origins of protein interactions, we will be able to rationally engineer novel molecules 
(peptides, peptidomimetics, and de novo designed proteins) with characteristics suitable 
for a particular application. 
With this objective in mind, during this project I have applied novel strategies to extend 
the possibilities of MLCE toward the prediction of MHC-II binding epitopes, and worked 
at the code level to implement a full prediction software based on MLCE, BEPPE, on a 
web-based freely accessible platform. This new version of BEPPE should increment the 
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versatility of the predictive instrument while considerably reducing the time necessary for 
analysis, producing a free, convenient, effective, and user friendly tool for the GtA project 
as well as for other initiatives, whether they are interested in SV or structure-based protein 
targeting. 
 
The investigation of protein structures and interactions, on the other hand, has other 
essential implications. From the fundamental point of view, the development of rational 
approaches to predict and design sequences with specific properties can help in 
understanding the physical basis of molecular recognition as well as furthering our 
understanding of the relationships between protein sequence, structure, dynamics, and 
function. In this framework, I have investigated the energetic footprint of 15 interacting 
proteins, both in monomeric and dimeric form, in search of a specific property of 
interaction. This lead to the observation of clear motifs in the local energetic coordination 
of the monomers, showing that surface regions characterized by weak energetic 
uncoupling outline specific motifs on the protein isolates. When mapped on their 
respective crystallographic complexes, the motifs tend to identify a unique and 
continuous feature, a “blue stripe”, connected at the interface border. An effect that was 
also visible across those proteins of the dataset forming trimeric or tetrameric assemblies. 
Analyzing the energy of the entire complexes, we obtained similar results, suggesting that 
these marks are persistent. The presence of this pattern in the local energetic coordination 
of isolate proteins suggests a form of energetic coordination retaining information on the 
bound forms, like the presence of a binding site or the binding orientation. This approach 
has been developed into an independent analysis tool, named BLUEPRINT. Future 
applications of BLUEPRINT to real case scenarios may either validate or reject this model. 
In case it proves reliable, it may be employed in a range of fundamental and practical 
applications, from the ab-initio characterization of PPIs, to protein-protein docking 
algorithms, to the evolutionary and functional investigation of interactions. 
 
 
 
Part I – 6 References 
 
66 
 
6 - REFERENCES 
 
1. Whitmore A, Krishnaswami CS (1912) An account of the discovery of a hitherto undescribed infective 
disease occuring among the population of Rangoon. Indian Med Gazette 47: 262–267. 
2. Stanton AT, Fletcher W. Melioidosis, a new disease of the tropics. Trans Fourth Congr Far East Assoc Trop 
Med 1921(2):196-8. 
3. Limmathurotsakul D, Wongratanacheewin S, et al. (2010) Increasing incidence of human melioidosis in 
Northeast Thailand. Am J Trop Med Hyg 82:1113–1117.  
4. Currie BJ, Fisher DA, Howard DM, Burrow JN, Selvanayagam S, et al. (2000) The epidemiology of 
melioidosis in Australia and Papua New Guinea. Acta Trop 74:121–127. 
5. Currie BJ, Dance DA, Cheng AC (2008) The global distribution of Burkholderia pseudomallei and 
melioidosis: an update. Trans R Soc Trop Med Hyg 102(1): 1–4.  
6. White NJ. (2003) Melioidosis. Lancet 361:1715-22. 
7. Cheng AC, Currie BJ. (2005) Melioidosis: Epidemiology, Pathophysiology, and Management. Clin Microbiol 
Rev 18:383-416. 
8. Peacock SJ. (2006). Melioidosis. Curr. Opin. Infect. Dis. 19(5): 421-428. 
9. Wiersinga WJ, van der Poll T, et al. (2006). Melioidosis: insights into the pathogenicity of Burkholderia 
pseudomallei. Nat. Rev. Microbiol. 4(4): 272-282. 
10. Wuthiekanun V and Peacock SJ (2006). Management of melioidosis. Expert. Rev. Anti. Infect. Ther. 4:445-
455. 
11. Atkins T, Prior RG, et al. (2002). A mutant of Burkholderia pseudomallei, auxotrophic in the branched-
chain amino acid biosynthetic pathway, is attenuated and protective in a murine model of melioidosis. 
Infect. Immun. 70:5290-5294. 
12. Haque A, Easton A, et al. (2006). Role of T cells in innate and adaptive immunity against murine 
Burkholderia pseudomallei infection. Journal of Infectious Diseases 193(3): 370-379. 
13. Cuccui J, Easton A, et al. (2007). Development of signature tagged mutagenesis in Burkholderia 
pseudomallei to identify mutants important in survival, attenuation and pathogenesis. Infect. Immun. 75: 
1186-1195. 
14. Breitbach K, Kohler J, et al. (2008). Induction of protective immunity against Burkholderia pseudomallei 
using attenuated mutants with defects in the intracellular life cycle. Trans R Soc Trop Med Hyg 102 Suppl 
1(1): S89-94. 
15. Nelson M, Prior JL, et al. (2004). Evaluation of lipopolysaccharide and capsular polysaccharide as subunit 
vaccines against experimental melioidosis. J. Med. Microbiol. 53(12): 1177-1182. 
16. Pollard AJ, Perrett KP, et al. (2009). Maintaining protection against invasive bacteria with protein-
polysaccharide conjugate vaccines. Nat. Rev. Immunol. 9(3): 213-20. 
Part I – 6 References 
67 
 
17. Jones SM, Ellis JF, et al. (2002). Passive protection against Burkholderia pseudomallei infection in mice by 
monoclonal antibodies against capsular polysaccharide, lipopolysaccharide or proteins. J. Med. Microbiol. 
51: 1055-1062. 
18. Healey GD, Elvin SJ, et al. (2005). Humoral and cell-mediated adaptive immune responses are required for 
protection against Burkholderia pseudomallei challenge and bacterial clearance post-infection. Infect. 
Immun. 73(9): 5945-5951. 
19. Haque A, Chu K, et al. (2006). A live experimental vaccine against Burkholderia pseudomallei elicits CD4(+) 
T cell-mediated immunity, priming T cells specific for 2 type III secretion system proteins. Journal of 
Infectious Diseases 194(9): 1241-1248. 
20. Sarkar-Tyson M, Smither SJ, et al. (2009). Protective efficacy of heat-inactivated B. thailandensis, B.mallei 
or B. pseudomallei against experimental melioidosis and glanders. Vaccine 27(33): 4447-51. 
21. Brett PJ and Woods DE. (1996). Structural and immunological characterization of Burkholderia 
pseudomallei O-polysaccharide-flagellin protein conjugates. Infect. Immun. 64(7):2824-2828. 
22. Harland DN, Chu K, et al. (2007). Identification of a LolC homologue in Burkholderia pseudomallei, a novel 
protective antigen for melioidosis. Infect. Immun. 75(8):4173-80. 
23. Hara Y, Mohamed R, et al. (2009). Immunogenic Burkholderia pseudomallei outer membrane proteins as 
potential candidate vaccine targets. PLoS One 4(8): e6496. 
24. Fenner F, Henderson DA, Arita L, Jezek Z, Ladnyi ID. (1988) Smallpox and its eradication. Geneva: World 
Health Organization. 
25. Jenner E. (1801) The Origin of the Vaccines Inoculation. London: Shury. 
26. Jenner E. (1798) Inquiry into the Causes and Effects of the Variolae Vaccine. London: Sampson Low, 45. 
27. Pasteur L. (1880) De l’attenuation du virus du Choléra des poules. CR Acad. Sci. 91:673–680. 
28. Rappuoli R. (2004) From Pasteur to genomics: progress and challenges in infectious diseases. Nat. Med. 
10:1177–1185. 
29. Levine MM, Lagos R, Esparza J. (2009) Vaccines and Vaccination in Historical Perspective. New Generation 
Vaccines. Fourth Edition. New York: Informa Healthcare USA, Inc.:pp. 1–11. 
30. Offit PA. (2007) Vaccinated: One Man’s Quest to Defeat the World’s Deadliest Diseases. New York: 
HarperCollins. 
31. Glenny AT, Hopkins BE. (1923) Diphtheria toxoid as an immunizing agent. Br J Exp Pathol. 4:283–288. 
32. Ramon G. (1924) Sur la toxine et sur l’anatoxine diphtériques. Pouvoir floculant et propriétés 
immunisantes. Ann Inst Pasteur 38:1–106. 
33. Buynak EB, Roehm RR, et al. (1976) Vaccine against human hepatitis B. J. Amer. Med. Assoc. 235(26):2832-
4. 
34. Clare S, Dougan G. (2004). Live recombinant bacterial vaccines in Novel Vaccination Strategies, ed 
Kaufmann S. H. E., editor. (Weinheim: Wiley-VCH; ), 319–341. 
35. Ada G. (2001) Vaccines and vaccination. N. Engl. J. Med. 345(14):1042-53. 
36. Fleischmann RD, Adams MD, et al. (1995) Whole-genome random sequencing and assembly of 
Haemophilus influenzae Rd. Science. 269(5223):496-512. 
37. Rappuoli R. (2000) Reverse vaccinology. Curr. Opin. Microbiol. 3(5):445-50. 
Part I – 6 References 
 
68 
 
38. World Health Organization. Meningococcal meningitis fact sheet. Available at: 
http://www.who.int/mediacentre/factsheets/fs141/en/ 
39. Sette A, Rappuoli R. (2010) Reverse Vaccinology: Developing Vaccines in the Era of Genomics. Immunity 
33(4):530-41. 
40. Tettelin H, Saunders NJ, et al. (2000) Complete genome sequence of Neisseria meningitidis serogroup B 
strain MC58. Science. 287(5459):1809-15. 
41. Pizza M, Scarlato V, et al. (2000) Identification of vaccine candidates against serogroup B meningococcus 
by whole-genome sequencing. Science. 287(5459):1816-20. 
42. Giuliani MM, Adu-Bobie J, et al. (2006) A universal vaccine for serogroup B meningococcus. Proc. Natl. 
Acad. Sci. USA. 103(29):10834-9. 
43. Maione D, Margarit I, et al. (2005) Identification of a universal Group B streptococcus vaccine by multiple 
genome screen. Science. 309(5731):148-50. 
44. Rodriguez-Ortega MJ, Norais N, Bensi G, et al. (2006) Characterization and identification of vaccine 
candidate proteins through analysis of the group A Streptococcus surface proteome. Nat. 
Biotechnol. 24: 191–197. 
45. Thorpe C, Edwards L, Snelgrove R, et al. (2007) Discovery of a vaccine antigen that protects mice from 
Chlamydia pneumoniae infection. Vaccine. 25(12):2252-60. 
46. Vidor E. (2010) Evaluation of the persistence of vaccine-induced protection with human vaccines. J Comp 
Pathol. 142(1):S96–101. 
47. Felgner PL, Kayala MA, et al. (2009). A Burkholderia pseudomallei protein microarray reveals serodiagnostic 
and cross-reactive antigens. Proc Natl Acad Sci USA 106(32): 13499-504. 
48. Holden MT, Titball RW, Peacock SJ, et al. (2004). Genomic plasticity of the causative agent of melioidosis, 
Burkholderia pseudomallei. Proc. Natl. Acad. Sci. USA. 101:14240–14245. 
49. Nandi T, Ong C, Singh AP, et al. (2010). A genomic survey of positive selection in Burkholderia 
pseudomallei provides insights into the evolution of accidental virulence. PLoS Pathog. 6(4):e1000845. 
50. Sarkar-Tyson M, Thwaite JE, Harding SV, et al. (2007) Polysaccharides and virulence of Burkholderia 
pseudomallei. J. Med. Microbiol. 56:1005–1010. 
51. Shalom G, Shaw JG, Thomas MS. (2007) In vivo expression technology identifies a type VI secretion system 
locus in Burkholderia pseudomallei that is induced upon invasion of macrophages. Microbiology 153:2689–
2699. 
52. Kim HS, Schell MA, Yu Y, Ulrich RL, Sarria SH, et al. (2005) Bacterial genome adaptation to niches: 
divergence of the potential virulence genes in three Burkholderia species of different survival 
strategies. BMC Genomics 6: 174. 
53. Galyov EE, Brett PJ, DeShazer D (2010) Molecular insights into Burkholderia pseudomallei and Burkholderia 
mallei pathogenesis. Annu Rev Microbiol 64: 495–51. 
54. Peano C, Chiaramonte F, Motta S. et al (2014) Gene and Protein Expression in Response to Different Growth 
Temperatures and Oxygen Availability in Burkholderia thailandensis. PLoS One. 2014; 9(3):e93009. 
55. Glass MB, Gee JE, Steigerwalt AG, Cavuoti D, Barton T, et al. (2006) Pneumonia and septicemia caused by 
Burkholderia thailandensis in the United States. J. Clin. Microbiol. 44: 4601–460. 
Part I – 6 References 
69 
 
56. Ooi WF, Ong C, Nandi T, et al. (2013) The condition-dependent transcriptional landscape 
of Burkholderia pseudomallei. PLoS Genet. 9(9):e1003795. 
57. Moule MG, Hemsley CM, Seet Q, et al. (2014) Genome-wide saturation mutagenesis 
of Burkholderia pseudomallei K96243 predicts essential genes and novel targets for antimicrobial 
development. MBio.5(1):e00926-13. 
58. Conaty S, Watson L, Dinnes J and Waugh N. (2004) The effectiveness of pneumococcal polysaccharide 
vaccines in adults: a systematic review of observational studies and comparison with results from 
randomised controlled trials. Vaccine 22(23-24): 3214-24. 
59. Janeway C. (2001) Immunobiology. (5th ed.). Garland Publishing. 
60. Pier GB, Lyczak JB, Wetzler LM. (2004) Immunology, Infection, and Immunity. ASM Press. 
61. Rus H, Cudrici C, Niculescu F. (2005) The role of the complement system in innate immunity. Immunol 
Res 33 (2): 103–112. 
62. Dormitzer PR, Ulmer JB, Rappuoli R. (2008). Structure-based antigen design: a strategy for next generation 
vaccines. Trends in Biotechnology 26: 659-6667. 
63. Azoitei ML, Correia BE, Ban Y-EA et al. (2011) Computation-guided backbone grafting of a discontinuous 
motif onto a protein scaffold. Science 334:373–376. 
64. Correia BE, Ban Y-EA, Holmes Ma et al. (2010) Computational design of epitope-scaffolds allows induction 
of antibodies specific for a poorly immunogenic HIV vaccine epitope. Structure 18:1116–1126. 
65. Ofek G, Guenaga FJ, Schief WR et al. (2010) Elicitation of structure-specific antibodies by epitope scaffolds. 
Proc Natl Acad Sci USA 107:17880–17887. 
66. Burton DR. (2010) Scaffolding to build a rational vaccine design strategy. Proc Natl Acad Sci USA 107:17859–
17860. 
67. Wu X, Yang Z-Y, Li Y, et al. (2010) Rational design of envelope identifies broadly neutralizing human 
monoclonal antibodies to HIV-1. Science 329:856–861. 
68. Zhou T, Georgiev I, Wu X, et al. (2010) Structural basis for broad and potent neutralization of HIV-1 by 
antibody VRC01. Science. 329:811–817. 
69. Scheid JF, Mouquet H, Ueberheide B, et al. (2011) Sequence and structural convergence of broad and potent 
HIV antibodies that mimic CD4 binding. Science. 333:1633–1637. 
70. West AP, Diskin R, Nussenzweig MC, Bjorkman PJ. (2012) Structural basis for germ-line gene usage of a 
potent class of antibodies targeting the CD4-binding site of HIV-1 gp120. PNAS. 109:E2083-E2090. 
71. McGuire AT, Hoot S, et al. (2013) Engineering HIV envelope protein to activate germline B cell receptors 
of broadly neutralizing anti-CD4 binding site antibodies. J Exp Med. 210(4):655-663. 
72. Jardine J, Julien J-P, Menis S, et al. (2013) Rational HIV immunogen design to target specific germline B cell 
receptors. Science 340(6):711-716. 
73. Scarselli M, Arico B, Brunelli B et al. (2011) Rational design of a meningococcal antigen inducing broad 
protective immunity. Sci Transl Med 2011; 3: 91ra62. 
74. Nuccitelli A, Cozzi R, Gourlay LJ et al. (2011). Structure-based approach to rationally design a chimeric 
protein for an effective vaccine against Group B Streptococcus infections. Proc Natl Acad Sci 
USA 108: 10278–10283. 
Part I – 6 References 
 
70 
 
75. Heitler W. and London F. (1927) Wechselwirkung neutraler Atome und homöopolare Bindung nach der 
Quantenmechanik. Zeitschrift für Physik, 44, 455—472. 
76. Pauling L, Wilson EB. (1935) Introduction to Quantum Mechanics: With Applications to Chemistry. 
McGraw-Hill Book Company, inc. New York and London. 
77. Heitler W. (1945) Elementary Wave Mechanics – With Applications to Quantum Chemistry. Oxford / 
Clarendon Press, Oxford. 
78. Coulson CA. (1952) Valence. Oxford University Press, Oxford. 
79. Metropolis N, Ulam S. (1949). The Monte Carlo Method. J. Am. Stat. Assoc. 44 (247): 335–341. 
80. Alder BJ, Wainwright TE. (1959). Studies in Molecular Dynamics. I. General Method. J. Chem. Phys. 31 (2): 
459. 
81. Zhao G, Perilla JR, Yufenyuy EL, Meng X, et al. (2013) Mature HIV-1 capsid structure by cryo-electron 
microscopy and all-atom molecular dynamics. Nature 497: 643-646. 
82. Shaw DE, Dror RO, Salmon JK, et al. (2009). Millisecond-Scale Molecular Dynamics Simulations on 
Anton (Portland, Oregon). Proceedings of the ACM/IEEE Conference on Supercomputing (SC09) (New York, 
NY, USA: ACM): 1–11. 
83. http://www.rcsb.org/pdb/static.do?p=general_information/pdb_statistics/index.html 
84. van Gunsteren WF, Billeter SR, Eising AA, et al. (1996) Biomolecular simulation: The GROMOS96 manual 
and user guide. Zürich, Switzerland: Vdf Hochschulverlag. 
85. van Gunsteren WF, Daura X, Mark AE. (1998) GROMOS force field. Encyclopaedia of Comput Chem 2: 1211–
1216. 
86. Oostenbrink C, Villa A, Mark AE, van Gunsteren W. (2004) A biomolecular force field based on the free 
enthalpy of hydration and solvation: the GROMOS force-field parameter sets 53A5 and 53A6. J. Comput. 
Chem. 25: 1656–1676. 
87. Van Regenmortel MHV. (2009) What is a B-cell epitope? Meth. Mol. Biol. 524: 3–20. 
88. Greenbaum JA, Andersen PH, Blythe M, et al. (2007) Towards a consensus on datasets and evaluation 
metrics for developing B-cell epitope prediction tools. J. Mol. Recognit. JMR 20: 75–82. 
89. Novotny´ J, Handschumacher M, Haber E, et al. (1986) Antigenic determinants in proteins coincide with 
surface regions accessible to large probes (antibody domains). Proc. Natl. Acad. Sci. USA 83: 226–230. 
90. Westhof E, Altschuh D, Moras D, et al. (1984) Correlation between segmental mobility and the location of 
antigenic determinants in proteins. Nature 311: 123–126. 
91. Fiorucci S, Zacharias M. (2010) Prediction of protein–protein interaction sites using covering algorithms. 
Biophys. J. 98: 1921–1930. 
92. Ponomarenko J, Bui H–H, Li W, et al. (2008) ElliPro: a new structurebased tool for the prediction of 
antibody epitopes. BMC Bioinform 9: 514. 
93. Thornton JM, Edwards MS, Taylor WR, Barlow DJ (1986) Location of ‘‘continuous’’ antigenic determinants 
in the protruding regions of proteins. Eur. Mol. Biol. Organiz. J. 5: 409–413. 
94. Moreau V, Granier C, Villard S, et al. (2006) Discontinuous epitope prediction based on mimotope analysis. 
Bioinformatics 22: 1088–1095. 
Part I – 6 References 
71 
 
95. Scarabelli G, Morra G, Colombo G. (2010) Predicting interaction sites from the energetics of isolated 
proteins: a new approach to epitope mapping. Biophys. J. 98:1966–1975. 
96. Ma B, Wolfson H, Nussinov R. (2001) Protein functional epitopes: hot spots, dynamics and combinatorial 
libraries. Curr. Opin. Struct. Biol. 11:364-369. 
97. Ponomarenko JV, Bourne PE. (2007) Antibody-protein interactions: benchmark datasets and prediction 
tools evaluation. BMC Struct. Biol. 7:64. 
98. Tiana G, Simona F, De Mori GM, Broglia RA, Colombo G. (2004) Understanding the determinants of 
stability and folding of small globular proteins from their energetics. Protein Sci. 13(1): 113-24. 
99. Morra G, Colombo G. (2008) Relationship between energy distribution and fold stability: insights from 
molecular dynamics simulations of native and mutant proteins. Proteins 72(2): 660-72 
100. Lassaux P, Peri C, Ferrer-Navarro M, et al. (2013) A Structure-Based Strategy for Epitope Discovery in 
Burkholderia pseudomallei OppA Antigen. Structure 21(1): 167-175. 
101. Garmory HS, Titball RW. (2004) ATP-binding cassette transporters are targets for the development of 
antibacterial vaccines and therapies. Infect. Immun. 72: 6757–6763. 
102. Tanabe M, Atkins HS, Harland DN, Elvin SJ, et al. (2006) The ABC transporter protein OppA provides 
protection against experimental Yersinia pestis infection. Infect. Immun. 74: 3687–3691 
103. Monnet V. Bacterial oligopeptide-binding proteins. (2003) Cell. Mol. Life Sci. 60: 2100–2114.. 
104. Borezee E, Pellegrini E, Berche P. (2000) OppA of Listeria monocytogenes, an oligopeptide-binding protein 
required for bacterial growth at low temperature and involved in intracellular survival. Infect. Immun. 68: 
7069–7077. 
105. Genoni A, Morra G, Colombo G. (2012) Identification of domains in protein structures from the analysis of 
intramolecular interactions. J. Phys. Chem. B 116: 3331–3343. 
106. Gourlay LJ, Peri C, Ferrer-Navarro M, et al. (2013) Exploiting the Burkholderia pseudomallei Acute Phase 
Antigen BPSL2765 for Structure-Based Epitope Discovery/Design in Structural Vaccinology. Chem. Biol. 
20(9): 1147-1156 
107. Amadei A, et al. (1993) Essential dynamics of proteins. Proteins 17(4): 412-425. 
108. Morra G, Verkhivker G, Colombo G. (2009) Modeling signal propagation mechanisms and ligand-based 
conformational dynamics of the Hsp90 molecular chaperone full length dimer. PLOS Comp. Biol. 2009, 
5:e1000323. 
109. Suwannasaen D, Mahawantung J, Chaowagul W, et al. (2011) Human immune responses to Burkholderia 
pseudomallei characterized by protein microarray analysis. J. Infect. Dis. 203:1002-1011. 
110. Chen YS, Hsiao YS, Lin HH, et al. (2006) CpG-modified plasmid DNA encoding flagellin improves 
immunogenicity and provides protection against Burkholderia pseudomallei infection in BALB/c mice. 
Infect. Immun. 74:1699-1705. 
111. Hayashi F, Smith KD, Ozinsky A, et al. (2001) The innate immune response to bacterial flagellin is mediated 
by Toll-like receptor 5. Nature 410:1099-1103. 
112. Larsen JE, Lund O, Nielsen M. (2006) Improved method for predicting linear B-cell epitopes. Immunome 
Res 2:2. 
Part I – 6 References 
 
72 
 
113. Saha S, Raghava GP. (2006). Prediction of continuous B-cell epitopes in an antigen using recurrent neural 
network. Proteins 65: 40-48. 
114. Scrima M, Le Chevalier-Isaad A, Rovero P, et al. (2010) CuI-Catalyzed Azide–Alkyne Intramolecular i-to-
(i+4) Side-Chain-to-Side-Chain Cyclization Promotes the Formation of Helix-Like Secondary Structures. 
Eur. J. Org. Chem. v2010(3): 446-457. 
115. Marenholz I, Heizmann CW, Fritz G (2004). S100 proteins in mouse and man: from evolution to function 
and pathology (including an update of the nomenclature). Biochem. Biophys. Res. Commun. 322(4): 1111–
22. 
116. Chiasserini, D., Parnetti, L., Andreasson, et al. (2010) CSF levels of heart fatty acid binding protein are 
altered during early phases of Alzheimer’s disease. J. Alzheimer’s Dis. 22: 1281−1288. 
117. Steiner J, Bogerts B, Schroeter ML, Bernstein HG. (2011) S100B protein in neurodegenerative disorders. Clin. 
Chem. Lab. Med. 49:409−424. 
118. Peri C, Gagni P, Combi F, et al. (2013) Rational Epitope Design for Protein Targeting. ACS Chem. Biol. 8(2): 
397-404. 
119. Vita R, Zarebski L, Greenbaum JA, et al. (2010) The immune epitope database 2.0. Nucleic Acids Res. 2010 
Jan;38(Database issue):D854-62. doi: 10.1093/nar/gkp1004. 
120. Singh H, Raghava GP. (2001) ProPred: Prediction of HLA-DR binding sites. Bioinformatics 17 (12): 1236-7. 
121. Blum JS, Wearsch PA, Cresswell P. (2013) Pathways of antigenic processing. Annu. Rev. Immunol. 31: 443-
73. 
122. Mimura Y, Mimura-Kimura Y, Dorees K, et al. (2007) Folding of an MHC class II-restricted tumor antigen 
controls its antigenicity via MHC-guided processing. Proc. Natl. Acad. Sci. USA 104(14): 5983-8. 
123. Sercarz EE, Maverakis E. (2003) Mhc-guided processing: binding of large antigen fragments. Nat. Rev. 
Immunol. 3(8):621-9. 
124. Moss CX, Tree TI, Watts C. (2007) Reconstruction of a pathway of antigen processing and class II MHC 
peptide capture. EMBO J. 26(8): 2137-47. 
125. Matthews  BW. (1975) Comparison of the predicted and observed secondary structure of T4 phage 
lysozyme. BBA-protein struct. M 405(2): 442–451. 
126. Hwang H, et al. (2008) Protein-Protein Docking Benchmark Version 3.0. Proteins 73(3): 705-709. 
127. Hess B, Kutzner C, van der Spoel D, Lindahl E. (2008) GROMACS 4: Algorithms for highly efficient, load-
balanced, and scalable molecular simulation. J. Chem. Theory Comput. 4(3): 435-447. 
128. http://ambermd.org 
 
 
 
 
 
 
 
Part I – 7 Acknowledgements 
73 
 
7 – ACKNOLEDGEMENTS 
 
The projects described in this thesis were supported by Fondazione CARIPLO (Progetto 
Vaccini, contract number 2009-3577) and Regione Lombardia - Fondazione CARIPLO, 
(Progetto PROVA: “discovery/development of diagnostic PRObes and VAccine candidates 
targeting Burkholderia infections”). 
 
I want to thank and acknowledge all the people that worked with me on these projects: 
CNR-ICRM, Milano 
Alessandro Gori, Dario Corrada, Giulia Morra, Renato Longhi Giorgio Colombo. 
UNIMI, dept. Biosciences, Milano 
Louise Gourlay, Patricia Lassaux, Lucia Perletti, Martino Bolognesi. 
UEX-CLES, Exeter 
Rachael J. Thomas, Olivia L. Champion, Stephen L. Michell, Richard W. Titball. 
UAB-IBB, Barcelona 
Mario Ferrer-Navarro, Oscar Conchillo-Solé, Xavier Daura. 
CMDL, Khon Kaen 
DarawanRinchai, Chidchamai Kewcharoenwong, Arnone Nithichanon, Ganjana 
Lertmemongkolchai. 
 
 
 
 
 
 
 
 
 
 
Part I – 8 Credits 
74 
 
8 – CREDITS 
 
 
 
 
 
 
 
 
 
 
C’è stato un istante, durante la stesura della tesi, in cui avuto una strana sensazione di 
disagio. In quel momento stavo sostituendo il campo in copertina “Name Initials, Last 
name” con il mio nome. Ho sentito come se non fosse del tutto vero, come se quel nome 
non bastasse. Certamente, la tesi di dottorato appartiene al dottorando. Lui svolge il 
lavoro, redige il testo, accompagna un progetto dalla carta da blocco alla carta stampata 
mettendoci il suo impegno, un po’ imparando quello che non sa e un po’ facendo a pezzi 
quello che crede di sapere… 
Eppure penso che una tesi non appartenga solo al dottorando. Molto è dovuto ai suoi 
colleghi, che hanno creato un luogo in cui è piacevole sia lavorare che perdere tempo 
(perché le idee migliori vengono in pausa caffè, è risaputo). Hanno riportato sulla terra le 
ansie e le aspettative, e gli hanno fatto capire presto che anche le persone esperte chiedono 
quando non si sanno rispondere da sole. Di sicuro appartiene al suo supervisore, che prima 
gli ha spiegato le regole e poi gli ha mostrato come si gioca da professionisti. Gli ha dato 
entusiasmo, fiducia e carta bianca, permettendogli di tracciare i contorni dei propri limiti 
in cerca di una via attorno. Ne reclamano la proprietà tutte le persone che hanno 
contribuito allo stesso progetto con le loro differenti competenze, concertando gli sforzi 
e proiettando i risultati verso un traguardo più ampio. Un pezzo appartiene infine alla 
donna che in questi anni di dottorato gli ha custodito il cuore, i pensieri, i sogni. 
 
I miei ringraziamenti sono per voi.  
Thank you Mario, but our 
princess is in another castle! 
Toad 
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Prediction of antigenic B and T cell epitopes via Energy Decomposition analysis. 
Description of the web-based prediction tool BEPPE. 
Claudio Peri1, Oscar C. Solé1, Dario Corrada1, Alessandro Gori, Xavier Daura and Giorgio 
Colombo* 
1All authors contributed equally to this new version of the web tool BEPPE. 
*corresponding author 
 
Summary: 
Unraveling the molecular basis of immune recognition still represents a challenging task 
for current biological sciences, both in terms of theoretical knowledge and practical 
implications. Here, we describe the physical-chemistry methods and computational 
protocols for the prediction of antibody-binding epitopes and MHC-II loaded epitopes, 
starting from the atomic coordinates of antigenic proteins (PDB file). These concepts are 
the base of the web tool BEPPE (Binding Epitope Prediction from Protein Energetics), a 
free service that returns a list of putative epitope sequences and related blast searches 
against the Uniprot human complete proteome. BEPPE can be employed for the study of 
the biophysical processes at the basis of the immune recognition, as well as for 
immunological purposes such as the rational design of biomarkers and targets for 
diagnostics, therapeutics and vaccine discovery. 
 
1.Introduction 
The increasing availability of experimentally solved protein structures and the advances 
in theoretical knowledge and computational resources permitted to obtain a deeper 
understanding of proteins and their physico-chemical properties. This in turn paved the 
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way for the development of dedicated computational tools for the analysis and the 
functional prediction of these properties. In this context, BEPPE (Binding Epitope 
Prediction from Protein Energetics) is a web-based tool for the prediction of antibody 
binding sites and MHC-II loaded epitopes, based on the analysis of protein internal 
energetics. BEPPE is rooted in a computational biophysics approach, defined MLCE, for 
the prediction of antigenic substructures in isolated proteins (1). 
The method was initially applied to the prediction of B-cell epitopes, i.e. epitopes that can 
be recognized and bound by antibodies. (2, 3, 4). The predictive performance (5) of the 
method, originally benchmarked on 19 antibody-antigen interactions, yielded 0.46 
percentage in sensitivity and 0.84 specificity, with a PPV (positive predicted value, also 
referred as precision) of 0.32 and AUC values (Area Under the Curve) (6) of 0.71, at the 
variation of the prediction cutoff. Now we have expanded the possibilities of BEPPE to 
include the prediction of MHC-II epitopes. Our latest benchmark composed of 13 antigens 
and 57 non-redundant MHC-II epitopes, indicate a prediction performance scoring 
sensitivity, specificity and PPV of 0.41, 0.83, and 0.31 respectively, which is very close to 
the predictivity observed for antibody-binding sites [Table 1]. One obvious use of the 
results is the design of synthetic epitope sequences. Moreover, our methods can be 
exploited for the design of optimized antigens. This can be achieved, e.g., through the 
identification of antigen conformations that optimally present immunogenic regions to 
the recognition by the immune system molecules, and the identification of mutations that 
can block the protein in such conformation. BEPPE can be accessed as a free web service 
at the following URL: http://bioinf.uab.es/BEPPE 
 
2. Materials 
BEPPE is largely composed of code written in-house, yet relies on some public free and 
commercial packages to perform the Energy Decomposition Analysis (as described by 
Tiana et al. (7)) and BLAST search (8). Here we describe in detail the conditions and 
parameters integrated in the automated analysis procedure. 
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2.1. MM-GBSA calculation parameters 
The input structure is treated in implicit solvent by means of the MM-GBSA calculation 
approach (Molecular Mechanics Generalized Born Surface Area) included in the AMBER 
(Assisted Model Building with Energy Refinements) software package (9). 
Molecular Mechanics (MM) parameters for interactions are described by the forcefield 
ff03 (10, 11). The MM calculations are carried out with the sander module. 
The polar solvation term is approximated with the Generalized Born (GB) model (12, 13) 
and OBC re-scaling (14) for solvation energy. The dielectric constant is set to 80 for the 
bulk (water as solvent) and 1 for the protein and internal cavities. The GB approach used 
by AMBER takes into account the shielding effect; we have adopted a physiological salt 
concentration (0.1 M). 
The non-polar solvation term is calculated through the evaluation of the solvent accessible 
surface area (SA) using the icosahedra approximation. The non polar contribution to the 
free energy of solvation is calculated as Enp = surften*SA  (no offset correction, SURFOFF 
= 0) and the surface tension (surften) used is 0.0072 kcal/mol/A^2. 
 
2.2. Energy minimization and residue pairwise decomposition 
Input structures undergo a preliminary energy minimization procedure before any 
subsequent analysis, consisting of 200 minimization steps with the steepest descent 
optimization algorithm. Short range and long-range non-bonded interactions are 
considered within a 12 Å cutoff. 
The interaction terms are used to build a matrix, describing the interaction energy 
between every residue pair in the sequence. This matrix is simplified through Principal 
Component Analysis decomposition. The resulting main eigenvectors and eigenvalues are 
used to generate a simplified matrix recapitulating the most relevant stabilizing 
interactions within the protein structure.  
 
2.3 Matrix of Local Coupling Energy (MLCE) and epitope prediction 
The simplified energy matrix reconstructed after PCA is used as the input for epitope 
prediction. BEPPE intersects the energy matrix with information on the protein topology, 
expressed as a contact matrix (6 Å cutoff from beta carbons): the result is the Matrix of 
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Local Coupling Energies (MLCE) (1). From this, the algorithm selects the list of contacting 
amino acids with a minimal coupling to the rest of the protein residues. This list forms 
the final epitope prediction, expressed in the form of patches. The selection of the residues 
carrying the weakest coupling energy depends upon a cutoff, defined as the percentage of 
most-uncoupled pairs over all possible ones in the structure. The cutoff is set by default 
to 15% of all contributions. 
 
2.4 BLAST search of epitopes 
As reported in the bibliography, immunoreactive bacterial epitopes should not match 
sequences present in the human proteome (15). To check for this, predicted epitope 
sequences are blasted against the human proteome, downloaded from Uniprot ftp (16) 
(this file is updated every four weeks). NCBI blast+ version 2.2.23 is executed with 
parameters adjusted for short input sequences using a strategy file downloaded from a 16-
residue query NCBI blast search result. This file contains parameters optimized for short 
sequences as described in the blast help (17). Blast results are provided with the prediction 
output file. 
 
3. Methods 
This section explains in details the procedures and calculation steps to run a prediction 
job. In Fig. 1 we illustrate the individual modules of the server and the job pipeline. 
1. Access the web page for BEPPE at URL http://bioinf.uab.es/BEPPE 
2. Upload your antigen pdb file or pdb file bundle in zip format. The program is 
compatible with single and multiple chain files (see Note 1). Upon submitting the 
job, each structure is passed to the core module for analysis and prediction (see 
Note 2). 
3. The “check and fix” module is composed of a Python script, analyzing the PDB for   
common format anomalies, such as missing residues, presence of 
selenomethionines (MSE), duplicate residues (alternative sidechain position and 
mutations), and alternative atom positions. The script will automatically convert 
any MSE to MET, and remove any atom/residue duplicate, keeping only the first 
one indicated in the PDB file. In case of chain holes the calculation of the pairwise 
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energetic contributions may be dramatically affected. In this case the program 
will be terminated and an error returned via email (see Notes 3 and 4). 
To avoid any unexpected inconvenience, we strongly encourage the user to 
manually check the coordinates file before submitting. 
4. Once the PDB file is accepted, it is passed to a comprehensive automated pipeline, 
converting the PDB file format to AMBER standard, launching the energy 
minimization and the energy decomposition, as described in the Materials 
section. This independent code layer is named “ISABEL” (ISabel is Another BEppe 
Layer). After decomposition, the interaction energy matrix is diagonalized into 
its eigenvalues and related eigenvectors. By default only the first eigenvector will 
be taken into account (7). Alternatively, it is possible to select a subset of the most 
representative eigenvectors according to the method proposed by Genoni et al. 
(18). On the basis of the eigenvector(s) selected, a simplified interaction energy 
matrix will be generated (Fig. 2); such a procedure is intended to emphasize the 
more relevant (from an energetic point of view) non-bonded interactions from 
the initial “raw” interaction energy matrix, as described in details in (1, 19, 20). 
The user can select the alternative energy matrix by checking the box “alternative 
energy matrix” before submission. The use of the alternative matrix is limited to 
large, multidomain proteins, or in presence of multi-chain complexes. The default 
energy matrix should be preferable in the vast majority of cases (see Note 5) 
5. The newly built energy matrix is passed to the module BEPPE, which builds the 
MLCE matrix as the intersection of energy and contact matrices. The energetic 
cutoff for the selection of the epitope patches is set by default to 15% of all 
contributions, which generally scored best for antibody-antigen interfaces (1), but 
other cutoffs may be chosen depending on the user requirements. A stricter cutoff 
will limit the results to the most uncoupled residues, usually located in very small 
patches. Conversely, loosening the cutoff will produce larger patches. The optimal 
range for prediction goes from 5% to 25% of all low-energy contacts (see Note 6). 
The cutoff can be manually adjusted from the drop-down menu “Strictness of 
prediction”. Note that the actual percentages have been substituted in the web 
page with a much simpler notation, being 1 for a strict prediction (5%),  and 5 for 
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a soft one (25%). Clearly, in this simple values notation, the standard cutoff is set 
to 3. 
6. Finally, the patches are blasted against the human proteome for similar motifs. 
Given the fact that most of the applications of BEPPE, including the discovery of 
biomarkers for diagnostics and targets for vaccines and therapeutics, would 
require immunogenic epitopes with no resemblance of pre-existent, endogenous 
proteins, we provide the end-user with a quick outlook on the sequence 
alignment of the results. 
7. The output provided includes the prediction at the residue level in text format 
subdivided in patches, along with the blast search results for each one. In 
attachments, the system provides a pictorial representation of the energy matrix 
as regenerated after decomposition and diagonalization (such as shown in Fig. 
2), and a Pymol script (21) for an automatic, easy visualization of the results 
mapped on the protein structure. 
 
4. Notes 
1. The program is compatible with PDB files including multiple chains. If the user 
needs to run a prediction on individual subunits of a protein complex, or different 
conformations of the same protein, it is required that each structure is submitted 
as an individual PDB file. In a multi-chain file, the total energy of the system will 
be estimated, guiding the predictor towards the most uncoupled patches of the 
whole assembly. Such an analysis may be indicated in the case of complexes 
undergoing obligate interactions. 
2. BEPPE is a web tool returning one prediction for each input PDB file. One can use 
the reference structure obtained by diffraction techniques or NMR solution, but 
we would like to stress the possibility of using multiple conformations of the same 
protein to draw a consensus prediction out of different snapshots (e.g. 3 files), to 
help reduce the noise and focus on the significant patches. These conformations 
may be different fits of an NMR bundle, or representative frames from a Molecular 
Dynamics simulation. 
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3. The script ignores any missing residue as commonly annotated in the PDB 
remarks, since occasionally chain gaps are present within the protein structure 
even if not indicated. For similar reasons, it neither fully relies on the annotated 
numbering of the amino acids. The program progressively evaluates the distance 
of alpha carbons of consecutive residues. If large distances are found ( >2.8 Å) the 
chain gap is evident, even if not indicated, and the job for that file is aborted. If 
smaller distances are found, the annotated chain gap may be just nominal and the 
chain integrity is likely to be maintained. In this case, the PDB file will be 
renumbered, since an uneven numbering may produce artifacts. The renumbered 
PDB file is accepted and a warning is returned (take into account that any 
prediction will follow the numbering of this new file, not the original one!). 
4. The program automatically rejects any input structure containing chain gaps, 
since the extent of the energy perturbations and their effect on the predictivity 
have never been addressed in our benchmarks. Nevertheless, if you wish to run a 
prediction on a protein structure containing chain holes, try submitting it as a 
multiple chain file. 
5. Usually, the first eigenvector is sufficient to reconstruct the energetic signature 
of a protein (7). However, when attempting to reconstruct the energy matrix of 
proteins composed of independent domains (or subunits, considering 
complexes), the first eigenvector may be insufficient for a complete protein 
coverage. The user can be aware of this issue by looking at the graphic 
representation of the energy matrix (provided as an email attachment. An 
example is shown in Fig. 2). When the energetic information (the colored 
clusters) is not spread along the whole energy matrix (i.e. in presence of large, 
white bands in correspondence of one domain), this may be due to the inability 
of the first eigenvector to represent the full matrix. The alternative method 
reconstructs the matrix with the specific task of maximizing coverage while 
considering only the most cohesive and representative energy modules from the 
top-ranked principal eigenvectors. This method is to be intended as a recovery 
system for those areas that would be left undescribed, since its efficacy has never 
been validated for the purpose of epitope prediction. 
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6. BEPPE is particularly sensitive to extremely low-coupling energies. Meaning that 
unstructured regions extended towards the solvent, thus bearing minimal 
contacts with the rest of the protein (such as long, flexible loops), will inevitably 
mark the local energy matrix (MLCE) with a strong uncoupled signal. Albeit these 
regions may actually include an epitope, the presence of such strong signals may 
mask the presence of other regions worth of attention. Such an event can be easily 
acknowledged by looking at your reference structural data, and comparing it with 
the energy matrix provided as an email attachment. If the energy matrix shows 
an overwhelming signal in correspondence of such motifs, we strongly 
recommend to use a very low cutoff (values 1-2 from the drop-down menu) for 
your primary prediction (returning the core of the uncoupled motif/region), and 
run a subsequent prediction with a loose cutoff (value 5 from the drop-down 
menu). The second run can extend the prediction to include other, distal 
significant patches. In this case, one can ignore the “bleaching” noise effect 
produced at high cutoffs around the primary patch (due to the extremely strong 
signal) and focus on the core patch identified with the first prediction and the 
“secondary” patches highlighted at higher cutoff. 
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Figures 
Fig. 1. Layout of the web tool BEPPE: 
each individual PDB file is passed by 
the User Interface to the prediction 
pipeline (double line hexagons). The 
main modules processing the 
structure, existent even in stand-alone 
format, consist of a preliminary input 
check script, the package ISABEL for 
the energy decomposition and 
analysis, the program BEPPE for the 
prediction of epitopes, and the BLAST 
script. All results (and eventually all 
errors) are gathered in a unique text 
file accompanied by supplementary 
data, and sent to the user via email 
(red, shaded background, single line 
hexagons). 
 
Fig. 2. Example of simplified energy 
matrix of the human Cyclin-
dependent kinases regulatory subunit 
1 (CKS1B), reconstructed from the first 
eigenvector of the non-bonded energy 
matrix, after diagonalization. The 
information is expressed on a residue 
pair basis, so each value represent the 
coupling energy of two amino acids on 
the protein sequence (x and y axis). The weaker the signal, the more intense is the color, 
highlighting the most energetically uncoupled residues. Conversely, those areas that carry 
the strongest energy of stabilization are depicted here as light bands. 
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Tables 
Table 1. Overall performance analysis of BEPPE in the task of MHC II epitopes prediction. 
For every protein (PDB code) is reported the optimal cutoff for prediction and the 
classification performance parameters sensitivity, specificity, precision and accuracy (5). 
The Matthews Correlation Coefficient (MCC) (22) test and statistical significance of the 
analysis (p-value) are also reported. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 MHC-II EPITOPES
 PREDICTION PERFORMANCE ANALYSIS
PDB ID Cutoff SENS. SPEC. PREC. ACC. MCC p-value
1CB0.A 25% 0.55 0.63 0.06 0.63 0.07 1.42E-059
1D3B.A 15% 0.20 0.94 0.33 0.84 0.17 5.05E-003
1EA3.A 10% 0.14 1.00 1.00 0.36 0.20 4.00E-009
1HA0.A 25% 0.00 0.88 0.00 0.85 -0.06 7.16E-065
1I7Z.A 10% 0.44 0.90 0.16 0.88 0.22 7.32E-021
1OVA.D 25% 0.27 0.59 0.19 0.51 -0.12 3.41E-022
2GIB.B 25% 0.38 1.00 1.00 0.59 0.41 9.80E-008
2JK2.A 15% 0.87 0.86 0.28 0.86 0.44 6.36E-028
2VB1.A 25% 0.34 0.83 0.62 0.60 0.19 1.60E-001
2WA0.A 20% 0.70 0.82 0.16 0.82 0.27 4.27E-031
3BZH.A 25% 0.89 0.74 0.18 0.75 0.33 1.35E-026
3FEY.C 25% 0.50 0.74 0.08 0.73 0.11 1.28E-078
3HLA.A 15% 0.00 0.78 0.00 0.59 -0.25 1.09E-020
AVERAGE 20% 0.41 0.82 0.31 0.69 0.15
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Abstract 
Bulkholderia pseudomallei is the etiological agent of melioidosis, a severe endemic disease 
in South-East Asia, causing septicemia and organ failure with high mortality rates. Current 
treatments and diagnostic approaches are largely ineffective. The development of new 
diagnostic tools and vaccines towards effective therapeutic opportunities against B. 
pseudomallei is therefore an urgent priority. In the framework of a multidisciplinary 
project tackling melioidosis through reverse and structural vaccinology, BPSL1050 was 
identified as a candidate for immunodiagnostic and vaccine development based on its 
reactivity against the sera of melioidosis patients. We determined its NMR solution 
structure and dynamics, and by novel computational methods we predicted immunogenic 
epitopes that once synthesized were able to elicit the production of antibodies inducing 
the agglutination of the bacterium and recognizing both BPSL1050 and B. pseudomallei 
crude extracts. Overall, these results hold promise for novel chemical biology approaches 
in the discovery of new diagnostic and prophylactic tools against melioidosis. 
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Introduction 
Bulkholderia pseudomallei is the etiological agent of melioidosis, a severe endemic disease 
in South-East Asia, Australia, the Indian subcontinent, southern China, and with sporadic 
cases in South America 1. The global incidence of the disease is unknown, but in rural areas 
of north Thailand it accounts for 40% of all deaths from community-acquired septicemia 
2. Because of its airborne transmission, high mortality rate, and multidrug resistance the 
Gram negative B. pseudomallei is also considered a potential bioterrorism agent and has 
been defined as category B priority pathogen by the US Centers for Disease Control and 
Prevention 3, 4. B. pseudomallei is inherently resistant to many antibiotics, including first, 
second and third generation cephalosporins, aminoglycosides, penicillins and polymyxin 
5, making its treatment extremely difficult. Moreover, it is a facultative intracellular 
bacterium with the ability to infect different cell types 6, 7. Conceivably, intracellular 
replication and survival can assist the bacteria in circumventing the humoral immune 
system, explaining the long periods of latency, recrudescent or relapsing infections 
following many years after the initial infection. For all these reasons, development of 
effective B. pseudomallei vaccines and diagnostics is an urgent priority. However, at 
present there are neither effective methods of diagnosis nor approved vaccines for 
melioidosis in humans or animals 8, 9. Of note, several melioidosis symptoms, e.g. 
pneumonia, chronic disease, septicemia, inner organ failure and localized abscesses, are 
shared by other pathologies, thus hampering a timely and correct diagnosis. The high 
mortality rate (between 30% to 70%) is mainly ascribed to the short time (24-48 h) 
available for antibiotic therapy intervention before the appearance of the acute phase 
symptoms 10. In this respect, serological diagnosis assays based on the indirect 
hemagglutination test (IHA) 11 are preferred to the time consuming bacterial cultures 12. 
However, IHA has several limitations: i. high background levels of antibody titers found 
in healthy persons living in endemic areas confuse the diagnostic results13, ii. patient sera 
aspecific immunorecognition of whole bacterial lysate increases the probability of false-
positive results, iii. limited test standardization leads to poor characterization of the 
different B. pseudomallei strains 14. Reliable, specific and rapid diagnostic tools, such as 
serologic assays, using antigens that can differentiate asymptomatic from clinical 
infection, are essential for diagnosis prior to antibiotic treatment 10. 
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The identification, characterization and optimization of such antigens may constitute an 
important starting point towards the development of efficient management of B. 
pseudomallei infections.  
In this context reverse vaccinology (RV), i.e. the process of genome-based antigen 
discovery, could strongly contribute to the efficient identification of surface-located 
proteins both as candidate vaccines against B. pseudomallei and as diagnostic bioprobes. 
This approach, complemented by recombinant antigen production and immunological 
tests to assess their antigenic/protective properties 15, 16 has proven to be essential both for 
the development of selective diagnostic tools and of therapeutic vaccines for other 
pathogens 17. Structural vaccinology (SV) supports RV predicting epitopes recognized by 
antibodies (Abs) 18, 19, 20. It provides a structural rationale for the synthesis of epitope 
mimics as bioprobes to selectively capture disease specific antibodies in patient sera, thus 
facilitating infection diagnosis 21, 22. Furthermore, SV can be used as the starting point to 
rationally design peptides and to optimize the properties of antigenic proteins (or 
domains) that elicit the production of bacteria-neutralizing antibodies or that trigger a T-
cell response.  
Recently, a protein array of 1,205 B. pseudomallei proteins was used to map the antibody 
response in 747 serum samples from well-defined melioidosis positive and negative 
patients. This led to the identification of 49 protein antigens that are significantly more 
reactive to sera from B. pseudomallei infected patients, opening new opportunities for the 
generation of better diagnostics and vaccines 23. Herein we present a successful example 
of a structural vaccinology approach on BPSL1050, a candidate for immunodiagnostic and 
vaccine development. Its solution structure and dynamics, combined to Matrix of Local 
Coupling Energy (MLCE) and Electrostatic Desolvation Profiles (EDP) methods 24 allowed 
for prediction of immunogenic epitopes. Structural and physicochemical principles, 
complemented and corroborated by experimental epitope mapping methods, guided the 
synthesis of reactive epitopes that elicited the production of Abs, which in turn effectively 
induced the bacterium agglutination. Notably, these Abs were even more effective in 
amplifying this immune response than Abs raised against the whole protein, thus 
supporting the development of strategies focussing on single antigenic protein elements. 
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Results and discussion 
In this work we adopted a SV pipeline that entails: i. NMR structural characterization of 
an antigenic protein from B. pseudomallei; ii. computational prediction of epitope 
sequences; iii. their chemical synthesis as free or conjugated peptides; iv. elicitation of 
specific antibodies; v. Abs induced bacterial agglutination. We focused on BPSL1050, a 
highly immunoreactive hit emerging from the analysis of a protein array displaying RV-
selected B. pseudomallei proteins 23. The predicted pathogen surface exposure of 
BPSL1050, a highly conserved protein in the Burkholderia family (Figure S1), along with 
its relative small dimensions made it particularly suitable for SV investigations by means 
of multidimensional heteronuclear NMR spectroscopy (Table 1). Importantly, the epitope 
mimics generated on the basis of our SV strategy was able to recapitulate the main 
immunogenic determinants of the whole protein, eliciting antibodies that recognized 
recombinant full-length BPLS1050 and crude extract of B. pseudomallei. Remarkably, 
these Abs turned out to be more effective than Abs raised against the whole protein in 
triggering bacterial agglutination. 
 
3D solution structure of BPSL1050 
Recombinant BPSL1050 (residues Met5-Ala130) behaves as a monomer in solution, as 
assessed by gel-filtration elution volumes 25 and by the rotational correlation time (τc~9 
ns, determined from 15N relaxation data) (Figure S2), which is in good agreement with the 
expected value for a folded 14KDa protein. The structure consists of three helical regions 
comprising residues Asp8-Leu29 (α1), Thr74-Met81 (α2) and Gly85-Arg107 (α3), that pack 
onto an antiparallel β sheet, formed by 4 strands spanning residues His34-Val38 (β1), 
Thr47-Ala53 (β2), Leu66-Thr71 (β3), and Leu120-G124 (β6) (Figure 1A, B). Notably, helix 
α3 is characterized by a pronounced bend around Pro97 and is connected by a short loop 
(Glu82-Ala83) to helix α2, which is on turn almost perpendicular to the N-terminus of 
helix α1. Finally, residues Val109-Asp110 (β4), Thr115-Gln116 (β5) form a small β-strand 
which folds back like a lid towards the C-termini of helices α1 and α3. The overall protein 
topology is α1, β1, β2, β3, α2, α3, β4, β5, β6. The four stranded antiparallel β-sheet is 
solvent exposed on one side and packs tightly against the three helices on the other side, 
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generating a network of hydrophobic and aromatic interactions that contribute to tight 
packing of the protein (Figure 1B,C). 
In agreement with its structural compactness, BPSL1050 is extremely stable, as assessed 
by the high melting temperature (Tm=67 C°) measured by Circular Dichroism thermal 
denaturation (Figure 1D). Interestingly, the C-terminal tail (spanning residues Gly125-
Glu129) is well ordered and fills a groove formed by helix α2 and α3, as supported by a 
dense network of NOE contacts between Leu126, Phe128 and distal residues (Figure 1C). 
Most of the fold is well defined in the bundle of structures, with a root mean square 
deviation (rmsd) of 0.92 ±0.15 Å on the backbone atoms from residue Thr8-Gly129. Only 
the N-terminal residues (Met1-Pro7, whereby the first four residues belong to the residual 
N-terminal tag) and the protruding loops comprising Gly41-Gly44 (L1) and Pro54-Pro65 
(L2) are highly disordered, as assessed by the paucity of NOEs. Of note, the amide of Gly42 
and Gly44 are not visible in HSQC spectra, due to exchange with the solvent, and residues 
located in L2 display a clear decrease of their heteronuclear NOE values, indicative of 
motions in the ps-ns timescale (Figure 1E). Collectively, the high exposure and high 
internal mobility of L1 and L2 anticipate for these loops a potential role as antibody 
recognition sites.  
Structure similarity searches with the DALI 26 server did not produce a significant match 
with any other protein except for CYAY from Burkholderia cenocepacia (with an rmsd of 
4.2 Å over 82 residues and a Z score of 4.2). CYAY is a bacterial homolog of human 
frataxin, a mitochondrial protein important in iron homeoastasis 27. Similarly to CYAY and 
human frataxin, BPSL1050 displays a patch of negatively charged residues on one edge of 
the protein (Figure 1E), reminiscent of a possible iron binding site. However NMR 
titrations with Fe2+ and Fe3+ and other metal ions (Mg2+, Ca2+, Zn2+) did not show any 
interaction (data not shown), excluding a possible functional relationship between 
BPSL1050 and CYAY/Frataxin. BPSL1050 is highly conserved along the Burkholderia 
family, suggesting a fundamental yet unidentified function in the life of the pathogen. In 
this respect, the availability of an atomically detailed characterization of its structure and 
dynamics will be important in the screening/development of antimicrobial molecules 
targeting B. pseudomallei, as a complementary strategy to vaccine development 
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Characterization of protein dynamics via MD simulations and comparison with 
NMR-derived parameters.  
Three 100ns MD simulation runs were performed, starting from BPSL1050 NMR solution 
structure. The Root Mean Square Fluctuation profile of the Cα atoms from the initial 
structure is well conserved among the three runs, and shows that the region encompassing 
residues Ala53 to Asn67, including loop L2, displays the largest degree of mobility (Figure 
2A), in agreement with heteronuclear NOE data (Figure 1E). This loop is mostly 
unstructured and undergoes rearrangements paralleled by conformational changes of the 
lid region Val109-Ala119.  
To investigate the major, non-random large-scale displacements of the protein 
substructures, the pair wise covariance matrix of atomic displacements was calculated for 
each trajectory. This matrix accounts for correlations in atomic motions and is used to 
highlight protein regions that move coherently. Principal components analysis (PCA) or 
Essential Dynamics (ED) analysis 28 can then be used to reduce the dimensionality of the 
matrix by diagonalization. This emphasizes the amplitude and direction of dominant 
global protein motions, which correspond to the ones occurring along the matrix 
eigenvectors associated to the main eigenvalues. PCA shows that the protein core, 
composed of the four main anti-parallel ß-sheets and part of the two principal α-helices, 
is stable and rigid throughout the simulations. Conversely, loop L1 and the hinge between 
helices α2 and α3, together with loop L2 and the Val109-Ala119 lid account for the 
principal conformational changes (Figures 2B, C). As non-random, cooperative 
displacements involve two opposite sides of the protein, the atomic details governing their 
mechanical connection were investigated by means of Coordination Propensity (CP) 
analysis whereby mechanically coordinated pairs of aminoacids are defined on the basis 
of their distance fluctuations: the lower the distance fluctuation, the higher the 
mechanical coordination (Figure 3A). Applying this analysis to all possible pairs within 
the protein and selecting the ones with minimal distance fluctuations we defined the 
network that connects the two regions undergoing non-random displacements, that 
encompasses helix α1, Ala53 and Pro54, and finally loop L2 (Figure 3B, C). In contrast, the 
region between Leu96 and the C-terminus, including part of helix α3 and β4 and β5 
strands, appears mechanically uncoupled from the rest of the protein. 
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According to the CP profile (Figure 3B) helix α3 is characterized by a strong internal 
coordination and behaves as an independent rigid body.  
 
In silico epitope prediction 
Next, we investigated the antigenic determinants of the novel structure of BPSL1050. The 
3D representative structures obtained from the clustering analysis of the MD simulations 
were used to predict the location of antibody-binding epitopes. To this end, a consensus 
prediction was generated using the MLCE and EDP methods. This pipeline for epitope 
prediction has already been successfully validated in other applications based on the 
concept that the 3D structure of an epitope, its related dynamics and exposure properties 
determine its antibody-binding, and consequently its antigenic potential 21, 22. In this 
context, MLCE integrates the analysis of the dynamical and energetic properties of 
proteins to identify non-optimized energetic interaction-networks on the surface of the 
isolated antigens, which correspond to substructures that can aptly be recognized by a 
binding partner (the antibody). EDP calculates the free energy penalty for desolvation by 
placing a neutral probe at various protein surface locations. Surface regions with a small 
free energy penalty for water removal may correspond to preferred interaction sites. The 
sequences of the individual predictions resulting from the two methods and their location 
on the protein structure are reported in Table 2 and Figure 4A, respectively. Based on the 
resulting consensus, composed of different sequences located on two main areas 
(39GYGGHGHP46-53APHAEHVRGYAP65 and 94AALPRK99-101AA102-104ENARGVD110-115T-
117ADA119), we predicted the presence of three main immunogenic sequences: the small 
loop L1, the main loop L2, and part of helix α3 extending until Leu120. These substructures 
are energetically uncoupled with respect to the rest of the protein, and their contribution 
to the overall fold stability is minimal. This finding is consistent with the dynamic 
behavior observed by CP analysis, whereby the main loop shows the highest mobility, and 
helix α3 is not mechanically coordinated with respect to the protein core. Combining this 
information with the previous analysis, we hypothesized that these regions may represent 
viable candidate epitope sequences.  
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Experimental epitope mapping 
The sequences identified by computational epitope predictions were next cross-validated 
with experimental epitope mapping experiments that were carried out using recombinant 
BPSL1050, cognate polyclonal sera and polyclonal rabbit sera using a protocol developed 
in-house 22, 29, 30. Rabbit sera were collected before and after immunization. The pre-
immune serum was used as control, to discard non-specific binding. Three different 
peptides were captured by the polyclonal IgGs from BPSL1050-immunised rabbit, with 
masses 2213.1 Da, 3268.430 Da and 6533.364 Da. In order to unequivocally determine the 
sequences of these peptides, MS/MS spectra were obtained (Figure S3). The 
corresponding sequences are 61GYAHPLNLALTWNTDEIER79 for the 2213.1 Da ion and 
93LAAWENARGVDFGSRTQADALVLLGGLDFEA130 (EXP-2) for the 3268.430 Da ion. No 
MS/MS spectra could be obtained for the peak with a mass-to-charge ratio of 6533.364 Da 
due to its large mass and scanty ionization. Nevertheless, peptide mass fingerprinting 
assigns this peak to 
21IARAIADLLNHRAHTDVVGYGGHGHPTQVRIVAPHAEHVRGYAHPLNLALTWNTD
EIER79 (EXP-1) that contains the sequence of 2213.1 Da identified by MS/MS. Interestingly 
the two peptides are located in the same region of the protein (Figure 4A). 
 
Synthesis and conjugation of predicted epitopes. 
To obtain a minimal number of peptides eliciting the production of Abs, we synthesized 
two sequences recapitulating the consensus between the computational and experimental 
epitope mapping methods. To this aim we used microwave-assisted Fmoc-chemistry, 
including triethyleneglycolate (O2Oc) spacer units, and coupling to keyhole limpet 
hemocyanin (KLH) to serve as carrier proteins. The two consensus peptides were L1050#1 
(connecting L1 and L2 Cys--(O2Oc)2-38VGYGGHGHPTQVRIVAPHAEHVRGYAP65) and 
L1050#2 (extending from helix α3 
 84DGAARFERYLAALPRKLAAWENARGVDFGSRTQADAL120-(O2Oc)2-Cys), with the 
computationally predicted mapped epitope residues highlighted in bold (Table 2, Figure 
4B). In both cases we combined short predicted sequences in two unique constructs to 
allow for the simultaneous presentation of different potential epitopes. 
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Evaluation of anti-L1050#1 and anti-L1050#2 rabbit Abs. 
The two synthetic epitopes were used to elicit Abs production in rabbits. After purification 
Abs were evaluated for specificity against full length BPSL1050 and single peptides using 
indirect ELISA. Notably, Abs raised against the individual peptides recognized full-length 
BPSL1050 (Figure 5B) as effectively as the immunizing peptide (Figure 5C, D). They also 
recognized a crude extract of B. pseudomallei (Figure 5A). These results confirm that the 
two epitope mimics recapitulate the immunogenic determinants of the protein. 
Remarkably, considering the lack of reliable diagnostic tools for melioidosis, the Abs 
ability to recognize cognate antigen could aptly be exploited to generate biomarkers for 
the efficient detection of B. pseudomallei infections. In this perspective, designed epitopes 
and Abs could be used as bioprobes in combination for microarray display or for 
multiplexed ELISA tests, fostering the development of rapid pathogen detection tests, and 
ultimately allowing a timely pharmacological intervention. 
 
Agglutination ability of anti-BPSL1050, anti-L1050#1 and anti-L1050#2 Abs 
We next tested the generated Abs for their agglutination ability (Figure 6A-D). 
Agglutination is a host defense mechanism in which antibodies recognize and bind to 
surface antigens on multiple bacteria eventually causing their aggregation and consequent 
microbial death 31. It also favors bacterial clearance by phagocytes and impedes pathogens 
migration through tissues, limiting the infection 32. Abs raised against BPSL1050, L1050#1 
and L1050#2 were all able to agglutinate B. pseudomallei cells and not E. coli control cells 
(data not shown), indicating that the effect promoted by our Abs is specific for B. 
pseudomallei. The full length protein was sufficient to induce a faint effect after 30 
minutes (as shown by the red arrow in Figure 6B). Of note, Abs against the peptides were 
more effective than Abs raised against the whole protein in triggering pathogens cells 
agglutination (Figure 6C, D), suggesting that it is possible to amplify the protective 
immune response using a single antigenic element of the antigen. Collectively, the 
agglutination and clearance effects elicited by the Abs against the designed peptides 
demonstrate the efficacy of strategies focussing on the specific immunogenic 
determinants of antigens to design biomolecules able to activate protective immune 
responses. 
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These Abs could for instance be exploited in passive immunization, as well as adjuvants 
in combination with other components in new therapeutic vaccines 
 
Conclusions and Perspectives 
In conclusion, the results presented on this previously unexplored B. pseudomallei protein 
provide support for the efficacy of strategies combining structural investigations, 
computational design approaches and experimental immunological analyses to 
understand the antigenic determinants of protein antigens. Our results might have 
applications in the design of specific bioprobes (e.g. peptides, and antibodies) that, 
combined to other antigenic derivatives, could be effective in the development of rapid 
diagnostic and therapeutic approaches against melioidosis.  
The increasing knowledge on the epitopes deriving from different B. pseudomallei proteins 
and their immunoreactivities opens new perspectives in the chemical biology strategies 
against the pathogen. These entail on the one hand the production of Abs for passive 
immunization, and on the other hand the design of chemical multipresentation systems 
33, 34 as potential immunogens. In particular, nanoparticles and dendrimers, 
simultaneously displaying multiple antigenic sequences that recapitulate the 
immunogenic determinants of various targets, could have therapeutic potential for the 
development of novel vaccination strategies.  
 
Methods 
 
Protein expression and purification 
Isotopically enriched BPSL1050 (15N/13C, or 15N labelled) was expressed and purified as 
described previously 25. NMR samples were prepared in a buffer containing 150 mM NaCl, 
20 mM NaH2PO4, 20 mM Na2HPO4, 2 mM DTT buffer at pH 7 with 0.16 mM 4,4-
dimethyl-4-silapentane-1-sulfonic acid (DSS) and 10% D2O. 
 
NMR measurements 
NMR experiments were performed at 25 °C on a 600-MHz spectrometer (Bruker Avance 
600 Ultra Shield TM Plus, Bruker BioSpin) equipped with a triple-resonance TCI 
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cryoprobe with a z-shielded pulsed-field gradient coil. Data were processed with Topspin 
(v. 2.2) (Bruker Biospin) and/or with NMRPipe 35 and analysed with CCPN analysis 2.2 
software 36. The 1H, 13C and 15N chemical shifts of backbone side and chains resonances 
have been assigned as described previously 25. Proton–proton distance constraints were 
obtained from 15N and 13C separated 3D NOESY spectra employing 100 ms mixing times. 
3J(HN, Ha) coupling constants were measured to derive restraints for φ dihedral angles. 
Additional φ/ψ restraints were obtained from backbone chemical shifts using TALOS+ 37. 
Hydrogen bond restraints were defined from slow-exchanging amide protons identified 
after H2O/D2O exchange . 1H–15N residual dipolar couplings were measured in isotropic 
and anisotropic phases obtained using polyacrylamide gel (8.5% (w/v). Heteronuclear {1H} 
15N nuclear Overhauser enhancements (hetNOEs), longitudinal and transversal 15N 
relaxation rates (T1, T2) were measured using standard 2D methods 38, duty-cycle heating 
compensation were used for both T1 and T2 relaxation experiments 39. T1 and T2 decay 
curves were sampled at 12 different time points (50–2000 ms and 12–244 ms, respectively) 
collected in random order, with 2.5 seconds recovery delay. The {1H}15N NOEs were 
measured recording HSQC 38 spectra with and without proton saturation in an interleaved 
fashion using a 4 seconds recycle delay. T1, T2 and hetNOE values have been obtained 
using the NMRView fitting routine 40.  
 
Structure calculation 
Structures were calculated using ARIA 2.3.1 41 in combination with CNS 42 using the 
experimentally derived restraints (Table 1). All NOEs were assigned manually and 
calibrated by ARIA 2.3.1. A total of eight iterations (20 structures in the first six iterations) 
were performed: 100 structures were computed in the last iteration. The ARIA2.3.1 default 
water refinement was performed on the 15 best structures of the final iteration. Structural 
quality was assessed using PROCHECK-NMR 43 and CING 44. The family of the 15 lowest 
energy structures has been deposited in the Protein Data Bank with the accession code 
2mpe. 
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Circular dichroism measurements 
CD spectra (20°C) were acquired on a Jasco J-815 using a rectangular quartz cuvette (1 mm 
path length, Hellma). Each spectrum was averaged over 4 scans collected in 0.1 nm  
 
intervals with an average time of 0.5 s. BPSL1050 concentration was 10 μM in 10 mM NaF, 
20 mM NaH2PO4/Na2HPO4 buffer (pH 7). Thermal denaturation curves were obtained 
monitoring the ellipticity at 222 nm and at 200 nm from 20 °C to 95 °C at a constant scan 
rate of 1 C°/min.  
 
Molecular Dynamics Simulations and Signal Propagation Analysis 
Three structures extracted from the NMR bundle where used for three independent MD 
simulations (100 ns each). Simulations and analyses were performed using the GROMACS 
4.51 software package 45, GROMOS96 force field 46 and the SPC water model 47. 
Simulations details are described in Supplemental Information.  
The main structural fluctuations of the protein were analyzed through Principal 
Component Analysis of the trajectories 28). Residue-pair Communication Propensity (CP) 
is calculated as a function of the fluctuations of interresidue distances 48. Details are 
described in Supplemental Information. 
 
In silico/in vitro epitope prediction, mapping and synthesis 
All details for computational epitope prediction, epitope mapping with murine sera, 
peptide synthesis and conjugation to the carrier protein are described in Supplemental 
Information.  
 
Rabbit immunizations and generation of Abs.  
New Zealand white rabbits were subcutaneously vaccinated in multiple sites in hind 
quarter locations with purified BPSL1050 in a 1 mL volume emulsion of complete Freud’s 
adjuvant (Sigma Chemicals co., St Louis, MO, USA). Boosters were administered at days 
14, 28, 42, 56, 70, 84 and 98 in a 1 mL volume emulsion of incomplete Freud’s adjuvant. 
Blood samples were collected from the central auricular artery in between immunizations 
and exsanguinations took place on day 107 (Harlan, Derby, UK). 
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Serum antibody concentration  
The concentration of antigen specific antibody in the terminal immune sera was 
determined by ELISA. Experimental details are summarized in Supplemental Information. 
Production and purification of anti-L1050#1 and anti-L1050#2 antibodies. 
Rabbit polyclonal antibodies were generated by Primm srl, Milano Italy. Antisera were 
immunopurified against peptide, chemically linked to Cyanogen Bromide Activated 
Sepharose (Sigma-Aldrich), following the manufacturer’s instructions.  
 
Indirect ELISA to detect antibodies to B. pseudomallei.  
Antibody recognition of the two synthesized peptides (L1050#1 and L1050#2) and the full 
BPSL1050 was detected using indirect ELISA using 96-well microtitre plates (Nunc 
Maxisorp) that were uncoated or coated with 1 μg/mL of crude B. pseudomallei extract as a 
control, 10 μg/ml of BPSL1050 protein, or 3 μg/mL peptides for L1050#1 and L1050#2 in 
0.1 M carbonate-bicarbonate buffer (pH 9.6), incubating at 37°C for 3 h.. The results were 
normalized with O.D. of uncoated well, and represented as Absorbance index = (O.D.450nm 
test - O.D.450nm uncoat) / O.D.450nm uncoat. 
 
Agglutination of B. pseudomallei after exposure to antibodies raised against 
BPSL1050, L1050#1 and L1050#2 
RFP-expressing B. pseudomallei K96243 49 or E. coli 29522 (ATCC), as negative control, 
were sub-cultured from overnight broths into LB and grown to log phase. Bacteria (1 x 
108) were incubated with either 1 µg BPSL1050 antisera or 1 µg antibody towards BPSL1050 
epitope 1 (L1050#1) or epitope 2 (L1050#2) reconstituted in PBS. Controls were pre-bleed 
from the rabbit before immunization, B. pseudomallei capsule antibody 4V1H12 50 and PBS 
alone. Incubation was performed static at 37 °C for 30 minutes. A 30 µL aliquot of culture 
was placed onto a glass cover slip and allowed to air dry before fixing in 1% 
paraformaldehyde for 10 min. The cover slips were washed three times in PBS and 
mounted onto glass microscope slides using VECTORshield hardset mounting media with 
DAPI (Vector laboratories, Burlingame, CA). Bacterial agglutination was observed under 
epi-fluorescence microscopy (Zeiss, Oberkochen, Germany). 
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Figures and Tables 
 
Prediction method Name Epitope sequence
MLCE MD1-E1 47IQAGL51
MLCE MD2-E1 45D 47IQAG50 54GGQTG58
MLCE MD3-E1 50GLIIGGQT58
MLCE MD1-E2 78SVG80 83AGAQS87
MLCE MD2-E2 78SVGLQAGAQSK88
MLCE MD3-E2 77LSVG80 83AG84
MLCE MD1-E3 110AAGADA115 117V 122MGANGAIDTTTATA135
MLCE MD2-E3 122MGANGAIDT130 132TATA135
MLCE MD3-E3 110A 112GADASVA118 121KMGANGAIDTTTATAP136
EDP EDP-1 44PDVIQAGLIIGGQTGN59
EDP EDP-2 76SLSVGLQAGAQSK88
Epitope mapping EXP-1 39GVLVFPDVIQAGLIIGGQTGNGALR63
Synthetic peptide Lipo#1 40VLVFPDVIQAGLIIGGQTGNGALRV64
Synthetic peptide Lipo#2 76SLSVGLQAGAQSK88
Synthetic peptide Lipo#3 110AAGADASVALVKMGANGAIDTTTATAPVE137
Table 2: List of computationally (MLCE; EDP) predicted epitopes and synthesized 
peptide 
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1861
353
234
282
937
55
49
72
72
0.0030 ±
0.00006
0.445 ±
0.008      
0.920 ±
0.145/ 
1.145 ±
0.132
0.368 ±
0.074/ 
0.650 ±
0.064
11, 14
13, 17
76, 99
b) No dihedral angle restraints was violated by more than 5°.
c) R.m.s. deviation between the ensemble of structures and the mean structure .
d) R.m.s. deviation between the ensemble of structures and the mean structure calculated on  residues 
8-29, 34-38, 47-53, 66-71, 74-81, 85-107, 109-110, 115-116 and 120-124.
e) Residues in disallowed regions are located on the flexible loops L1 and L2.
f) interactive Common Interface for NMR structure Generation ROG (Red, Orange, Green) factor: 
% residues percentage, # number of residues. Residues in red are located on the flexible loops L1a nd 
L2.
        Red, (%, #)
        Orange, (%, #)
        Green, (%, #)
a) No distance restraint was violated by more than 0.5Å. 
% residues in most favored region of Ramachandran plot           89.0
% residues in additionally allowed region                                     10.5
% residues in generously allowed region                                       0.2
% residues in disallowed region
e
                                                   0.2
iCING
f
Coordinate Precision (Å) 
N, C
α
, C’ / all heavy atoms (residues 8-129)
c
N, C
α
, C’ / all heavy atoms 2
nd
  structure
d 
Structural quality
Procheck
Dihedral angles (ψ)
Deviation from idealized covalent geometry
Bonds (Å)
Angles (º)
Medium range ( 1< |i-j| ≤ 4)
Long range ( |i-j| > 4)
Intraresidual 
Hydrogen bonds
1
DNH
Dihedral angles ()
Table 1: Summary of conformational constraints and statistics for
BPSL1050
Experimental distance restraints
a,b
All 
Sequential ( |i-j| = 1)
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Figure 1: Solution structure of BPSL1050. (A) Superposition of BPSL1050 of the best 15 
BPSL1050 structures, α-helices, ß-strands and mobile loops (L1 and L2) are represented in 
red, yellow and blue, respectively. (B) Cartoon representation of BPSL1050 showing the 
hydrophobic side-chains (in sticks) stabilizing the protein fold. (C) Zoom into the 
hydrophobic cluster around the C-terminal Phe128 (green). (D) Thermal denaturation 
curve of BPSL1050 (10 μM in 10 mM NaF, 20 mM NaH2PO4/Na2HPO4 buffer, pH 7) 
monitored at 222 nm by far-UV circular dichroism. (E) Backbone dynamics of BPSL1050; 
residues of L2 display heteronuclear NOEs <0.65 (gray line). (F) Electrostatic surface 
representation of BPSL1050 showing a patch of negatively charged residues on one side of 
the protein, the image on the right is rotated by 180° around the z axis. 
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Figure 2: Visual representation of the principal motions of BPSL1050 according to MD1-3. 
(A) Root Mean Square Fluctuation (RMSF) of the residue positions with respect to the 
NMR starting structure calculated over the 3 combined MD trajectories. (B) Residue-
based RMSF calculated after projecting each trajectory along the main ED eigenvectors. 
(C) Structures representing the extreme conformations corresponding to a principal 
motion (solid color and most transparent structure). The coordinates of the two extremes 
were interpolated into three intermediate positions resulting in a blurry effect. The blur 
amplitude indicates the protein regions involved in the motion. Blue, red and green 
structures are representative of the principal component (eigenvector) of simulations 
MD1, MD2 and MD3, respectively. 
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Figure 3: Communication propensities (CP) on BPSL1050. (A) Distance Fluctuation (DF) 
Matrix calculated on the timeframes of MD1. The non-dimensional color intensity 
indicates the coordination between any pair of residues of the protein sequence. (B) The 
Coordination Propensity (CP) profile is obtained from the DF Matrix after diagonalization 
and the selection of all coordinated pairs beyond a fixed range distance retaining a DF 
intensity higher than local average. The percentage of coordination of these residues is 
displayed in the profile. (C) Spheres representation highlights on the 3D structures the 
coordinated residues as reported by the profiles of MD1, MD2 and MD3 (in blue, red and 
green respectively). The network connecting two distal regions of BPSL1050 by means of 
helix α1 is visible in all three simulations. 
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Figure 4: Cartoon and color representation of the predicted, mapped and synthesized 
epitopes. (A) All the antibody-binding regions predicted from three MD simulations are 
displayed in red (MLCE) and blue (EDP). The sequences captured by experimental epitope 
mapping are shown in green. (B) Based on the predictions and experimental indications, 
two epitopes have been chosen for synthesis, in yellow and orange for L1050#1 and 
L1050#2, respectively. 
 
Figure 5: Recognition of 
BPSL1050 protein/peptides 
by anti-L1050#1 and anti-
L1050#2 antisera (A) Crude 
Bps antigen, (B) BPSL1050 
protein, BPSL1050 peptides 
(C) L1050#1 and (D) 
L1050#2 were individually 
coated into 96-well 
polystyrene plates. Then, 
0.5 μg/ml of either un-immunised rabbit sera or sera from rabbits immunised with 
L1050#1 (hatched bars) or L1050#2 (solid bars) were tested in duplicate for binding to the 
plate-immobilised antigens. Rabbit antibodies that bound were detected using a suitable 
HRP-anti-hIgG conjugate. 
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Figure 6: Agglutination of B. pseudomallei after exposure to antibodies raised against 
BPSL1050 or L1050#1 and L1050#2. RFP-expressing B. pseudomallei was incubated with 1 
µg of antibodies for 30 min at 37°C. Bacterial agglutination was observed under 
fluorescence microscopy. Panels show (A) RFP-expressing B. pseudomallei incubated with 
PBS as negative control, (B) antibodies raised against BPSL1050 whole protein where red 
arrow indicates agglutination, (C) antibodies raised against L1050#1 and (D) antibodies 
raised against L1050#2. Magnification = X100. 
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PART III - SUPPLEMENTARY MATERIALS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The final part gathers additional information and data regarding works still unpublished. 
All data is presented in form of figures and tables. The methods employed (MD 
simulations and predictions) are consistent with the procedures described in part II. 
Computer science is no more 
about computers than 
astronomy is about telescopes 
Edsger Dijkstra 
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Figure S1: Sequence alignment of all in silico and in vitro B-cell epitope prediction 
and mapping techniques, compared to final, synthesized T-cell/B-cell peptides. 
FliCBp full-length sequence illustrating epitope residues predicted by MLCE (blue), EDP 
(green) based on the FliCBp crystal structure and MD simulations; the consensus of three 
(BepiPred, BCPred and AAP) B-cell sequence-based prediction servers (purple), 
experimentally mapped peptides (red) and the three synthesized peptides (orange) that 
represent the final choice of putative B-cell epitopes, coinciding with sequence-based 
predictions. Grey shaded boxes indicate residues shared between two or more 
independent identification methods. The N and C-terminal residues visible in the electron 
density of the structure are underlined. (The synthesized peptides include also sequence 
213-231, selected as a putative T-cell epitope) 
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Figure S2: Distribution of human antibody against B. pseudomallei related 
proteins and peptides among seronegative (S- ; n = 24), seropositive (S+ ; n = 24) 
and melioidosis recovered individuals (R ; n = 24) detected by Indirect ELISA. A) 
Crude B. pseudomallei antigens B) recombinant FliCBp C) synthesized epitope F51-69 D) 
F96-111 E) F270-288. The samples were coated into 96-well polystyrene plate and then 
probed with diluted plasma samples of healthy and recovered individuals and quantified 
by indirect ELISA. The results were represented by Absorbance index (O.D.test – 
O.D.uncoated / O.D.uncoated). Experiments were performed in duplicate and results represent 
the mean of the Absorbance index  SE. * P < 0.05, ** P < 0.01, *** P < 0.001, ns = not 
significant compared between plasma sample groups using one-tailed Mann-Whitney U 
test. 
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Figure S3: Rabbit anti-FliCBp 
predicted peptide antibodies 
enhance phagocytosis and 
oxidative burst against B. 
pseudomallei in purified 
human PMNs (N = 5). Rabbit 
anti-FliCBp, prebleed antisera at 
dilution 1:50 or anti-predicted 
peptide antibodies at 40 g/ml 
were used for opsonization. * P 
< 0.05, ** P < 0.01, *** P < 
0.001, ns, not significant 
compared between with or 
without antibody groups using 
one-tailed paired t test.  
 
 
 
Figure S4: Rabbit anti-FliCBp protein, 
anti-F51-69 and anti-270-288 enhance B. 
pseudomallei intracellular killing activity 
in purified human PMNs (N = 2). Paired t 
test was applied for testing between each 
antibody conditions and no antibody. * P < 
0.05, ** P < 0.01, *** P < 0.001, ns, not 
significant. 
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Figure S5: FliCBp peptides induced human IFN- and IL-10 production from PBMCs. 
PBMCs at 5 x 105 cells/well from 20 seropositive healthy donors were stimulated with fixed 
Bps (PBMCs : organism = 1:30), 3 µg/ml of phytohaemagglutinin (PHA), 10 µg/ml of FliCBp 
protein, and 50 g/ml of FliCBp peptides (F51-69, F96-111, F270-288 and F213-231) for 48 
h, level of IFN- and IL-10 were quantified by ELISA. Vertical lines are median and dash 
lines are representing for a limit of detection. The comparisons between stimuli were 
performed by Friedman test and post tested by Dunn’s Multiple Comparison Test. * P < 
0.05, ** P < 0.01, *** P < 0.001, ns, not significant. 
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Figure S6: CD measurements of peptides PAL3 and PAL3b. Circular Dicroism spectra 
acquired for A) peptide PAL3, 25mM aqueous phosphate buffer, 0.1 mg/mL concentration 
(25°C, 0.1 cm quartz cell ). B) PAL3B at different temperatures (5°C-95°C) and PB 0.2 mM, 
NaF 1.5 mM, pH 6.24. The CD spectra were plotted as molar ellipticity (degree 
*cm2/dmol) versus wavelength (nm). C) The table reports the percentage of helix 
composition for peptide PAL3B at nearly physiological temperature (40°C). 
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Figure S7: Study of the prophylactic effect of anti-PAL3 and anti PAL3B antibodies 
ip administered against an acute in infection with Bps576 in C57BL6 mice. Passive 
immunization with anti-PAL3 antibodies (n=8) and anti PAL3B antibodes (n=8) was 
administered intraperitoneal route 6 hours before challenge, 1mg/ mouse of the 
corresponding antibody dissolved in PBS 7.2pH (2.5 mg/ml). Administration volume of 
20ml/kg. Control mice were injected PBS 7.2pH (n=6), and a control antibody (n=6). Mice 
infection intranasal route, 50µL/mouse. 
 
 
Figure S8: Sequence and predicted secondary structure of PalBp mimic model 
before MD simulations. The sequence at step B represents the excised folding unit 
connected by Pro 45 and Gly 46, while mimic at step C features a N-ter reduction (with 
the addition of Ile 4) and the addition of the helix stabilizer, here simplified as “residue” 
X at position 28. A black line is connecting the disulphide bridge positions, Cys 34 and 
Cys 49. Helices are depicted red, while strands are colored blue. 
 
 
Part III – 11.1 Supplementary materials 
 
116 
 
Figure S9: Time evolution of the secondary structure of PalBp mimics across MD 
simulations. The stability of PalBp mimics in solution have been assessed as a measure of 
the secondary structure elements throughout 100 ns of MD simulation. A) The upper 
panels represent two replicas of PalBp mimic, step C, deprived of the helix stabilizer 
fragment. The pronounced stability of the three β elements is opposed to the partial 
(upper replica) and total (lower replica) instability of the α helix. B) Two replicas of  PalBp 
mimic, step C, with the helix stabilizer connected in cis orientation. The α helix is fully 
stable throughout the simulations, but the stability of the β strands is impaired. 
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Figure S10: Overall occurrence propensity of each amino acid into BLUESTRIPE 
results. The percentage of occurrence of each amino acid in the results of BLUESTRIPE 
analysis is displayed together with the occurrence of each amino acid on the surface of the 
protein dataset. As it appears clear, the propensities are very similar comparing monomer 
and complex analyses, and both are consistent with the surface propensity control for the 
majority of residues. This result indicate that the analysis, and possibly the blue stripe 
formation, may not be dependent on the chemical peculiarity of the amino acids involved. 
Exceptions include Gly and Pro (higher propensity). The difference is most likely an 
artefact, since the energy matrix approximation relies on a local definition of energetic 
coupling. Glycine is lacking a full side chain, and Proline is not a strong interactor, making 
the two amino acids constitutively uncoupled and more easily selected by the analysis. 
The large Standard Deviations depicted by the error bars is due to the heterogeneous 
nature of the sample, purposely selected to account for different types of proteins and 
transient interactions. 
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Table S1: List of computationally and experimentally determined putative 
epitopes of protein BPSL1445. B) MLCE predictions are subdivided into individual 
epitopes (E1-E3) spotted on each MD replica (MD1-MD3). The sequences identified across 
the different replicas are largely overlapping. EDP predictions highlighted two putative 
epitopes (EDP1-EDP2), while one sequence was identified by experiental epitope mapping 
(EXP-1). The overall consensus epitopes are represented by sequences Lipo#1 – Lipo#3. 
 
Prediction method Name Epitope sequence
MLCE MD1-E1 47IQAGL51
MLCE MD2-E1 45D 47IQAG50 54GGQTG58
MLCE MD3-E1 50GLIIGGQT58
MLCE MD1-E2 78SVG80 83AGAQS87
MLCE MD2-E2 78SVGLQAGAQSK88
MLCE MD3-E2 77LSVG80 83AG84
MLCE MD1-E3 110AAGADA115 117V 122MGANGAIDTTTATA135
MLCE MD2-E3 122MGANGAIDT130 132TATA135
MLCE MD3-E3 110A 112GADASVA118 121KMGANGAIDTTTATAP136
EDP EDP-1 44PDVIQAGLIIGGQTGN59
EDP EDP-2 76SLSVGLQAGAQSK88
Epitope mapping EXP-1 39GVLVFPDVIQAGLIIGGQTGNGALR63
Synthetic peptide Lipo#1 40VLVFPDVIQAGLIIGGQTGNGALRV64
Synthetic peptide Lipo#2 76SLSVGLQAGAQSK88
Synthetic peptide Lipo#3 110AAGADASVALVKMGANGAIDTTTATAPVE137
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PDB code Mapped epitope Epitope data source test
1CB0 218-HEEAVSVDRVL-230 Purif ied MHC - X-ray crystall. Structure (crystal, NMR, etc.)
1D3B 52-RVAQLEQVYI-63 Purif ied MHC - X-ray crystall. Structure (crystal, NMR, etc.)
1EA3 0-SLLTEVETYVL-12 Cell bound MHC - Fluorescence Association (or direct binding)
1-LLTEVETYVL-12 Cell bound MHC - Fluorescence Association (or direct binding)
11-SIIPSGPLK-21 Cell bound MHC - Radioactivity Competition (or eq. binding)
115-LSYSAGAL-124 Cell bound MHC - Fluorescence Association (or direct binding)
123-ASCMGLIY-132 Lysate - Radioactivity Association (or direct binding)
126-MGLIYNRM-135 Cell bound MHC - Fluorescence Association (or direct binding)
132-RMGAVTTEV-142 Cell bound MHC - Fluorescence Association (or direct binding)
138-TEVAFGLV-147 Cell bound MHC - Fluorescence Association (or direct binding)
143-GLVCATCEQIA-155 Cell bound MHC - Fluorescence Association (or direct binding)
15-SGPLKAEIAQRLEDV-31 Purif ied MHC - Radioactivity Association (or direct binding)
25-RLEDVFAGK-35 Purif ied MHC - Radioactivity Association (or direct binding)
31-AGKNTDLEVLMEWLKTRPIL-52 Purif ied MHC - Fluorescence Competition (or eq. binding)
45-KTRPILSPLTK-57 Cell bound MHC - Radioactivity Competition (or eq. binding)
48-PILSPLTKGI-59 Cell bound MHC - Fluorescence Association (or direct binding)
55-KGILGFVFTLTVPSER-72 Purif ied MHC - Radioactivity Association (or direct binding)
56-GILGFVFTL-66 Cell bound MHC - Fluorescence Association (or direct binding)
94-AVKLYRKL-103 Cell bound MHC - Fluorescence Association (or direct binding)
1HA0 297-PKYVKQNTLKLAT-311 Purif ied MHC - X-ray crystall. Structure (crystal, NMR, etc.)
1I7Za 205-LSSPVTKSF-215 null null
1OVA 123-LYRGGLEPI-133 Purif ied MHC - Radioactivity Competition (or eq. binding)
175-NAIVFKGL-184 Purif ied MHC - Radioactivity Competition (or eq. binding)
24-ENIFYCPI-33 Purif ied MHC - Radioactivity Competition (or eq. binding)
256-SIINFEKL-265 Cell bound MHC - Fluorescence Association (or direct binding)
257-IINFEKLTEWTSSNVM-274 Cell bound MHC - Fluorescence Association (or direct binding)
26-IFYCPIAI-35 Purif ied MHC - Radioactivity Competition (or eq. binding)
270-NVMEERKIKVYLPRM-286 Purif ied MHC - Radioactivity Competition (or eq. binding) approx. KD
272-MEERKIKVYLPRMKME-289 Cell bound MHC - Fluorescence Dissociation
306-SSSANLSGISSAESLKISQA-327 Purif ied MHC - Radioactivity Competition (or eq. binding) approx. KD
322-ISQAVHAAHAEINEAGR-340 Cell bound MHC - Fluorescence Competition (or eq. binding)
95-VYSFSLASRL-106 Purif ied MHC - Radioactivity Competition (or eq. binding)
2GIB 32-AQFAPSASA-42 Purif ied MHC - Radioactivity Competition (or eq. binding)
35-APSASAFFGM-46 Purif ied MHC - Radioactivity Competition (or eq. binding)
37-SASAFFGMSR-48 Purif ied MHC - Radioactivity Competition (or eq. binding)
44-MSRIGMEVTPSGTWL-60 Purif ied MHC - Radioactivity Competition (or eq. binding) approx. KD
51-VTPSGTWLTY-62 Purif ied MHC - Radioactivity Competition (or eq. binding)
55-GTWLTYHGAIKLDDK-71 Purif ied MHC - Radioactivity Competition (or eq. binding) approx. KD
70-DPQFKDNVILLNKHI-86 Purif ied MHC - Radioactivity Competition (or eq. binding) approx. KD
78-ILLNKHIDA-88 Cell bound MHC - Fluorescence Association (or direct binding)
81-NKHIDAYKTFPPTEP-97 Purif ied MHC - Radioactivity Competition (or eq. binding) approx. KD
88-KTFPPTEPK-98 Purif ied MHC - X-ray crystall. Structure (crystal, NMR, etc.)
2JK2 18-GELIGTLNAAKVPAD-34 Purif ied MHC - X-ray crystall. Structure (crystal, NMR, etc.)
2VB1 10-AMKRHGLDNYRGYSL-26 Purif ied MHC - Fluorescence Dissociation
113-RCKGTDVQAWIRGCRL-130 Purif ied MHC - Radioactivity Competition (or eq. binding)
19-YRGYSLGNWVCAAKFE-36 Purif ied MHC - Fluorescence Dissociation
45-NTDGSTDYGILQINSR-62 Cell bound MHC - Fluorescence Association (or direct binding)
9-AAMKRHGLDNYRGY-24 Purif ied MHC - Fluorescence Competition (or eq. binding)
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Table S2: List of proteins and MHC-II epitopes in the dataset: from left to right, we 
show for each protein the PDB code structure used, the list of IEDB mapped epitopes, the 
data source and the experimental means employed for mapping. Shaded rows highlight 
such epitopes whose structure has been deposited in Protein Data Bank (in complex with 
MHC molecules). 
a This antigen protein is not featured in IEDB repository. 
 
 
 
 
 
 
 
Table S3. Formal description of 
the statistical parameters used 
in the evaluation of MLCE and 
BLOCKS as epitope predictors. 
Starting from the classification of 
results into four categories 
expressed in the contingency 
tables, sensitivity, specificity, 
precision, random precision, 
accuracy and MCC are calculated 
as measures of the predictive 
performance. 
PDB code Mapped epitope Epitope data source test
2WA0 134-GVYDGREHTV-145 Purif ied MHC - X-ray crystall. Structure (crystal, NMR, etc.)
3BZH 43-ILGPPGSVY-53 Purif ied MHC - X-ray crystall. Structure (crystal, NMR, etc.)
3FEY 135-GAVDPLLAL-145 Purif ied MHC - X-ray crystall. Structure (crystal, NMR, etc.)
237-ELPIVTPAL-247 Purif ied MHC - Fluorescence Association (or direct binding) approx. KD
3HLA 102-VGSDWRFLRGYHQYA-118 Purif ied MHC - X-ray crystall. Structure (crystal, NMR, etc.)
102-VGSDWRFLRGYHQYAYDG-121 Purif ied MHC - Fluorescence Competition (or eq. binding)
27-VDDTQFVRFDSDAASQRMEPR-49 Purif ied MHC - Fluorescence Association (or direct binding)
29-DTQFVRFDSDAASQRMEP-48 Purif ied MHC - Fluorescence Association (or direct binding)
59-WDGETRKVKAHSQTHRVDLGTLRGY-85 Cell bound MHC - T cell response Competition (or eq. binding)
Contingency 
Table
POSITIVES NEGATIVES
 TRUE  TP  TN
 FALSE  FP  FN
 SENSITIVITY (RECALL)
 SPECIFICITY
 PRECISION (PPV)
 ACCURACY (Q2)
Matthews  Corr. Coeff
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Table S4. Comparison of BLUEPRINT analysis on individual monomers vs full 
complexes. The number of residues identified by BLUEPRINT analysis (performed on the 
monomers as well as on the complexes) is reported next to the ID of each pair of interacting 
proteins. The cells highlighted in blue correspond to proteins forming a blue stripe (14/15 
for monomers, 12/15 for complexes). The percentage of identity is a quantitative measure 
of the number of residues in common between monomer and complex analysis. The 
number of residues identified in both conditions is very similar, and the overall identity is 
considerably high, indicating a general propensity over the prediction of the same protein 
areas. 
 
 
 
 
 
 
 
PDB ID No. of residues identified 
COMPLEX MONOMERS MONOMER COMPLEX Identity (%)
1acb 1egl 2cga 63 61 36.1
1ay7 1a19 1rgh 53 49 46.9
1b6c 1d6o 1ias 90 82 57.3
1buh 1hcl 1dks 70 87 61.4
1dfj 9rsa 2bnh 152 125 64
1f51 1ixm 1srr 80 61 62.3
1gpw 1thf 1k9v 102 95 61.1
1ira 1ilr 1g0y 99 104 55.6
1k74 1mzn 1zgy 125 100 65
1kac 1nob 1f5w 75 61 49.2
1ktz 1tgk 1m9z 59 51 43.1
1kxp 1ijj 1kw2 174 151 65.6
1pxv 1x9y 1nyc 63 45 48.9
1r0r 2grk 1scn 73 63 66.7
1tmq 1jae 1b1u 109 82 64.6
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11.3   SUPPLEMENTARY METHODS 
The references for the supplementary methods are listed at the end of the section. 
 
MD simulation protocol 
The majority of the computational investigations performed throughout this thesis are 
made upon MD simulations of the structural data. 
The following protocol has been used for epitope prediction purposes, and has been 
employed also for BLUESTRIPE analysis and for the dynamic characterization of antigens 
and peptides. Each replica simulation was performed using the GROMACS 4.51 or 4.54 
software package1, GROMOS 96A6 force field2 and the SPC water model3. The charge state 
of ionizable groups was chosen to mimic physiological pH conditions. The systems were 
solvated in cubic boxes large enough to contain 1 to 1.2 nm of solvent around the protein 
solute. The systems were subsequently energy minimized with a steepest descent method 
for 1000 steps, followed by another 1000 steps of steepest descent restraining the 
backbone and 1000 steps of conjugated gradient with no restraints. After minimization, 
MD simulations were carried out using the following set-up: the calculation of 
electrostatic forces utilized the PME implementation of the Ewald summation method. 
The constraining of all bond lengths was performed with the LINCS algorithm4. A 
dielectric permittivity, c=1, and a time step of 2 fs were used. All atoms were given an 
initial velocity obtained from a Maxwellian distribution at the temperature of 300 K. The 
density of the system was adjusted by weak coupling to a bath of constant pressure (P0=1 
bar, coupling time τP=1 ps)5. The temperature was maintained close to the intended values 
using Berendsen thermostat with a coupling constant of 0.2 ps5. The proteins and the rest 
of the systems were coupled separately to the temperature bath. The runs were carried 
out using NPT conditions for a variable simulation time, usually 5ns for BLUESTRIPE 
analysis and 50 ns for antigen characterization and epitope prediction. The first portion 
of each trajectory (in the aforementioned cases 1 and 10 ns respectively) was not used in 
the subsequent analyses in order to minimize convergence artifacts. 
RMSD and RMSF measures were used to assess the convergence of the simulation as well 
as the overall protein flexibility. 
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Essential Dynamics Analysis 
The main structural fluctuations of the protein were analyzed through Principal 
Component or Essential Dynamics (ED) Analysis of the covariance matrix of atomic 
positions obtained from the trajectories. This allows the relevant motions to be separated 
from the background fluctuation noise6. The principal eigenvectors are in general 
associated with the slow modes, which are responsible for protein functions. Translational 
and rotational degrees of freedom are eliminated and the average atomic coordinates, 
xi,ave, are calculated along the MD trajectories. The essential directions of correlated 
motions were then calculated by diagonalizing the covariance matrix Cij of atomic 
positions from MD. The ED analysis has been performed with GROMACS 4.51 and 
GROMACS 4.54 software package. 
 
Signal Propagation Analysis 
The analysis of signal propagation is derived from the Distance Fluctuations (DF) analysis, 
which can be used along with various related quantities to characterize the salient internal 
dynamics properties of a protein undergoing structural fluctuations {{14;20;44}}. Signal 
transduction events in proteins are directly related to the fluctuation dynamics of atoms, 
defining the communication propensities (CP) of a pair of residues as a function of the 
fluctuations of inter residue distances {{74}}. Residues whose Cα-Cα distance fluctuates 
with a relatively small intensity during the trajectory are supposed to communicate more 
efficiently than residues whose distance fluctuations are large. The Communication 
Propensity (CP) of any two residues is defined as the mean-square fluctuation of the inter 
residue distance (dij) defined  as distance between the Cα atoms of residue i and residue j. 
 
  (1) 
 
By projecting these quantities on the 3D structures of the proten, it is possible to identify 
the regions affected in their motion by the mechanic propagation of the fluctuation signal. 
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Computational analysis of S2 order parameter  
The S2 order parameter is a generalized descriptor of the spatial aspects of reorientational 
motion of N-HN vectors of heteronuclear NMR relaxation of 15N-labeled proteins. It 
represents a rich source of dynamic and thermodynamic information, ranging in the time 
scales of nanoseconds and sub-nanoseconds. An analytical estimation of NMR S2 order 
parameter may be calculated from the backbone of high resolution protein structures, in 
the form introduced by Brüschweiler et al. {{75}} (2) and adapted to be evaluated on a 
bundle of time frames collected from a protein simulation trajectory. 
 
(2) 
 
r0i-1k is the distance between the carbonyl oxygen of amino acid i − 1 to heavy atom k and 
rHi,k is the distance between the amide proton H
N
 and heavy atom k. The parameter b is 
set to −0.1, which takes into account that order parameters of rigid protein regions 
typically lie around 0.9. The sum ranges over all heavy atoms k that do not belong to 
amino acids i and i − 1.  
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